IL222467A

Certain amino-pyrimidines, compositions thereof and methods for their use

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

50 claims: 24 independent, 26 dependent

1
222467/3 CLaims 1. A compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen;R2 is selected from C6-10 aryl, and 5-10 membered heteroaryl , wherein each of the C6-10 aryl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, oxo, (CH2)nORa, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdSO2Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, C1-6 alkyl, and C1-6 haloalkyl, wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents;R3 is selected from hydrogen, halogen, C1-6 alkyl, and C1-6 haloalkyl;R4 is hydrogen;R5 and R6 are each independently C1-6 alkyl;or alternatively, R5 and R6 together with the carbon atom to which they are bound form C3-8 cycloalkyl optionally substituted with 1 or 2 halogens;R7 is selected from C6-10 aryl and 5-10 membered heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, ORa, SRa, S(O)Ra, SO2Ra, C1-6 alkyl, and C1-6 haloalkyl;161 222467/3 89 R8 and R9, at each occurrence, are each hydrogen;X is a bond;Ra, at each occurrence, is independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3-8 membered heterocycloalkyl, and 5-10 membered heteroaryl, wherein each of the C1-6 alkyl, C3-8 cycloalkyl, 3-8 membered heterocycloalkyl, and 5-10 f membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents;Rb and Rc, at each occurrence, are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, and 3-8 membered heterocycloalkyl, , wherein each of the C1-6 alkyl, C3-8 cycloalkyl and 3-8 membered heterocycloalkenyl groups is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents;Rd, at each occurrence, is hydrogen;Rf, at each occurrence, is independently selected from halogen, CN, ORh, NRiRj, NRdC(O)ORh, C(O)Rh, C(O)NRiRj, SO2Rh, C1-6 alkyl, and C1-6 haloalkyl;Rg, at each occurrence, is independently selected from C1-6 alkyl, and C1-6 haloalkyl;Rh, at each occurrence, is independently selected from hydrogen, C1-6 alkyl, and C1-6 haloalkyl;Ri and Rj, at each occurrence, are each independently selected from hydrogen, C1-6 alkyl, and C1-6 haloalkyl;m is 0 or 1;and n, at each occurrence, independently is 0, 1 or 2.
4
The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R5 and R6 are each C1-6 alkyl.
6
The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R5 and R6 together with the carbon atom to which they are bound form C3-8 cycloalkyl optionally substituted with 1 or 2 halogens.
14
The compound of any one of claims 10 to 13, or a pharmaceutically acceptable salt thereof, wherein one of Rm and Rn is hydrogen and the other is fluorine.
15
The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R7 is phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, ORa, SRa, S(O)Ra, SO2Ra, C1-6 alkyl, and C1-6 haloalkyl.
16
The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt 7 thereof, wherein R7 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, ORa, SRa, S(O)Ra, SO2Ra, C1-6 alkyl, and C1-6 haloalkyl. 7
19
The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R2 is phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, (CH2)nORa, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, 165 222467/3 (CH2)nNRdSO2Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, C1-6 alkyl, and C1-6 haloalkyl;wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents.
20
The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein R2 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, oxo, (CH2)nORa, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdSO2Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, C1-6 alkyl, and C1-6 f haloalkyl wherein the C1-6 alkyl is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents.
25
The compound of any one of claims 1 to 24, or a pharmaceutically acceptable salt thereof, wherein R3 is selected from hydrogen, halogen, CF3 and methyl. 3
34
A pharmaceutical composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof.
37
The use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disease or condition selected from neuromuscular disorders, conditions of muscle wasting, muscular myopathies, rehabilitation-related deficits, peripheral vascular disease, peripheral arterial disease, frailty, muscle atrophy and fatigue, metabolic syndrome, chronic fatigue syndrome obesity, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis.
38
The use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of Amyotrophic Lateral Sclerosis (ALS).
39
The use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of Spinal Muscular Atrophy (SMA).
40
The use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of myasthenia gravis.
41
The use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of chronic obstructive pulmonary disease (COPD).
42
The use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of heart failure.
43
The use of a compound of any one of claims 1 to 33, or a pharmaceutically acceptable 188 222467/1 salt thereof, for the preparation of a medicament for the treatment of frailty.
44
A composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of a disease or condition selected from neuromuscular disorders, conditions of muscle wasting, muscular myopathies, rehabilitation-related deficits, peripheral vascular disease, peripheral arterial disease, frailty, muscle atrophy and fatigue, metabolic syndrome, chronic fatigue syndrome obesity, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis.
45
A composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of Amyotrophic Lateral Sclerosis (ALS).
46
A composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of Spinal Muscular Atrophy (SMA).
47
A composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of myasthenia gravis.
48
A composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of chronic obstructive pulmonary disease (COPD). 189 222467/1
49
A composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of heart failure.
50
A composition comprising a compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of frailty. 190

Independent claims24

697 paragraphs in 44 sections, as filed

IL222467/2

Certain Amino-Pyrimidines, Compositions Thereof, and Methods for Their Use

The cytoskeleton of skeletal and cardiac muscle cells is unique compared to that of all other cells. It consists of a nearly crystalline array of closely packed cytoskeletal proteins called the sarcomere. The sarcomere is elegantly organized as an interdigitating array of thin and thick filaments. The thick filaments are composed of myosin, the motor protein responsible for transducing the chemical energy of ATP hydrolysis into force and directed movement. The thin filaments are composed of actin monomers arranged in a helical array. There are four regulatory proteins bound to the actin filaments, which allows the contraction to be modulated by calcium ions. An influx of intracellular calcium initiates muscle contraction; thick and thin filaments slide past each other driven by repetitive interactions of the myosin motor domains with the thin actin filaments.

Of the thirteen distinct classes of myosin in human cells, the myosin-ll class is responsible for contraction of skeletal, cardiac, and smooth muscle. This class of myosin is significantly different in amino acid composition and in overall structure from myosin in the other twelve distinct classes. Myosin-ll forms homo-dimers resulting in two globular head domains linked together by a long alpha-helical ooiled-coiled tail to form the core of the sarcomere’s thick filament. The globular heads have a catalytic domain where the actin binding and ATPase functions of myosin take place. Once bound to an actin filament, the release of phosphate (cf. ADP-Pi to ADP) signals a change in structural conformation of the catalytic domain that in turn alters the orientation of the light-chain binding lever arm domain that extends from the globular head; this movement is termed the powerstroke. This change in orientation of the myosin head in relationship to actin causes the thick filament of which it is a part to move with respect to the thin actin filament to which it is bound. Unbinding of the globular head from the actin filament (Ca2+ regulated) coupled with return of the catalytic domain and light chain to their starting l WO 2011/133888 PCT/US2011/033614 conformation/orientation completes the catalytic cycle, responsible for intracellular movement and muscle contraction.

Tropomyosin and troponin mediate the calcium effect on the interaction on actin and myosin. The troponin complex is comprised of three polypeptide 5 chains: troponin C, which binds calcium ions; troponin I, which binds to actin; and troponin T, which binds to tropomyosin. The skeletal troponin-tropomyosin complex regulates the myosin binding sites extending over several actin units at once.

Troponin, a complex of the three polypeptides described above, is an 10 accessory protein that is closely associated with actin filaments in vertebrate muscle. The troponin complex acts in conjunction with the muscle form of tropomyosin to mediate the Ca2+ dependency of myosin ATPase activity and thereby regulate muscle contraction. The troponin polypeptides T, I, and C, are named for their tropomyosin binding, inhibitory, and calcium binding 15 activities, respectively. Troponin T binds to tropomyosin and is believed to be responsible for positioning the troponin complex on the muscle thin filament. Troponin I binds to actin, and the complex formed by troponins I and T, and tropomyosin inhibits the interaction of actin and myosin. Skeletal troponin C is capable of binding up to four calcium molecules. Studies suggest that when 20 the level of calcium in the muscle is raised, troponin C exposes a binding site for troponin I, recruiting it away from actin. This causes the tropomyosin molecule to shift its position as well, thereby exposing the myosin binding sites on actin and stimulating myosin ATPase activity.

Human skeletal muscle is composed of different types of contractile 25 fibers, classified by their myosin type and termed either slow or fast fibers. Table 1 summarizes the different proteins that make up these types of muscle. 2 WO 2011/133888 PCT/US2011/033614

Table 1

Muscle Fiber Type Fast skeletal Slow Skeletal Myosin Heavy Chain Ila, (lib*), llx/d Cardiac β Troponin I (Tnl) Tnl fast SK Tnl slow SK Troponin T (TnT) TnT fast SK TnT slow SK Troponin C (TnC) TnC fast SK TnC slow/cardiac Tropomyosin ΤΜ-β / TM-o/TPM 3 ΤΜ-β / TM-os *MHC lib is not expressed in human muscle but is present in rodents and other mammals.

In healthy humans most skeletal muscles are composed of both fast and slow fibers, although the proportions of each vary with muscle type. Slow skeletal fibers, often called type I fibers, have more structural similarity with cardiac muscle and tend to be used more for fine and postural control. They 10 usually have a greater oxidative capacity and are more resistant to fatigue with continued use. Fast skeletal muscle fibers, often called type II fibers, are classified into fast oxidative (Ila) and fast glycolytic (type llx/d) fibers. While these muscle fibers have different myosin types, they share many components including the troponin and tropomyosin regulatory proteins. Fast 15 skeletal muscle fibers tend to exert greater force but fatigue faster than slow skeletal muscle fibers and are functionally useful for acute, large scale movements such as rising from a chair or correcting falls.

Muscle contraction and force generation is controlled through nervous stimulation by innervating motor neurons. Each motor neuron may innervate 20 many (approximately 100-380) muscle fibers as a contractile whole, termed a motor unit. When a muscle is required to contract, motor neurons send stimuli as nerve impulses (action potentials) from the brain stem or spinal cord to each fiber within the motor unit. The contact region between nerve and 3 WO 2011/133888 PCT/US2011/033614 muscle fibers is a specialized synapse called the neuromuscular junction (NMJ). Here, membrane depolarizing action potentials in the nerve are translated into an impulse in the muscle fiber through release of the neurotransmitter acetylcholine (ACh). ACh triggers a second action potential in the muscle that spreads rapidly along the fiber and into invaginations in the membrane, termed t-tubules. T-tubules are physically connected to Ca2+ stores within the sarcoplasmic reticulum (SR) of muscle via the dihydropyridine receptor (DHPR). Stimulation of the DHPR activates a second Ca2+ channel in the SR, the ryanodine receptor, to trigger the release of Ca2+ from stores in the SR to the muscle cytoplasm where it can interact with the troponin complex to initiate muscle contraction. If muscle stimulation stops, calcium is rapidly taken back up into the SR through the ATP dependent Ca2+ pump, SERCA.

Muscle function can become compromised in disease by many mechanisms. Examples include the frailty associated with old age (termed sarcopenia) and cachexia syndromes associated with diseases such as cancer, heart failure, chronic obstructive pulmonary disease (COPD), and chronic kidney disease/dialysis. Severe muscular dysfunction can arise from neuromuscular diseases (such as Amyotrophic Lateral Sclerosis (ALS), spinal muscular atrophy (SMA) and myasthenia gravis) or muscular myopathies (such as muscular dystrophies). Additionally, muscle function may become compromised due to rehabilitation-related deficits, such as those associated with recovery from surgery (e.g. post-surgical muscle weakness), prolonged bed rest, or stroke rehabilitation. Additional examples of diseases or conditions where muscle function becomes compromised include peripheral vascular disease (e.g., claudication), chronic fatigue syndrome, metabolic syndrome, and obesity.

Accordingly, there is a need for the development of new compounds that modulate skeletal muscle contractility. There remains a need for agents that exploit new mechanisms of action and which may have better outcomes in terms of relief of symptoms, safety, and patient mortality, both short-term and long-term and an improved therapeutic index. 4 222467/1

The following are prior art documents that relate to the field of the present invention.

Erin F DiMauro et al; Structure-Guided design of Aminopyrimidine Amides as Potent selective Inhibitors of Lymphocyte Specific Kinases: Synthesis, Structure- Activity Relationships, and Inhibition of in Vivo T-Cell Activation (J. Med. Chem. 2008, 51, 16811694) discusses the lymphocyte-specific kinase (LcK), a member of the SRc family of cytoplasmic tyrosine kinases, and expressed in T-cells and natural killer (NK) cells. Genetic evidence demonstrates that Lck kinase activity is critical for normal T-cell development, activation and signaling. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell mediated autoimmune and inflammatory diseases. With the aid of X-ray structure-based analysis, aminopyrimidine amides were designed from aminoquinazolines which had previously been demonstrated to exhibit potent inhibition of Lck and T-cell proliferation. This document describes the synthesis and structure-activity relationships of a series of novel aminopyrimidine amides possessing improved cellular potency. F. Shigeo Okumura et al: Synthesis of Isokinetin 2-N-furfurylaminopurine and its Leaf-Growth Activity (Studies of Isokinetin and its Analogs Part I) (Bull. Chem. Soc. Jap. Vol. 33, no 10, 1 January 1960 (1960-1-1) 1471-1472) describes investigations of more than 50 kinetin-analogs which have been prepared and which belong to the group of 6-(N-substituted)-aminopurine. It was found that some of them have a leaf-growth stimulating activity. This study investigates whether the leaf-growth activity is retained after the furfurylamino group at the 6-position of the purine ring migrates to the 2-position.

Hiroshi Ishida et al: Novel and orally active 5- (1, 3, 4-oxadiazol-2-yl) pyrimidine derivatives as selective FLT3 inhibitors (Bioorganic and Medicinal Chemistry Letters 18 (2008) 5472-5477) discusses a 5-(1, 3, 4-oxadiazol-2-yl)-pyrimidine derivative that was identified as a new class of FLT 3 inhibitor. With the aim of enhancement of anti-tumor activity, compounds with minor modifications of the aforementioned compound were prepared. Several variants were prepared which showed increased efficacy against MOLM -13 xenograft model in mice by oral administration.

James M Hamby et al; Structure Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors (J. Med. Chem. ACS, US; vol. 40, no 15 1 January 1997 (1997-1-1) 2296-2303) discusses screening of compounds for inhibitors of the fibroblast growth factor (FGFr) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. This led to the development of a novel series of ATP competitive pyrido[2,3-d]pyrimide tyrosine kinase inhibitors. The initial lead compound, 1-[2-amino-6-(2, 6-dichlorophenyl)pyridol[2,3-d]pyrimidin-7-yl]-3-tert-butylurea, was found to be a

4A 222467/1 broadly active tyrosine kinase inhibitor. Subsequent studies led to the synthesis of new analogs with improved potency, solubility, and bioavailability relative to the lead compound.

Jerome C Bressi et al: Adenosine Analogues as Inhibitors of Trypanosoma brucei Phosphoglycerate Kinase: Elucidation of a novel binding mode for a 2-Amino-N6-Substituted Adenosine (J. Med. Chem., 2000, 43, 4135-4150) discusses structure based design of adenosine analogues as drugs against African trypanosomiasis. N6-, 2-amino-N6-, and N2- substituted adenosine analogues were synthesized and tested to establish structural activity relationships for inhibiting Trypanosoma brucei kinases and dehydrogenases. US Pub Application 2007/0197505 (23 August 2007) to Bradley P Morgan et al, Certain chemical entities, compositions and methods, discusses certain substituted urea derivatives that modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including their fragments and isoforms, as well as the skeletal sarcomere. They are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, familial or acquired myopathies or muscular dystrophies), post-surgical and post-traumatic muscle weakness, and other conditions. WO 2003/044021 to Guolin Chai et al; Substituted indolizine-like compounds and methods of use discusses selected novel substituted indolizine-like compounds that are effective for treatment of diseases, such as TNF-ά, IL-Ιβ, IL-6 and/or IL-8 mediated diseases, and other maladies, such as cancer, pain and diabetes. The invention in this document encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving inflammation, cancer, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. WO 2006/066172 to Adrian L Smith et al; Aminopyrimidine compounds and methods of use discusses an invention that relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.

4B WO 2011/133888 PCT/US2011/033614

Provided is a compound of Formula I: R1

Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, 5 R7, R8, R9, X and m are as defined herein.

Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Also provided are methods for treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere, for 10 example, modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof.

As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the 15 extent that the context in which they are used indicates otherwise.

Throughout this application, unless the context indicates otherwise, references to a compound of Formula I includes all subgroups of Formula I defined herein, including all substructures, subgenera, preferences, embodiments, examples and particular compounds defined and/or described 20 herein.

References to a compound of Formula I and subgroups thereof include ionic forms, polymorphs, pseudopolymorphs, amorphous forms, solvates, cocrystals, chelates, isomers, tautomers, oxides (e.g., N-oxides, S-oxides), esters, prodrugs, isotopes and/or protected forms thereof. "Crystalline form," 25 "polymorph," and "novel form" may be used interchangeably herein, and are meant to include all crystalline and amorphous forms of the compound, including, for example, polymorphs, pseudopolymorphs, solvates (including 5 WO 2011/133888 PCT/US2011/033614 hydrates), co-crystals, unsolvated polymorphs (including anhydrates), conformational polymorphs, and amorphous forms, as well as mixtures thereof, unless a particular crystalline or amorphous form is referred to. In some embodiments, references to a compound of Formula I and subgroups thereof include polymorphs, solvates, co-crystals, isomers, tautomers and/or oxides thereof. In some embodiments, references to a compound of Formula I and subgroups thereof include polymorphs, solvates, and/or co-crystals thereof. In some embodiments, references to a compound of Formula I and subgroups thereof include isomers, tautomers and/or oxides thereof. In some embodiments, references to a compound of Formula I and subgroups thereof include solvates thereof. Similarly, the term “salts” includes solvates of salts of compounds.

By "optional" or "optionally" is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined herein. It will be understood by those skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible, and/or inherently unstable.

When a range of values is given (e.g., Ci_6 alkyl), each value within the range as well as all intervening ranges are included. For example, “Ci.6 alkyl” includes Ci, C2, C3, C4, C5, C6, C1-6, C2-6, C3-6, C4-6, C5-6, C1-5, C2-5, C3-5, C4-5, C1-4, C2-4, C3-4, C1-3, C2-3, and C-i-2 alkyl.

When a moiety is defined as being optionally substituted, it may be substituted as itself or as part of another moiety. For example, if Rx is defined as “C1-6 alkyl or OC1-6 alkyl, wherein C1-6 alkyl is optionally subsituted with halogen”, then both the Ci.6 alkyl group alone and the Ci.6 alkyl that makes up part of the OCi_6 alkyl group may be substituted with halogen. "Alkyl" encompasses straight and branched carbon chains having the indicated number of carbon atoms, for example, from 1 to 20 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms. For example, Ci_6 alkyl encompasses both straight and branched chain alkyl of from 1 to 6 carbon 6 WO 2011/133888 PCT/US2011/033614 atoms. When an alkyl residue having a specific number of carbons is named, all branched and straight chain versions having that number of carbons are intended to be encompassed; thus, for example, "propyl" includes n-propyl and isopropyl; and "butyl" includes n-butyl, sec-butyl, isobutyl and t-butyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. "Lower alkyl" refers to alkyl groups having 1 to 6 carbons. "Haloalkyl" includes straight and branched carbon chains having the indicated number of carbon atoms (e.g., 1 to 6 carbon atoms) substituted with at least one halogen atom. In instances wherein the haloalkyl group contains more than one halogen atom, the halogens may be the same (e.g., dichloromethyl) or different (e.g., chlorofluoromethyl). Examples of haloalkyl groups include, but are not limited to, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 1.2- difluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 1.2- dichloroethyl, pentachloroethyl, and pentafluoroethyl. "Alkenyl" refers to an unsaturated branched or straight-chain alkyl group having the indicated number of carbon atoms (e.g., 2 to 8, or 2 to 6 carbon atoms) and at least one carbon-carbon double bond derived by the removal of one molecule of hydrogen from adjacent carbon atoms of the corresponding alkyl. The group may be in either the cis or trans configuration (Z or E configuration) about the double bond(s). Alkenyl groups include, but are not limited to, ethenyl, propenyl (e.g., prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl), and butenyl (e.g., but-1 -en-1 -yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl). "Lower alkenyl" refers to alkenyl groups having 2 to 6 carbons. "Alkynyl" refers to an unsaturated branched or straight-chain alkyl group having the indicated number of carbon atoms (e.g., 2 to 8 or 2 to 6 carbon atoms) and at least one carbon-carbon triple bond derived by the removal of two molecules of hydrogen from adjacent carbon atoms of the corresponding alkyl. Alkynyl groups include, but are not limited to, ethynyl, 7 WO 2011/133888 PCT/US2011/033614 propynyl (e.g., prop-1-yn-1-yl, prop-2-yn-1-yl) and butynyl (e.g., but-1 -yn-1 -yl, but-1-yn-3-yl, but-3-yn-1-yl). "Lower alkynyl" refers to alkynyl groups having 2 to 6 carbons. "Cycloalkyl" indicates a non-aromatic, fully saturated carbocyclic ring having the indicated number of carbon atoms, for example, 3 to 10, or 3 to 8, or 3 to 6 ring carbon atoms. Cycloalkyl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl and cyclohexyl, as well as bridged and caged ring groups (e.g., norbornane, bicyclo[2.2.2]octane). In addition, one ring of a polycyclic cycloalkyl group may be aromatic, provided the polycyclic cycloalkyl group is bound to the parent structure via a nonaromatic carbon. For example, a 1,2,3,4-tetrahydronaphthalen-1-yl group (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is a cycloalkyl group, while 1,2,3,4-tetrahydronaphthalen-5-yl (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is not considered a cycloalkyl group. Examples of polycyclic cycloalkyl groups consisting of a cycloalkyl group fused to an aromatic ring are described below. "Cycloalkenyl" indicates a non-aromatic carbocyclic ring, containing the indicated number of carbon atoms (e.g., 3 to 10, or 3 to 8, or 3 to 6 ring carbon atoms) and at least one carbon-carbon double bond derived by the removal of one molecule of hydrogen from adjacent carbon atoms of the corresponding cycloalkyl. Cycloalkenyl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). Examples of cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl, as well as bridged and caged ring groups (e.g., bicyclo[2.2.2]octene). In addition, one ring of a polycyclic cycloalkenyl group may be aromatic, provided the polycyclic alkenyl group is bound to the parent structure via a non-aromatic carbon atom. For example, inden-1-yl (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is considered a cycloalkenyl group, while inden-4-yl (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is not considered a cycloalkenyl group. Examples of polycyclic cycloalkenyl groups consisting of a cycloalkenyl group fused to an aromatic ring are described below. 8 WO 2011/133888 PCT/US2011/033614 "Aryl" indicates an aromatic carbon ring having the indicated number of carbon atoms, for example, 6 to 12 or 6 to 10 carbon atoms. Aryl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). In some instances, both rings of a polycyclic aryl group are aromatic (e.g., naphthyl). In other instances, polycyclic aryl groups may include a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) fused to an aromatic ring, provided the polycyclic aryl group is bound to the parent structure via an atom in the aromatic ring. Thus, a 1,2,3,4- tetrahydronaphthalen-5-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is considered an aryl group, while 1,2,3,4-tetrahydronaphthalen-1-yl (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is not considered an aryl group. Similarly, a 1,2,3,4-tetrahydroquinolin-8-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is considered an aryl group, while 1,2,3,4-tetrahydroquinolin-1-yl group (wherein the moiety is bound to the parent structure via a non-aromatic nitrogen atom) is not considered an aryl group. However, the term “aryl” does not encompass or overlap with “heteroaryl”, as defined herein, regardless of the point of attachment (e.g., both quinolin-5-yl and quinolin-2-yl are heteroaryl groups).

In some instances, aryl is phenyl or naphthyl. In certain instances, aryl is phenyl. Additional examples of aryl groups comprising an aromatic carbon ring fused to a non-aromatic ring are described below. "Aralkyl" refers to a residue having the indicated number of carbon atoms (e.g., 7 to 12 or 7 to 10 carbon atoms) in which an aryl moiety is attached to the parent structure via an alkyl residue. The alkyl residue may be straight-chain or branched. Examples include benzyl, phenethyl and 1-phenylethyl. "Heteroaryl" indicates an aromatic ring containing the indicated number of atoms (e.g., 5 to 12, or 5 to 10 membered heteroaryl) made up of one or more heteroatoms (e.g., 1,2, 3 or 4 heteroatoms) selected from N, O and S and with the remaining ring atoms being carbon. Heteroaryl groups do not contain adjacent S and O atoms. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the heteroaryl group is 9 WO 2011/133888 PCT/US2011/033614 not more than 1. Unless otherwise indicated, heteroaryl groups may be bound to the parent structure by a carbon or nitrogen atom, as valency permits. For example, “pyridyl” includes 2-pyridyl, 3-pyridyl and 4-pyridyl groups, and “pyrrolyl” includes 1 -pyrrolyl, 2-pyrrolyl and 3-pyrrolyl groups. When nitrogen is present in a heteroaryl ring, it may, where the nature of the adjacent atoms and groups permits, exist in an oxidized state (i.e., N+-O'). Additionally, when sulfur is present in a heteroaryl ring, it may, where the nature of the adjacent atoms and groups permits, exist in an oxidized state (i.e., S+-O' or SO2). Heteroaryl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic).

In some instances, a heteroaryl group is monocyclic. Examples include pyrrole, pyrazole, imidazole, triazole (e.g., 1,2,3-triazole, 1,2,4-triazole, 1,2,4-triazole), tetrazole, furan, isoxazole, oxazole, oxadiazole (e.g., 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole), thiophene, isothiazole, thiazole, thiadiazole (e.g., 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole), pyridine, pyridazine, pyrimidine, pyrazine, triazine (e.g., 1,2,4-triazine, 1,3,5-triazine) and tetrazine.

In some instances, both rings of a polycyclic heteroaryl group are aromatic. Examples include indole, isoindole, indazole, benzoimidazole, benzotriazole, benzofuran, benzoxazole, benzoisoxazole, benzoxadiazole, benzothiophene, benzothiazole, benzoisothiazole, benzothiadiazole, 1H-pyrrolo[2,3-b]pyridine, 1 H-pyrazolo[3,4-b]pyridine, 3H-imidazo[4,5-b]pyridine, 3H-[1,2,3]triazolo[4,5-b]pyridine, 1 H-pyrrolo[3,2-b]pyridine, 1 H-pyrazolo[4,3-bjpyridine, 1 H-imidazo[4,5-b]pyridine, 1 H-[1,2,3]triazolo[4,5-b]pyridine, 1H-pyrrolo[2,3-c]pyridine, 1 H-pyrazolo[3,4-c]pyridine, 3H-imidazo[4,5-c]pyridine, 3H-[1,2,3]triazolo[4,5-c]pyrid ine, 1 H-pyrrolo[3,2-c]pyridine, 1 H-pyrazolo[4,3-cjpyrid ine, 1 H-imidazo[4,5-c]pyridine, 1 H-[1,2,3]triazolo[4,5-c]pyrid ine, furo[2,3-b]pyridine, oxazolo[5,4-b]pyridine, isoxazolo[5,4-b]pyridine, [1.2.3] oxadiazolo[5,4-b]pyridine, furo[3,2-b]pyridine, oxazolo[4,5-b]pyridine, isoxazolo[4,5-b]pyridine, [1,2,3]oxadiazolo[4,5-b]pyridine, furo[2,3-c]pyridine, oxazolo[5,4-c]pyridine, isoxazolo[5,4-c]pyridine, [1,2,3]oxadiazolo[5,4-cjpyridine, furo[3,2-c]pyridine, oxazolo[4,5-c]pyridine, isoxazolo[4,5-c]pyridine, [1.2.3] oxadiazolo[4,5-c]pyridine, thieno[2,3-b]pyridine, thiazolo[5,4-b]pyridine, isothiazolo[5,4-b]pyridine, [1,2,3]thiadiazolo[5,4-b]pyridine, thieno[3,2- 10 WO 2011/133888 PCT/US2011/033614 b] pyridine, thiazolo[4,5-b]pyridine, isothiazolo[4,5-b]pyridine, [1.2.3] thiadiazolo[4,5-b]pyridine, thieno[2,3-c]pyridine, thiazolo[5,4-c]pyridine, isothiazolo[5,4-c]pyridine, [1,2,3]thiadiazolo[5,4-c]pyridine, thieno[3,2- c] pyridine, thiazolo[4,5-c]pyridine, isothiazolo[4,5-c]pyridine, [1.2.3] thiadiazolo[4,5-c]pyridine, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, naphthyridine (e.g., 1,8-naphthyridine, 1,7-naphthyridine, 1,6-naphthyridine, 1,5-naphthyridine, 2,7-naphthyridine, 2,6-naphthyridine), imidazo[1,2-a]pyridine, 1H-pyrazolo[3,4-d]thiazole, 1H-pyrazolo[4,3-d]thiazole and imidazo[2,1-b]thiazole.

In other instances, polycyclic heteroaryl groups may include a nonaromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) fused to a heteroaryl ring, provided the polycyclic heteroaryl group is bound to the parent structure via an atom in the aromatic ring. For example, a 4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is considered a heteroaryl group, while 4,5,6,7-tetrahydrobenzo[d]thiazol-5-yl (wherein the moiety is bound to the parent structure via a non-aromatic carbon atom) is not considered a heteroaryl group. Examples of polycyclic heteroaryl groups consisting of a heteroaryl ring fused to a non-aromatic ring are described below. “Heterocycloalkyl" indicates a non-aromatic, fully saturated ring having the indicated number of atoms (e.g., 3 to 10, or 3 to 7, membered heterocycloalkyl) made up of one or more heteroatoms (e.g., 1, 2, 3 or 4 heteroatoms) selected from N, O and S and with the remaining ring atoms being carbon. Heterocycloalkyl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). Examples of heterocycloalkyl groups include oxiranyl, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl. When nitrogen is present in a heterocycloalkyl ring, it may, where the nature of the adjacent atoms and groups permits, exist in an oxidized state (i.e., N+-O'). Examples include piperidinyl N-oxide and morpholinyl-N-oxide. Additionally, when sulfur is present in a heterocycloalkyl ring, it may, where the nature of the adjacent atoms and groups permits, exist in an oxidized state (i.e., S+-O' or -SO2-). Examples include thiomorpholine S-oxide and thiomorpholine S,S-dioxide. In 11 WO 2011/133888 PCT/US2011/033614 addition, one ring of a polycyclic heterocycloalkyl group may be aromatic (e.g., aryl or heteroaryl), provided the polycyclic heterocycloalkyl group is bound to the parent structure via a non-aromatic carbon or nitrogen atom. For example, a 1,2,3,4-tetrahydroquinolin-1-yl group (wherein the moiety is bound to the parent structure via a non-aromatic nitrogen atom) is considered a heterocycloalkyl group, while 1,2,3,4-tetrahydroquinolin-8-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is not considered a heterocycloalkyl group. Examples of polycyclic heterocycloalkyl groups consisting of a heterocycloalkyl group fused to an aromatic ring are described below. "Heterocycloalkenyl" indicates a non-aromatic ring having the indicated number of atoms (e.g., 3 to 10, or 3 to 7, membered heterocycloalkyl) made up of one or more heteroatoms (e.g., 1,2, 3 or 4 heteroatoms) selected from N, O and S and with the remaining ring atoms being carbon, and at least one double bond derived by the removal of one molecule of hydrogen from adjacent carbon atoms, adjacent nitrogen atoms, or adjacent carbon and nitrogen atoms of the corresponding heterocycloalkyl. Heterocycloalkenyl groups may be monocyclic or polycyclic (e.g., bicyclic, tricyclic). When nitrogen is present in a heterocycloalkenyl ring, it may, where the nature of the adjacent atoms and groups permits, exist in an oxidized state (i.e., N+-O'). Additionally, when sulfur is present in a heterocycloalkenyl ring, it may, where the nature of the adjacent atoms and groups permits, exist in an oxidized state (i.e., S+-O' or-SO2-). Examples of heterocycloalkenyl groups include dihydrofuranyl (e.g., 2,3-dihydrofuranyl, 2,5-dihydrofuranyl), dihydrothiophenyl (e.g., 2,3-dihydrothiophenyl, 2,5-dihydrothiophenyl), dihydropyrrolyl (e.g., 2,3-dihydro-1 H-pyrrolyl, 2,5-dihydro-1 H-pyrrolyl), dihydroimidazolyl (e.g., 2,3-dihydro-1H-imidazolyl, 4,5-dihydro-1H-imidazolyl), pyranyl, dihydropyranyl (e.g., 3,4-dihydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl), tetrahydropyridinyl (e.g., 1,2,3,4-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl) and dihydropyridine (e.g., 1,2-dihydropyridine, 1,4-dihydropyridine). In addition, one ring of a polycyclic heterocycloalkenyl group may be aromatic (e.g., aryl or heteroaryl), provided the polycyclic heterocycloalkenyl group is bound to the parent structure via a non-aromatic carbon or nitrogen atom. For example, a 1,2-dihydroquinolin-1 -yl group (wherein the moiety is bound to the 12 WO 2011/133888 PCT/US2011/033614 parent structure via a non-aromatic nitrogen atom) is considered a heterocycloalkenyl group, while 1,2-dihydroquinolin-8-yl group (wherein the moiety is bound to the parent structure via an aromatic carbon atom) is not considered a heterocycloalkenyl group. Examples of polycyclic heterocycloalkenyl groups consisting of a heterocycloalkenyl group fused to an aromatic ring are described below.

Examples of polycyclic rings consisting of an aromatic ring (e.g., aryl or heteroaryl) fused to a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl) include indenyl, 2,3-dihydro-1 H-indenyl, 1,2,3,4-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, tetrahydroquinolinyl, 2.3- dihydrobenzo[1,4]dioxinyl, indolinyl, isoindolinyl, 2,3-dihydro-1 H-indazolyl, 2.3- dihydro-1 H-benzo[d]imidazolyl, 2,3-dihydrobenzofuranyl, 1.3- dihydroisobenzofuranyl, 1,3-dihydrobenzo[c]isoxazolyl, 2.3- dihydrobenzo[d]isoxazolyl, 2,3-dihydrobenzo[d]oxazolyl, 2.3- dihydrobenzo[b]thiophenyl, 1,3-dihydrobenzo[c]thiophenyl, 1.3- dihydrobenzo[c]isothiazolyl, 2,3-dihydrobenzo[d]isothiazolyl, 2.3- dihydrobenzo[d]thiazolyl, 5,6-dihydro-4H-cyclopenta[d]thiazolyl, 4.5.6.7- tetrahydrobenzo[d]thiazolyl, 5,6-dihydro-4H-pyrrolo[3,4-d]thiazolyl , 4.5.6.7- tetrahydrothiazolo[5,4-c]pyridinyl, indolin-2-one, indolin-3-one, isoindol in-1 -one, 1,2-dihydroindazol-3-one, 1 H-benzo[d]imidazol-2(3H)-one, benzofuran-2(3H)-one, benzofuran-3(2H)-one, isobenzofuran-1 (3H)-one, benzo[c]isoxazol-3(1 H)-one, benzo[d]isoxazol-3(2H)-one, benzo[d]oxazol-2(3H)-one, benzo[b]thiophen-2(3H)-one, benzo[b]thiophen-3(2H)-one, benzo[c]thiophen-1 (3H)-one, benzo[c]isothiazol-3(1 H)-one, benzo[d]isothiazol-3(2H)-one, benzo[d]thiazol-2(3H)-one, 4,5- dihydropyrrolo[3,4-d]thiazol-6-one, 1,2-dihydropyrazolo[3,4-d]thiazol-3-one, quinolin-4(3H)-one, quinazolin-4(3H)-one, quinazoline-2,4(1 H,3H)-dione, quinoxalin-2(1 H)-one, quinoxaline-2,3(1 H,4H)-dione, cinnolin-4(3H)-one, pyridin-2(1 H)-one, pyrimidin-2(1 H)-one, pyrimidin-4(3H)-one, pyridazin-3(2H)-one, 1 H-pyrrolo[3,2-b]pyridin-2(3H)-one, 1 H-pyrrolo[3,2-c]pyridin-2(3H)-one, 1 H-pyrrolo[2,3-c]pyridin-2(3H)-one, 1 H-pyrrolo[2,3-b]pyridin-2(3H)-one, 1,2-dihydropyrazolo[3,4-d]thiazol-3-one and 4,5-dihydropyrrolo[3,4-d]thiazol-6-one. As discussed herein, whether each ring is considered an aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl 13 WO 2011/133888 PCT/US2011/033614 group is determined by the atom through which the moiety is bound to the parent structure. "Halogen" or "halo" refers to fluorine, chlorine, bromine or iodine. "Isomers" are different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. "Enantiomers" are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. The symbol "(±)" may be used to designate a racemic mixture where appropriate. "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. A “meso compound” or “meso isomer” is a non-optically active member of a set of stereoisomers. Meso isomers contain two or more stereocenters but are not chiral (i.e., a plane of symmetry exists within the molecule). The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.

Certain of the compounds disclosed and/or described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, meso isomers and other stereoisomeric forms. Unless otherwise indicated, compounds disclosed and/or described herein include all such possible enantiomers, diastereomers, meso isomers and other stereoisomeric forms, including racemic mixtures, optically pure forms and intermediate mixtures. Enantiomers, diastereomers, meso isomers and other stereoisomeric forms can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Unless specified otherwise, when the compounds disclosed and/or described herein contain olefinic double bonds or other centers of geometric asymmetry, it is intended that the compounds include both E and Z isomers.

The stereochemistry depicted in the structures of cyclic meso compounds is not absolute; rather the stereochemistry is intended to indicate the positioning of the substituents relative to one another, e.g., cis or trans. 14 WO 2011/133888 PCT/US2011/033614

For example

is intended to designate a compound wherein the fluorine and pyridyl substituents on the cyclobutyl ring are in a cis configuration to one another, while 10 10 is intended to designate a compound wherein the fluorine and pyridyl substituents on the cyclobutyl ring are in a trans configuration to one another.

When a compound can exist as one or more meso isomers, all possible meso isomers are intended to be included. For example, the compound {[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}pyrimidin-2-ylamine is intended to include both cis and trans meso isomers: 15 15 and mixtures thereof. Unless otherwise indicated, compounds disclosed and/or described herein include all possible meso isomers and mixtures thereof. "Tautomers" are structurally distinct isomers that interconvert by tautomerization. Tautomerization is a form of isomerization and includes prototropic or proton-shift tautomerization, which is considered a subset of acid-base chemistry. Prototropic tautomerization or proton-shift tautomerization involves the migration of a proton accompanied by changes in bond order, often the interchange of a single bond with an adjacent double bond. Where tautomerization is possible (e.g. in solution), a chemical 15 WO 2011/133888 PCT/US2011/033614 equilibrium of tautomers can be reached. An example of tautomerization is keto-enol tautomerization. A specific example of keto-enol tautomerization is the interconverision of pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(1 H)-one tautomers. When the compounds described herein contain moieties capable of tautomerization, and unless specified otherwise, it is intended that the compounds include all possible tautomers. “Protecting group” has the meaning conventionally associated with it in organic synthesis, i.e., a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site, and such that the group can readily be removed after the selective reaction is complete. A variety of protecting groups are disclosed, for example, in T.H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley &amp; Sons, New York (1999). For example, a “hydroxy protected form” contains at least one hydroxy group protected with a hydroxy protecting group. Likewise, amines and other reactive groups may similarly be protected.

The term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of the compounds described herein and are not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts can be found in Berge et al.,

Pharmaceutical Salts, J. Pharmaceutical Sciences, January 1977, 66(1), 1-19. In many cases, the compounds described herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 16 WO 2011/133888 PCT/US2011/033614 cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, p-toluenesulfonic acid, stearic acid and salicylic acid. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines; substituted amines including naturally occurring substituted amines; cyclic amines; and basic ion exchange resins. Examples of organic bases include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts.

If the compound described herein is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the compound is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds (see, e.g., Berge et al., Pharmaceutical Salts, J. Pharmaceutical Sciences, January 1977, 66(1), 1-19). Those skilled in the art will recognize various synthetic methodologies that may be used to prepare pharmaceutically acceptable addition salts. A “solvate” is formed by the interaction of a solvent and a compound. Suitable solvents include, for example, water and alcohols (e.g., ethanol). Solvates include hydrates having any ratio of compound to water, such as monohydrates, dihydrates and hemi-hydrates. A “chelate” is formed by the coordination of a compound to a metal ion at two (or more) points. The term “compound” is intended to include chelates of compounds. Similarly, “salts” includes chelates of salts and “solvates” includes chelates of solvates. A “non-covalent complex” is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through 17 WO 2011/133888 PCT/US2011/033614 van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding). Such non-covalent complexes are included in the term “compound”.

The term “prodrug” refers to a substance administered in an inactive or less active form that is then transformed (e.g., by metabolic processing of the prodrug in the body) into an active compound. The rationale behind administering a prodrug is to optimize absorption, distribution, metabolism, and/or excretion of the drug. Prodrugs may be obtained by making a derivative of an active compound (e.g., a compound of Formula I or another compound disclosed and/or described herein) that will undergo a transformation under the conditions of use (e.g., within the body) to form the active compound. The transformation of the prodrug to the active compound may proceed spontaneously (e.g., by way of a hydrolysis reaction) or it can be catalyzed or induced by another agent (e.g., an enzyme, light, acid or base, and/or temperature). The agent may be endogenous to the conditions of use (e.g., an enzyme present in the cells to which the prodrug is administered, or the acidic conditions of the stomach) or the agent may be supplied exogenously. Prodrugs can be obtained by converting one or more functional groups in the active compound into another functional group, which is then converted back to the original functional group when administered to the body. For example, a hydroxyl functional group can be converted to a sulfonate, phosphate, ester or carbonate group, which in turn can be hydrolyzed in vivo back to the hydroxyl group. Similarly, an amino functional group can be converted, for example, into an amide, carbamate, imine, urea, phosphenyl, phosphoryl or sulfenyl functional group, which can be hydrolyzed in vivo back to the amino group. A carboxyl functional group can be converted, for example, into an ester (including silyl esters and thioesters), amide or hydrazide functional group, which can be hydrolyzed in vivo back to the carboxyl group. Examples of prodrugs include, but are not limited to, phosphate, acetate, formate and benzoate derivatives of functional groups (such as alcohol or amine groups) present in the compounds of Formula I and other compounds disclosed and/or described herein.

The compounds disclosed and/or described herein can be enriched isotopic forms, e.g., enriched in the content of 2H, 3H, 11C, 13C and/or 14C. In 18 WO 2011/133888 PCT/US2011/033614 one embodiment, the compound contains at least one deuterium atom. Such deuterated forms can be made, for example, by the procedure described in U.S. Patent Nos. 5,846,514 and 6,334,997. Such deuterated compounds may improve the efficacy and increase the duration of action of compounds disclosed and/or described herein. Deuterium substituted compounds can be synthesized using various methods, such as those described in: Dean, D., Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development, Curr. Pharm. Des., 2000; 6(10); Kabalka, G. et al., The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E., Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in pharmaceutical compositions is contemplated. Supplementary active ingredients can also be incorporated into the pharmaceutical compositions.

The term "active agent" is used to indicate a compound that has biological activity. In some embodiments, an "active agent" is a compound having therapeutic utility. In some embodiments, the compound enhances at least one aspect of skeletal muscle function or activity, such as power output, skeletal muscle force, skeletal muscle endurance, oxygen consumption, efficiency, and/or calcium sensitivity. In some embodiments, an active agent is a compound of Formula I, or a pharmaceutically acceptable salt thereof.

The terms "patient" and “subject” refer to an animal, such as a mammal bird or fish. In some embodiments, the patient or subject is a mammal. Mammals include, for example, mice, rats, dogs, cats, pigs, sheep, horses, cows and humans. In some embodiments, the patient or subject is a human, for example a human that has been or will be the object of treatment, observation or experiment. The compounds, compositions and methods described herein can be useful in both human therapy and veterinary 19 WO 2011/133888 PCT/US2011/033614 applications.

As used herein, “skeletal muscle” includes skeletal muscle tissue as well as components thereof, such as skeletal muscle fibers, the myofibrils comprising the skeletal muscle fibers, the skeletal sarcomere which comprises the myofibrils, and the various components of the skeletal sarcomere described herein, including skeletal myosin, actin, tropomyosin, troponin C, troponin I, troponin T and fragments and isoforms thereof. In some embodiments, “skeletal muscle” includes fast skeletal muscle tissue as well as components thereof, such as fast skeletal muscle fibers, the myofibrils comprising the fast skeletal muscle fibers, the fast skeletal sarcomere which comprises the myofibrils, and the various components of the fast skeletal sarcomere described herein, including fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, troponin T and fragments and isoforms thereof. Skeletal muscle does not include cardiac muscle or a combination of sarcomeric components that occurs in such combination in its entirety in cardiac muscle.

As used herein, the term "therapeutic" refers to the ability to modulate the contractility of fast skeletal muscle. As used herein, "modulation" (and related terms, such as “modulate”, “modulated”, “modulating”) refers to a change in function or efficiency of one or more components of the fast skeletal muscle sarcomere, including myosin, actin, tropomyosin, troponin C, troponin I, and troponin T from fast skeletal muscle, including fragments and isoforms thereof, as a direct or indirect response to the presence of a compound described herein, relative to the activity of the fast skeletal sarcomere in the absence of the compound. The change may be an increase in activity (potentiation) or a decrease in activity (inhibition), and may be due to the direct interaction of the compound with the sarcomere, or due to the interaction of the compound with one or more other factors that in turn affect the sarcomere or one or more of its components. In some embodiments, modulation is a potentiation of function or efficiency of one or more components of the fast skeletal muscle sarcomere, including myosin, actin, tropomyosin, troponin C, troponin I, and troponin T from fast skeletal muscle, including fragments and isoforms thereof. Modulation may be mediated by any mechanism and at any physiological level, for example, through 20 WO 2011/133888 PCT/US2011/033614 sensitization of the fast skeletal sarcomere to contraction at lower Ca2+ concentrations. As used herein, “efficiency” or “muscle efficiency” means the ratio of mechanical work output to the total metabolic cost.

The term "therapeutically effective amount" or "effective amount" refers to that amount of a compound disclosed and/or described herein that is sufficient to affect treatment, as defined herein, when administered to a patient in need of such treatment. A therapeutically effective amount of a compound may be an amount sufficient to treat a disease responsive to modulation of fast skeletal muscle. The therapeutically effective amount will vary depending upon, for example, the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the particular compound, the dosing regimen to be followed, timing of administration, the manner of administration, all of which can readily be determined by one of ordinary skill in the art. The therapeutically effective amount may be ascertained experimentally, for example by assaying blood concentration of the chemical entity, or theoretically, by calculating bioavailability. "Treatment" (and related terms, such as “treat”, “treated”, "treating") includes one or more of: preventing a disease or disorder (i.e., causing the clinical symptoms of the disease or disorder not to develop); inhibiting a disease or disorder; slowing or arresting the development of clinical symptoms of a disease or disorder; and/or relieving a disease or disorder (i.e., causing relief from or regression of clinical symptoms). The term encompasses situations where the disease or disorder is already being experienced by a patient, as well as situations where the disease or disorder is not currently being experienced but is expected to arise. The term covers both complete and partial reduction or prevention of the condition or disorder, and complete or partial reduction of clinical symptoms of a disease or disorder. Thus, compounds described and/or disclosed herein may prevent an existing disease or disorder from worsening, assist in the management of the disease or disorder, or reduce or eliminate the disease or disorder. When used in a prophylactic manner, the compounds disclosed and/or described herein may prevent a disease or disorder from developing or lessen the extent of a disease or disorder that may develop. 21 WO 2011/133888 PCT/US2011/033614

As used herein, “power output” of a muscle means work/cycle time and may be scaled up from PoLo/cycle time units based on the properties of the muscle. Power output may be modulated by changing, for example, activating parameters during cyclical length changes, including timing of 5 activation (phase of activation) and the period of activation (duty cycle.) "ATPase" refers to an enzyme that hydrolyzes ATP. ATPases include proteins comprising molecular motors such as the myosins.

As used herein, “selective binding” or “selectively binding” refers to preferential binding to a target protein in one type of muscle or muscle fiber as 10 opposed to other types. For example, a compound selectively binds to fast skeletal troponin C if the compound preferentially binds troponin C in the troponin complex of a fast skeletal muscle fiber or sarcomere in comparison with troponin C in the troponin complex of a slow muscle fiber or sarcomere or with troponin C in the troponin complex of a cardiac sarcomere. 15 Provided is a compound of Formula I: R1

Formula I or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from hydrogen, halogen, CN, Ci_6 alkyl, Ci_6 haloalkyl, 20 C(O)ORa, C(O)NRbRc, ORa, NRbRc, C6-io aryl and 5-10 membered heteroaryl; R2 is selected from C3-8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-10 aryl, 5-10 membered heteroaryl and NRbRc, wherein each of the C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered 25 heterocycloalkenyl, Ce-ιο aryl and 5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, 22 WO 2011/133888 PCT/US2011/033614 CN, oxo, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NRe)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, C1-6 alkyl, C1-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, (CH2)nC3. s cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nC6-io aryl and (CH2)n5-10 membered heteroaryl, wherein each of the Ci_6 alkyl, C2.6 alkenyl, C2_6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nC6-io aryl and (CH2)n5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents; R3 is selected from hydrogen, halogen, CN, Ci-6 alkyl, Ci-6 haloalkyl, C(O)ORa, C(O)NRbRc, ORa, NRbRc, Ce-10 aryl and 5-10 membered heteroaryl; R4 is selected from hydrogen, Ci-θ alkyl, Ci-θ haloalkyl, C(O)Ra, C(O)ORa, C(O)NRbRc and SO2Ra; R5 and R6 are each independently selected from hydrogen, halogen, Ci-6 alkyl and Ci-e haloalkyl; or alternatively, R5 and R6 together with the carbon atom to which they are bound form C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl, each optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, ΰή-θ alkyl and C-ι-θ haloalkyl; R7 is selected from C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-10 aryl and 5-10 membered heteroaryl, each optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, OC(O)NRbRc, NRbRc, NRdC(O)Ra, NRdC(O)ORa, NRdC(O)NRbRc, NRdC(O)C(O)NRbRc, NRdC(S)Ra, NRdC(S)ORa, NRdC(S)NRbRc, NRdC(NRe)NRbRc, NRdS(O)Ra, NRdSO2Ra, NRdSO2NRbRc, C(O)Ra, C(O)ORa, 23 WO 2011/133888 PCT/US2011/033614 C(O)NRbRc, C(S)Ra, C(S)ORa, C(S)NRbRc, C(NRe)NRbRc, SRa, S(O)Ra, SO2Ra, SO2NRbRc, Ci-6 alkyl, Ci_6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, Ce-ιο aryl, C7-11 aralkyl, and 5-10 membered heteroaryi, wherein each of the C1-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3-8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryi groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents; R8 and R9, at each occurrence, are each independently selected from hydrogen, halogen and Ci-6 alkyl; X is selected from a bond, -(CH2)P-, -(CH2)pC(O)(CH2)q-, -(CH2)pO(CH2)q-, -(CH2)pS(CH2)q-, -(CH2)pNRd(CH2)q-, -(CH2)pC(O)O(CH2)q-, -(CH2)pOC(O)(CH2)q-, -(CH2)pNRdC(O)(CH2)q-, -(CH2)pC(O)NRd(CH2)q-, -(CH2)pNRdC(O)NRd(CH2)q-, -(CH2)pNRdSO2(CH2)q-, and -(CH2)pSO2NRd(CH2)q-; or alternatively, X, R2 and R3, together with the carbon atoms to which they are bound, form a 5-6 membered ring optionally containing one or more heteroatoms selected from oxygen nitrogen and sulfur, and optionally containing one or more double bonds, and optionally substituted with 1,2, 3, 4 or 5 Rf substituents;

Ra, at each occurrence, is independently selected from hydrogen, C-|.6 alkyl, Ci_6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-10 aryl, C7-11 aralkyl and 5-10 membered heteroaryi, wherein each of the Ci-θ alkyl, C2-6 alkenyl, C2.6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryi groups is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents;

Rb and Rc, at each occurrence, are each independently selected from hydrogen, Ci-θ alkyl, Ci-θ haloalkyl, C2_6 alkenyl, C2_6 alkynyl, C3.8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-10 aryl, C7-11 aralkyl, 5-10 membered heteroaryi, 24 WO 2011/133888 PCT/US2011/033614 C(O)Rg, C(O)ORg, C(O)NR'Rj and SO2Rg, wherein each of the Ci.6 alkyl, C2.6 alkenyl, C2.6 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, Ce-ιο aryl, C7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents;

Rd, at each occurrence, is independently selected from hydrogen and Ci-6 alkyl;

Re, at each occurrence, is independently selected from hydrogen, CN, OH, C1-6 alkoxy, Ci.6 alkyl and Ci.6 haloalkyl;

Rf, at each occurrence, is independently selected from halogen, CN, ORh, OC(O)Rh, OC(O)ORh, OC(O)NRRj, NR'Rj, NRdC(O)Rh, NRdC(O)ORh, NRdC(O)NR'Rj, NRdC(O)C(O)NR'Rj, NRdC(S)Rh, NRdC(S)ORh, NRdC(S)NR'Rj, NRdC(NRe)NR'RJ, NRdS(O)Rh, NRdSO2Rh, NRdSO2NR'Rj, C(O)Rh, C(O)ORh, C(O)NR'Rj, C(S)Rh, C(S)ORh, C(S)NRRj, C(NRe)NR'Rj, SRh, S(O)Rh, SO2Rh, SO2NR'Rj, C1-6 alkyl, Ci-e haloalkyl, C2.6 alkenyl, C2.6 alkynyl, C3.8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryl, wherein each of the Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rk substituents; or two Rf substituents bound to a single carbon atom, together with the carbon atom to which they are both bound, form a group selected from carbonyl, C3-s cycloalkyl and 3-8 membered heterocycloalkyl;

Rg, at each occurrence, is independently selected from Ci_6 alkyl, Ci_6 haloalkyl, phenyl, naphthyl, and C7.11 aralkyl, each optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, OH, C1-6 alkoxy, C1-6 alkyl and Ci.6 haloalkyl;

Rh, at each occurrence, is independently selected from hydrogen, C1-6 alkyl, Ci.6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryl, wherein each of the C1-6 alkyl, 25 WO 2011/133888 PCT/US2011/033614 C2-6 alkenyl, C2-6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-n aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 Rk substituents; R' and Rj, at each occurrence, are each independently selected from hydrogen, Ci_6 alkyl, Ci_6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, C3.8 cycloalkyl, C3-s cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-n aralkyl, 5-10 membered heteroaryl, C(O)Rg, and C(O)ORg, wherein each of the Ci_6 alkyl, Ci_6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, Ce-10 aryl, C7.n aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, OH, Ci.6 alkoxy, Ci.6 alkyl and Ci-6 haloalkyl;

Rk, at each occurrence, is independently selected from halogen, CN, OH, Ci-6 alkoxy, NH2, NH(Ci_6 alkyl), N(Ci_6 alkyl)2, NHC(O)Ci-6 alkyl, NHC(O)C7.ii aralkyl, NHC(O)OCi.6 alkyl, NHC(O)OC7.n aralkyl, ΟΟ(Ο)ΟΊ.6 alkyl, OC(O)C7.n aralkyl, OC(O)OCi.6 alkyl, OC(O)OC7.n aralkyl, C(O)Ci.6 alkyl, C(O)C7_n aralkyl, C(O)OCi_6 alkyl, C(O)OC7_n aralkyl, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein each Ci-θ alkyl, C2-6 alkenyl, C2_6 alkynyl, and C7_n aralkyl substituent is optionally substituted with 1,2 or 3 substituents selected from OH, Ci_6 alkoxy, NH2, NH(Ci_6 alkyl), N(Ci_6 alkyl)2, NHC(O)Ci.6 alkyl, NHC(O)C7.n aralkyl, NHC(O)OCi.6 alkyl, and NHC(O)OC7. 11 aralkyl; or two Rk substituents bound to a single carbon atom, together with the carbon atom to which they are both bound, form a carbonyl group; m is 0, 1 or 2; n, at each occurrence, independently is 0,1 or 2; p is 0, 1 or 2; and q is 0, 1 or 2.

In some embodiments of compounds of Formula I, m is 0, i.e., a 26 WO 2011/133888 PCT/US2011/033614 compound of Formula II, or a pharmaceutically acceptable salt thereof: R1

Formula II wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined herein. 5 In some embodiments of compounds of Formula I, m is 1, i.e., a compound of Formula III, or a pharmaceutically acceptable salt thereof: R1

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. 10 In some embodiments of compounds of Formula I, II or III, one of R5 and R6 is hydrogen and the other is Ci-θ alkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6 are each independently Ci_6 alkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6 15 are each methyl.

In some embodiments, the compounds are of Formula IV(a) or IV(b), or a pharmaceutically acceptable salt thereof: 27 WO 2011/133888 PCT/US2011/033614 R1

R4

Formula IV(a)

Formula IV(b) 5 wherein R1, R2, R3, R4, R7, R8, R9 and X are as defined herein.

In some embodiments of compounds of Formula I, II or III, R5 and R6 together with the carbon atom to which they are bound form C3-8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl, each optionally substituted with 1,2, 3, 4 or 5 substituents 10 selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci_6 alkyl and Ci_6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6, together with the carbon to which they are bound, form C3-6 cycloalkyl 15 optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci.6 alkyl and Ci.6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6, together with the carbon to which they are bound, form cyclopropyl, 20 cyclobutyl, cyclopentyl or cyclohexyl, each optionally substituted with 1,2, 3, 4 28 WO 2011/133888 PCT/US2011/033614 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci.6 alkyl and C1-6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6, 5 together with the carbon to which they are bound, form cyclobutyl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci-6 alkyl and Ci.6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6, 10 together with the carbon to which they are bound, form cyclobutyl substituted with one substituent selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, C1-6 alkyl and Ci-θ haloalkyl, wherein the substituent and R7 are in a trans configuration with respect to one another on the cyclobutyl ring. 15 In some embodiments of compounds of Formula I, II or III, R5 and R6, together with the carbon to which they are bound, form cyclobutyl substituted with one substituent selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, C1-6 alkyl and Ci-e haloalkyl, wherein the substituent and R7 are in 20 a cis configuration with respect to one another on the cyclobutyl ring.

In some embodiments, the compounds are of Formula V(a) or V(b), or a pharmaceutically acceptable salt thereof:

R4

Formula V(a) 29 WO 2011/133888 PCT/US2011/033614

Formula V(b) wherein Rm and Rn are each independently selected from hydrogen, halogen and C-i-6 alkyl, and R1, R2, R3, R4, R7, R8, R9 and X are as defined herein. 5 In some embodiments of compounds of Formula V(a) or V(b), Rm and

Rn are each hydrogen.

In some embodiments compounds of Formula V(a) or V(b), Rm and Rn are each halogen.

In some embodiments compounds of Formula V(a) or V(b), Rm and Rn 10 are each fluorine.

In some embodiments compounds of Formula V(a) or V(b), one of Rm and Rn is hydrogen and the other is halogen. In some embodiments of such compounds, the halogen and R7 are in a trans configuration with respect to one another on the cyclobutyl ring. In some embodiments of such 15 compounds, the halogen and R7 are in a cis configuration with respect to one another on the cyclobutyl ring.

In some embodiments compounds of Formula V(a) or V(b), one of Rm and Rn is hydrogen and the other is fluorine. In some embodiments of such compounds, the fluorine and R7 are in a trans configuration with respect to 20 one another on the cyclobutyl ring. In some embodiments of such compounds, the fluorine and R7 are in a cis configuration with respect to one another on the cyclobutyl ring.

In some embodiments of compounds of Formula I, II or III, R5 and R6, together with the carbon atom to which they are bound, form 3-6 membered 30 WO 2011/133888 PCT/US2011/033614 heterocycloalkyl, each of which is optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci-6 alkyl and C1-6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6, together with the carbon atom to which they are bound, form aziridine, azetidine, pyrrolidine, oxirane, oxetane or tetrahydrofuran, each of which is optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci.6 alkyl and Ci.6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6 are each independently C1-6 alkyl, or R5 and R6 together with the carbon atom to which they are bound form C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl, each optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, C1-6 alkyl and C-|.6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6 are each methyl, or R5 and R6 together with the carbon atom to which they are bound form C3-8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl or 3-8 membered heterocycloalkenyl, each optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, C1-6 alkyl and Ci.6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6 are each independently Ci_6 alkyl, or R5 and R6, together with the carbon to which they are bound, form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, each optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci.6 alkyl and Ci.6 haloalkyl.

In some embodiments of compounds of Formula I, II or III, R5 and R6 are each methyl, or R5 and R6, together with the carbon to which they are 31 WO 2011/133888 PCT/US2011/033614 bound, form cyclobutyl optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, S(O)Ra, SO2Ra, SO2NRbRc, Ci-6 alkyl and Ci-6 haloalkyl.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is selected from C3-8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, Ce-io aryl and 5-10 membered heteroaryl, each optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, OC(O)NRbRc, NRbRc, NRdC(O)Ra, NRdC(O)ORa, NRdC(O)NRbRc, NRdC(O)C(O)NRbRc, NRdC(S)Ra, NRdC(S)ORa, NRdC(S)NRbRc, NRdC(NRe)NRbRc, NRdS(O)Ra, NRdSO2Ra, NRdSO2NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, C(S)Ra, C(S)ORa, C(S)NRbRc, C(NRe)NRbRc, SRa, S(O)Ra, SO2Ra, SO2NRbRc, Ci-6 alkyl, Ci-6 haloalkyl, C2.6 alkenyl, C2.6 aikynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl, and 5-10 membered heteroaryl, wherein each of the Ci_6 alkyl, C2_6 alkenyl, C2_6 aikynyl, C3_8 cycloalkyl, C3_8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-10 aryl, C7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is phenyl optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, OC(O)NRbRc, NRbRc, NRdC(O)Ra, NRdC(O)ORa, NRdC(O)NRbRc, NRdC(O)C(O)NRbRc, NRdC(S)Ra, NRdC(S)ORa, NRdC(S)NRbRc, NRdC(NRe)NRbRc, NRdS(O)Ra, NRdSO2Ra, NRdSO2NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, C(S)Ra, C(S)ORa, C(S)NRbRc, C(NRe)NRbRc, SRa, S(O)Ra, SO2Ra, SO2NRbRc, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 aikynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7. 11 aralkyl, and 5-10 membered heteroaryl, wherein each of the Ci.6 alkyl, C2.6 alkenyl, C2-6 aikynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, Ce-ιο aryl, C7-n aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 32 WO 2011/133888 PCT/US2011/033614 or 5 Rf substituents.

In some embodiments, the compounds are of Formula VI, or a pharmaceutically acceptable salt thereof:

Formula VI wherein r is 0, 1,2, 3 or 4, and R1, R2, R3, R4, R5, R6, R8, R9, Rf, X and m are as defined herein.

In some embodiments, the compounds are of Formula Vll(a) or Vll(b), or a pharmaceutically acceptable salt thereof: R1

R1

33 WO 2011/133888 PCT/US2011/033614 wherein r is 0, 1,2, 3 or 4, and R1, R2, R3, R4, R8, R9, Rf and X are as defined herein.

In some embodiments, the compounds are of Formula Vlll(a) or Vlll(b), or a pharmaceutically acceptable salt thereof:

Formula Vlll(b) wherein Rm and Rn are each independently selected from hydrogen, halogen 10 and C-i-6 alkyl; r is 0, 1,2, 3 or 4; and R1, R2, R3, R4, R8, R9, Rf and X are as defined herein.

In some embodiments of compounds of Formula Vlll(a) or Vlll(b), Rm and Rn are each hydrogen.

In some embodiments compounds of Formula Vlll(a) or Vlll(b), Rm and 15 Rn are each halogen.

In some embodiments compounds of Formula VI11(a) or VI11(b), Rm and Rn are each fluorine. 34 WO 2011/133888 PCT/US2011/033614

In some embodiments compounds of Formula VI11(a) or Vlll(b), one of Rm and Rn is hydrogen and the other is halogen. In some embodiments of such compounds, the halogen and the phenyl ring are in a trans configuration with respect to one another on the cyclobutyl ring. In some embodiments of such compounds, the halogen and the phenyl ring are in a cis configuration with respect to one another on the cyclobutyl ring.

In some embodiments compounds of Formula VI11(a) or Vlll(b), one of Rm and Rn is hydrogen and the other is fluorine. In some embodiments of such compounds, the fluorine and the phenyl ring are in a trans configuration with respect to one another on the cyclobutyl ring. In some embodiments of such compounds, the fluorine and the phenyl ring are in a cis configuration with respect to one another on the cyclobutyl ring.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is selected from phenyl, 2-fluorophenyl, 3-fluorophenyl, 2, 4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2, 4-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-methylphenyl, 3-methylphenyl, 2, 4-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2- (hydroxymethyl)phenyl, 3-(hydroxymethyl)phenyl, 4-(hydroxymethyl)phenyl, 2-(aminomethyl)phenyl, 3-(aminomethyl)phenyl, 4-(aminomethyl)phenyl, 2-phenol, 3-phenol, 4-phenol, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-difluoromethoxyphenyl, 3-difluoromethoxyphenyl, 4-difluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-benzamine, 3-benzamide, 4-benzamide, N-mehtyl-2-benzamine, N-methyl-3-benzamide, N-methyl-4-benzamide, N,N-dimethyl-2-benzamine, N,N-dimethyl-3-benzamide, and N,N-dimethyl-4-benzamide.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is 5-10 membered heteroaryl optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, OC(O)NRbRc, NRbRc, NRdC(O)Ra, NRdC(O)ORa, NRdC(O)NRbRc, NRdC(O)C(O)NRbRc, NRdC(S)Ra, NRdC(S)ORa, NRdC(S)NRbRc, NRdC(NRe)NRbRc, NRdS(O)Ra, NRdSO2Ra, NRdSO2NRbRc, C(O)Ra, C(O)ORa, 35 WO 2011/133888 PCT/US2011/033614 C(O)NRbRc, C(S)Ra, C(S)ORa, C(S)NRbRc, C(NRe)NRbRc, SRa, S(O)Ra, SO2Ra, SO2NRbRc, Ci-6 alkyl, Ci_6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, C3-8 cycloalkyl, C3-s cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, Ce-ιο aryl, C7-11 aralkyl, and 5-10 membered heteroaryl, wherein each of the C1-6 alkyl, C2_6 alkenyl, C2_6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is pyridyl optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, OC(O)NRbRc, NRbRc, NRdC(O)Ra, NRdC(O)ORa, NRdC(O)NRbRc, NRdC(O)C(O)NRbRc, NRdC(S)Ra, NRdC(S)ORa, NRdC(S)NRbRc, NRdC(NRe)NRbRc, NRdS(O)Ra, NRdSO2Ra, NRdSO2NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, C(S)Ra, C(S)ORa, C(S)NRbRc, C(NRe)NRbRc, SRa, S(O)Ra, SO2Ra, SO2NRbRc, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl, and 5-10 membered heteroaryl, wherein each of the Ci_6 alkyl, C2.6 alkenyl, C2_6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is selected from 2-pyridyl, 3-pyridyl and 4-pyridyl, each optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, ORa, OC(O)Ra, OC(O)ORa, OC(O)NRbRc, NRbRc, NRdC(O)Ra, NRdC(O)ORa, NRdC(O)NRbRc, NRdC(O)C(O)NRbRc, NRdC(S)Ra, NRdC(S)ORa, NRdC(S)NRbRc, NRdC(NRe)NRbRc, NRdS(O)Ra, NRdSO2Ra, NRdSO2NRbRc, C(O)Ra, C(O)ORa, C(O)NRbRc, C(S)Ra, C(S)ORa, C(S)NRbRc, C(NRe)NRbRc, SRa, S(O)Ra, SO2Ra, SO2NRbRc, Ci.6 alkyl, Ci.6 haloalkyl, C2.6 alkenyl, C2-6 alkynyl, C3.6 cycloalkyl, C3.6 cycloalkenyl, 3-6 membered heterocycloalkyl, 3-6 membered heterocycloalkenyl, phenyl, naphthyl, C7-11 aralkyl, and 5-10 membered heteroaryl, wherein each of the Ci_6 alkyl, C2.6 36 WO 2011/133888 PCT/US2011/033614 alkenyl, C2-6 alkynyl, C3.8 cycloalkyl, C3.8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-io aryl, C7-11 aralkyl and 5-10 membered heteroaryl groups is optionally substituted with 1, 2, 3, 4 or 5 Rf substituents. 5 In some embodiments, the compounds are of Formula IX, or a pharmaceutically acceptable salt thereof:

Formula IX wherein r is 0, 1,2, 3 or 4, and R1, R2, R3, R4, R5, R6, R8, R9, Rf, X and m are 10 as defined herein.

In some embodiments, the compounds are of Formula X(a) or X(b), or a pharmaceutically acceptable salt thereof: R1

37 WO 2011/133888 PCT/US2011/033614 R1

Formula X(b) wherein r is 0, 1,2, 3 or 4, and R1, R2, R3, R4, R8, R9, Rf and X are as defined herein. 5 In some embodiments, the compounds are of Formula Xl(a) or Xl(b), or a pharmaceutically acceptable salt thereof:

10 Formula Xl(b) wherein Rm and Rn are each independently selected from hydrogen, halogen 38 WO 2011/133888 PCT/US2011/033614 and C-i-6 alkyl; r is 0, 1,2, 3 or 4; and R1, R2, R3, R4, R8, R9, Rf and X are as defined herein.

In some embodiments of compounds of Formula Xl(a) or Xl(b), Rm and Rn are each hydrogen.

In some embodiments compounds of Formula Xl(a) or Xl(b), Rm and Rn are each halogen.

In some embodiments compounds of Formula Xl(a) or Xl(b), Rm and Rn are each fluorine.

In some embodiments compounds of Formula Xl(a) or Xl(b), one of Rm and Rn is hydrogen and the other is halogen. In some embodiments of such compounds, the halogen and the pyridyl ring are in a trans configuration with respect to one another on the cyclobutyl ring. In some embodiments of such compounds, the halogen and the pyridyl ring are in a cis configuration with respect to one another on the cyclobutyl ring.

In some embodiments compounds of Formula Xl(a) or Xl(b), one of Rm and Rn is hydrogen and the other is fluorine. In some embodiments of such compounds, the fluorine and the pyridyl ring are in a trans configuration with respect to one another on the cyclobutyl ring. In some embodiments of such compounds, the fluorine and the pyridyl ring are in a cis configuration with respect to one another on the cyclobutyl ring.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is selected from pyrid-2-yl, 3-fluoro-pyrid-2-yl, 4-fluoro-pyrid-2-yl, 5-fluoro-pyrid-2-yl, 6-fluoro-pyrid-2-yl, 3-chloro-pyrid-2-yl, 4-chloro-pyrid-2-yl, 5-chloro-pyrid-2-yl, 6-chloro-pyrid-2-yl, 3-cyano-pyrid-2-yl, 4-cyano-pyrid-2-yl, 5-cyano-pyrid-2-yl, 6-cyano-pyrid-2-yl, 3-methyl-pyrid-2-yl, 4-methyl-pyrid- 2-yl, 5-methyl-pyrid-2-yl, 6-methyl-pyrid-2-yl, 3-difluoromethyl-pyrid-2-yl, 4-difluoromethyl-pyrid-2-yl, 5-difluoromethyl-pyrid-2-yl, 6-difluoromethyl-pyrid- 2-yl, 3-trifluoromethyl-pyrid-2-yl, 4-trifluoromethyl-pyrid-2-yl, 5-trifluoromethyl-pyrid-2-yl, 6-trifluoromethyl-pyrid-2-yl, 3-hydroxymethyl-pyrid-2-yl, 4- hydroxymethyl-pyrid-2-yl, 5-hydroxymethyl-pyrid-2-yl, 6-hydroxymethyl-pyrid-2-yl, 3-aminomethyl-pyrid-2-yl, 4-aminomethyl-pyrid-2-yl, 5- aminomethyl-pyrid-2-yl, 6-aminomethyl-pyrid-2-yl, 3-hydroxy-pyrid-2-yl, 39 WO 2011/133888 PCT/US2011/033614 4-hydroxy-pyrid-2-yl, 5-hydroxy-pyrid-2-yl, 6-hydroxy-pyrid-2-yl, 3-methoxy-pyrid-2-yl, 4-methoxy-pyrid-2-yl, 5-methoxy-pyrid-2-yl, 6-methoxy-pyrid-2-yl, 3- difluoromethoxy-pyrid-2-yl, 4-difluoromethoxy-pyrid-2-yl, 5-difluoromethoxy-pyrid-2-yl, 6-difluoromethoxy-pyrid-2-yl, 3-trifluoromethoxy-pyrid-2-yl, 4- trifluoromethoxy-pyrid-2-yl, 5-trifluoromethoxy-pyrid-2-yl, 6-trifluoromethoxy-pyrid-2-yl, 3-methylthio-pyrid-2-yl, 4-methylthio-pyrid-2-yl, 5-methylthio-pyrid- 2- yl, 6-methylthio-pyrid-2-yl, 3-carboxamide-pyrid-2-yl, 4-carboxamide-pyrid-2-yl, 5- carboxamide-pyrid-2-yl, 6- carboxamide-pyrid-2-yl and 3-fluoro-6-methyl-pyrid-2-yl.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a) or V(b), R7 is selected from pyrid-3-yl, 2-fluoro-pyrid-3-yl, 4-fluoro-pyrid-3-yl, 5-fluoro-pyrid-3-yl, 6-fluoro-pyrid-3-yl, 2-chloro-pyrid-3-yl, 4-chloro-pyrid-3-yl, 5-chloro-pyrid-3-yl, 6-chloro-pyrid-3-yl, 2-cyano-pyrid-3-yl, 4-cyano-pyrid-3-yl, 5-cyano-pyrid-3-yl, 6-cyano-pyrid-3-yl, 2-methyl-pyrid-3-yl, 4-methyl-pyrid- 3- yl, 5-methyl-pyrid-3-yl, 6-methyl-pyrid-3-yl, 2-difluoromethyl-pyrid-3-yl, 4- difluoromethyl-pyrid-3-yl, 5-difluoromethyl-pyrid-3-yl, 6-difluoromethyl-pyrid- 3- yl, 2-trifluoromethyl-pyrid-3-yl, 4-trifluoromethyl-pyrid-3-yl, 5-trifluoromethyl-pyrid-3-yl, 6-trifluoromethyl-pyrid-3-yl, 2-hydroxymethyl-pyrid-3-yl, 4- hydroxymethyl-pyrid-3-yl, 5-hydroxymethyl-pyrid-3-yl, 6-hydroxymethyl-pyrid-3-yl, 2-aminomethyl-pyrid-3-yl, 4-aminomethyl-pyrid-3-yl, 5- aminomethyl-pyrid-3-yl, 6-aminomethyl-pyrid-3-yl, 2-hydroxy-pyrid-3-yl, 4-hydroxy-pyrid-3-yl, 5-hydroxy-pyrid-3-yl, 6-hydroxy-pyrid-3-yl, 2-methoxy-pyrid-3-yl, 4-methoxy-pyrid-3-yl, 5-methoxy-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 2- difluoromethoxy-pyrid-3-yl, 4-difluoromethoxy-pyrid-3-yl, 5-difluoromethoxy-pyrid-3-yl, 6-difluoromethoxy-pyrid-3-yl, 2-trifluoromethoxy-pyrid-3-yl, 4-trifluoromethoxy-pyrid-3-yl, 5-trifluoromethoxy-pyrid-3-yl, 6-trifluoromethoxy-pyrid-3-yl, 2-methylthio-pyrid-3-yl, 4-methylthio-pyrid-3-yl, 5-methylthio-pyrid- 3- yl, 6-methylthio-pyrid-3-yl, 2-carboxamide-pyrid-3-yl, 4-carboxamide-pyrid-3-yl, 5- carboxamide-pyrid-3-yl and 6- carboxamide-pyrid-3-yl.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is selected from a bond, -(CH2)P-, -(CH2)pO(CH2)q-, -(CH2)pC(O)(CH2)q-, -(CH2)pS(CH2)q-, -(CH2)pNRd(CH2)q-, -(CH2)pC(O)O(CH2)q-, 40 WO 2011/133888 PCT/US2011/033614 -(CH2)pOC(O)(CH2)q-, -(CH2)pNRdC(O)(CH2)q-, -(CH2)pC(O)NRd(CH2)q-, -(CH2)pNRdC(O)NRd(CH2)q-, -(CH2)pNRdSO2(CH2)q-, and -(CH2)pSO2NRd(CH2)q-.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), 5 V(a), V(b), VI, Vll(a), Vll(b), VI 11(a), VI 11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is a bond.

In some embodiments, the compound is of Formula XI 1(a), XI 1(b),

Xll(c), Xll(d), Xll(e), Xll(f), Xll(g), Xll(h), Xll(i), Xll(j), Xll(k), Xll(l), Xll(m), Xll(n) or Xll(o), or a pharmaceutically acceptable salt thereof: 10 R1

Formula Xll(a) R1

R4

Formula Xll(b) 41 WO 2011/133888 PCT/US2011/033614

Formula XI 1(e) 42 WO 2011/133888 PCT/US2011/033614

Formula XI 1(f) R1

43 WO 2011/133888 PCT/US2011/033614

R1

Formula Xll(k) 44 WO 2011/133888 PCT/US2011/033614

R1

45 WO 2011/133888 PCT/US2011/033614

Formula Xll(o) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, Rf, Rm, Rn, m and r are as defined herein. 5 In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a) or Xl(b), X is -O-.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a) or Xl(b), X is 10 selected from -CH2O- and -OCH2-.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is -NRd-.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), 15 V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is selected from -CH2NRd- and -NRdCH2-.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is sleeted from -NRdC(O)- and -C(O)NRd-. 20 In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is sleeted from -CH2NRdC(O)- and -C(O)NRdCH2-.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), 46 WO 2011/133888 PCT/US2011/033614 V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a), Xl(b), Xll(a), Xll(b), Xll(c), Xll(d), Xll(e), Xll(f), Xll(g), Xll(h), Xll(i), Xll(j), Xll(k), Xll(l), Xll(m), Xll(n) orXII(o), R2 is selected from C3-8 cycloalkyl, C3-8 cycloalkenyl, 3-8 membered heterocycloalkyl, 3-8 membered heterocycloalkenyl, C6-10 aryl and 5-10 membered heteroaryl, each optionally substituted with 1,2, 3, 4 or 5 substituents selected from halogen, CN, oxo, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NRe)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, C^e alkyl, C^e haloalkyl, C2.6 alkenyl, C2.6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl, wherein each of the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a), Xl(b), Xll(a), Xll(b), Xll(c), Xll(d), Xll(e), Xll(f), Xll(g), Xll(h), Xll(i), Xll(j), Xll(k), Xll(l), Xll(m), Xll(n) orXII(o), R2 is phenyl substituted with (CH2)nNRdC(O)Ra, wherein Ra is Ci_6 alkyl or 3-8 membered heterocycloalkyl, each optionally substituted with 1,2 or 3 substituents selected from halogen, CN, oxo, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NR®)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, Ci-θ alkyl, Ci-θ haloalkyl, C2.6 alkenyl, C2.6 alkynyl, (CH2)nC3. s cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl; and optionally substituted with 1, 2 or 3 additional substituents selected from halogen, CN, 50 WO 2011/133888 PCT/US2011/033614 (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NRe)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, Ci-6 alkyl, Ci-6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, (CH2)nC3-s cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl, wherein each of the Ci_ 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a), Xl(b), Xll(a), Xll(b), Xll(c), Xll(d), Xll(e), Xll(f), Xll(g), Xll(h), Xll(i), Xll(j), Xll(k), Xll(l), Xll(m), Xll(n) orXII(o), R2 is phenyl substituted with (CH2)nNRdC(O)Ra, wherein Ra is selected from Ci_6 alkyl, Ci_6 alkyl-OH and Ci_6 alkyl-NH2, each optionally substituted with 1,2 or 3 substituents selected from halogen, CN, oxo, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, Ci-e alkyl, Ci_6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, and (CH2)n5-10 membered heteroaryl; and optionally substituted with 1,2 or 3 additional substituents selected from halogen, CN, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NRe)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, 51 WO 2011/133888 PCT/US2011/033614 (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, Ci.6 alkyl, Ci.6 haloalkyl, C2.6 alkenyl, C2.6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl, wherein each of the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a), Xl(b), Xll(a), Xll(b), Xll(c), Xll(d), Xll(e), Xll(f), Xll(g), Xll(h), Xll(i), Xll(j), Xll(k), Xll(l), Xll(m), Xll(n) orXII(o), R2 is selected from pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, triazolyl and tetrazolyl, each optionally substituted with a substituent selected from (CH2)nC(O)ORa and (CH2)nC(O)NRbRc; and optionally substituted with 1,2 or 3 additional substituents selected from halogen, CN, oxo, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NRe)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, 53 WO 2011/133888 PCT/US2011/033614 (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, Ci_6 alkyl, Ci_6 haloalkyl, C2-6 alkenyl, C2-6 aikynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl, wherein each of the Ci.6 alkyl, C2.6 alkenyl, C2.6 aikynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), 54 WO 2011/133888 PCT/US2011/033614 V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a), Xl(b), Xll(a), Xll(b), Xll(c), Xll(d), Xll(e), Xll(f), Xll(g), Xll(h), Xll(i), Xll(j), Xll(k), Xll(l), Xll(m), Xll(n) orXII(o), R2 is selected from pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, triazolyl and tetrazolyl, each optionally substituted with (CH2)nNRdC(O)Ra, wherein Ra is Ci.6 alkyl or 3-8 membered heterocycloalkyl, each optionally substituted with 1,2 or 3 substituents selected from halogen, CN, oxo, (CH2)nORa, (CH2)nOC(O)Ra, (CH2)nOC(O)ORa, (CH2)nOC(O)NRbRc, (CH2)nNRbRc, (CH2)nNRdC(O)Ra, (CH2)nNRdC(O)ORa, (CH2)nNRdC(O)NRbRc, (CH2)nNRdC(O)C(O)NRbRc, (CH2)nNRdC(S)Ra, (CH2)nNRdC(S)ORa, (CH2)nNRdC(S)NRbRc, (CH2)nNRdC(NRe)NRbRc, (CH2)nNRdS(O)Ra, (CH2)nNRdSO2Ra, (CH2)nNRdSO2NRbRc, (CH2)nC(O)Ra, (CH2)nC(O)ORa, (CH2)nC(O)NRbRc, (CH2)nC(S)Ra, (CH2)nC(S)ORa, (CH2)nC(S)NRbRc, (CH2)nC(NRe)NRbRc, (CH2)nSRa, (CH2)nS(O)Ra, (CH2)nSO2Ra, (CH2)nSO2NRbRc, Ci.6 alkyl, Ci.6 haloalkyl, C2_6 alkenyl, C2_6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl, wherein each of the Ci_6 alkyl, C2.6 alkenyl, C2.6 alkynyl, (CH2)nC3-8 cycloalkyl, (CH2)n3-8 membered heterocycloalkyl, (CH2)nphenyl, (CH2)nnaphthyl and (CH2)n5-10 membered heteroaryl groups is optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a) or Xl(b), R2 is NRbRc, wherein Rb and Rc are as defined herein.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a) or Xl(b), R2 is NRbRc, wherein one of Rb and Rc is hydrogen and the other is Ci-θ alkyl optionally substituted with 1,2, 3, 4 or 5 Rf substituents. 58 WO 2011/133888 PCT/US2011/033614

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is -C(O)- and R2 is NRbRc, wherein Rb and Rc are as defined herein.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), 5 V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is -C(O)- and R2 is NRbRc, wherein one of Rb and Rc is hydrogen and the other is Ci-e alkyl optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, Vll(a), Vll(b), Vlll(a), Vlll(b), IX, X(a), X(b), Xl(a) or Xl(b), X is 10 -(CH2)P- and R2 is NRbRc, wherein Rb and Rc are as defined herein.

In some embodiments of compounds of Formula I, II, III, IV(a), IV(b), V(a), V(b), VI, VI 1(a), VI 1(b), VI11(a), VI11(b), IX, X(a), X(b), Xl(a) or Xl(b), X is -(CH2)P- and R2 is NRbRc, wherein one of Rb and Rc is hydrogen and the other is Ci-6 alkyl optionally substituted with 1,2, 3, 4 or 5 Rf substituents. 15 In some embodiments, X, R2 and R3, together with the carbon atoms to which they are bound, form a 5-6 membered ring optionally containing one or more heteroatoms selected from oxygen nitrogen and sulfur, and optioanlly containing one or more double bonds, and optionally substituted with 1,2, 3, 4 or 5 Rf substituents. 20 In some embodiments, the compound is of Formula XIII, or a pharmaceutically acceptable salt thereof:

Formula XIII wherein A is a 5 or 6 membered ring optionally containing one or more 25 heteroatoms selected from oxygen nitrogen and sulfur, and optionally 59 WO 2011/133888 PCT/US2011/033614 containing one or more double bonds; t is 0, 1, 2, 3 or 4; and R1, R4, R5, R6, R7, R8, R9, Rf and m are as defined herein.

In some embodiments of compounds of Formula XIII, ring A together with the pyrimidine ring to which it is bound form a group selected from quinazoline, pyrido[2,3-d]pyrimidine, pyrido[3,4-d]pyrimidine, pyrido[4,3-djpyrimidine, pyrido[3,2-d]pyrimidine, 5,6,7,8-tetrahydroquinazoline, 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, 5,6,7,8-tetrahydropyrido[3,2-djpyrimidine, thieno[3,2-d]pyrimidine, thiazolo[4,5-d]pyrimidine, 5H-pyrrolo[3,2-d]pyrimidine, 7H-purine, thieno[2,3-d]pyrimidine, thiazolo[5,4-djpyrimidine, 7H-pyrrolo[2,3-d]pyrimidine, 9H-purine, 1 H-pyrazolo[4,3-djpyrim id ine, 1 H-pyrazolo[3,4-d]pyrimidine, 1 H-[1,2,3]triazolo[4,5-d]pyrim id ine, 3H-[1,2,3]triazolo[4,5-d]pyrimidine, 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine, 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine, 6,7-dihydro-5H-pyrrolo[3,2-djpyrimidine and 6,7-dihydro-5H-cyclopenta[d]pyrimidine, each optionally substituted with 1,2, 3, 4 or 5 Rf substituents.

In some embodiments of compounds of Formula XIII, Ring A together with the pyrimidine ring to which it is bound form a group selected from quinazoline, 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine, 1 H-pyrazolo[3,4-d]pyrimidine, thieno[2,3-djpyrimidine and thiazolo[5,4-d]pyrimidine, each optionally substituted with 1, 2, 3, 4 or 5 Rf substituents.

Xll(n) orXII(o), R1 and R3 are each hydrogen.

In some embodiments of compounds of Formula I, III, IV(b), V(b), VI, Vll(b), Vlll(b), IX, X(b), Xl(b), Xll(a), Xll(c), Xll(e), Xll(f), Xll(h), Xll(j), Xll(k), Xll(m), Xll(o) or XIII, R8 and R9, at each occurrence, are each independently selected from hydrogen, halogen and Ci_6 alkyl.

In some embodiments, the compound is selected from the compounds in Table 2, or a pharmaceutically acceptable salt thereof.

The compounds and compositions described and/or disclosed herein modulate the contractility of the skeletal sarcomere. Specifically, the compounds modulate the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof.

As used in this context, "modulate" means either increasing or decreasing activity. In some instances, the compounds described and/or disclosed herein potentiate (i.e., increase activity) of one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and 62 WO 2011/133888 PCT/US2011/033614 isoforms thereof. In other instances, the compounds described and/or disclosed herein inhibit (i.e., decrease activity) of one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof.

In both preclinical and clinical settings, activators of the fast skeletal troponin complex have been shown to amplify the response of fast skeletal muscle to nerve stimulation, resulting in an increase in muscle force development at sub-maximal muscle activation (see, e.g., Russell et al., “The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force in vitro and in situ", 2009 Experimental Biology Conference, New Orleans, LA, April 2009). Activators of the fast skeletal troponin complex have been shown to increase the sensitivity of skinned skeletal muscle fibers to calcium, and in living muscle to the frequency of stimulation, each of which results in an increase in muscle force development at sub-maximal muscle activation. Such activators have also been shown to reduce muscle fatigue and/or to increase the overall time to fatigue in normal and low oxygenated conditions (see, e.g., Russell et al., “The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force and Reduces Muscle Fatigue in vitro and in situ”, 5th Cachexia Conference, Barcelona, Spain, December 2009; Hinken etal., “The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency”, Society for Vascular Medicine’s 2010 Annual Meeting: 21st Annual Scientific Sessions, Cleveland, OH, April 2010). The increase in muscle force in response to nerve input has been demonstrated in healthy human volunteers as well (see, e.g., Hansen et al., “CK-2017357, a Novel Activator of Fast Skeletal Muscle, Increases Isometric Force Evoked by Electrical Stimulation of the Anterior Tibialis Muscle in Healthy Male Subjects”, Society for Neuroscience 40th Annual Meeting: Neuroscience 2010, November 2010). Work in additional preclinical models of muscle function suggests that activators of the fast skeletal troponin complex also cause an increase in muscle power and/or endurance. These pharmacological properties suggest this mechanism of action could have application in conditions, for example, where neuromuscular function is impaired. 63 WO 2011/133888 PCT/US2011/033614

Provided are methods for enhancing fast skeletal muscle efficiency in a patient in need thereof, comprising administering to said patient an effective amount of a compound or composition described and/or disclosed herein that selectively binds the troponin complex of fast skeletal muscle fiber or sarcomere. In some embodiments, the compound disclosed and/or described herein activates fast skeletal muscle fibers or sarcomeres. In some embodiments, administration of a compound disclosed and/or described herein results in an increase in fast skeletal muscle power output. In some embodiments, administration of a compound disclosed and/or described herein results in increased sensitivity of fast skeletal muscle fibers or sarcomeres to calcium ion, as compared to fast skeletal muscle fibers or sarcomeres untreated with the compound. In some embodiments, administration of a compound disclosed and/or described herein results in a lower concentration of calcium ions causing fast skeletal muscle myosin to bind to actin. In some embodiments, administration of a compound disclosed and/or described herein results in the fast skeletal muscle fiber generating force to a greater extent at submaximal levels of muscle activation.

Also provided is a method for sensitizing a fast skeletal muscle fiber to produce force in response to a lower concentration of calcium ion, comprising contacting the fast skeletal muscle fiber with a compound or composition described and/or disclosed herein that selectively binds to troponin complexes in the fast skeletal muscle sarcomere. In some embodiments, contacting the fast skeletal muscle fiber with the compound results in activation of the fast skeletal muscle fiber at a lower calcium ion concentration than in an untreated fast skeletal muscle fiber. In some embodiments, contacting the fast skeletal muscle fiber with the compound results in the production of increased force at a lower calcium ion concentration in comparison with an untreated fast skeletal muscle fiber.

Also provided is a method for increasing time to fast skeletal muscle fatigue in a patient in need thereof, comprising contacting fast skeletal muscle fibers with a compound or composition described and/or disclosed herein that selectively binds to the troponin complexes of the fast skeletal muscle fibers.

In some embodiments, the compound binds to form ligand-troponin-calcium ion complexes that activate the fast skeletal muscle fibers. In some 64 WO 2011/133888 PCT/US2011/033614 embodiments, formation of the complexes and/or activation of the fast skeletal muscle fibers results in enhanced force and/or increased time to fatigue as compared to untreated fast skeletal muscle fibers contacted with a similar calcium ion concentration.

The compounds and pharmaceutical compositions described and/or disclosed herein are capable of modulating the contractility of the fast skeletal sarcomere in vivo, and can have application in both human and animal disease. Modulation would be desirable in a number of conditions or diseases, including, but not limited to, 1) neuromuscular disorders, such as Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), peripheral neuropathies and myasthenia gravis; 2) disorders of voluntary muscle, including muscular dystrophies, myopathies and conditions of muscle wasting, such as sarcopenia and cachexia syndromes (e.g., cachexia syndromes caused by diseases such as cancer, heart failure, chronic obstructive pulmonary disease (COPD), and chronic kidney disease/dialysis), and rehabilitation-related deficits, such as those associated with recovery from surgery (e.g. post-surgical muscle weakness) prolonged bed rest or stroke rehabilitation; 3) central nervous system (CNS) disorders in which muscle weakness, atrophy and fatigue are prominent symptoms, such as multiple sclerosis, Parkinson’s disease, stroke and spinal cord injury; and 4) muscle symptoms stemming from systemic disorders, including Peripheral Vascular Disease (PVD) or Peripheral Arterial Disease (PAD) (e.g., claudication), metabolic syndrome, chronic fatigue syndrome, obesity and frailty due to aging.

The compounds and compositions described and/or disclosed herein may be used to treat neuromuscular diseases, i.e., diseases that affect any part of the nerve-muscle unit. Neuromuscular diseases include, for example: 1) diseases of the motor unit, including but not limited to Amyotrophic Lateral Sclerosis (ALS) including bulbar and primary lateral sclerosis (PLS) variants; spinal muscular atrophy types 1-4; Kennedy syndrome; post-polio syndrome; motor neuropathies including, for example, critical illness polyneuropathy; multifocal motor neuropathy with conduction block; Charcot-Marie-Tooth disease and other hereditary motor and sensory neuropathies; and Guillain-Barre Syndrome, 2) disorders of the neuromuscular junction, including 65 WO 2011/133888 PCT/US2011/033614 myasthenia gravis, Lambert-Eaton myasthenic syndrome, and prolonged neuromuscular blockade due to drugs or toxins; and 3) peripheral neuropathies, such as acute inflammatory demyelinating polyradiculoneuropathy, diabetic neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, traumatic peripheral nerve lesions, neuropathy of leprosy,vasculitic neuropathy, dermatomyositis/polymyositis and neuropathy of Friedreich Ataxia.

The compounds and compositions described and/or disclosed herein may be used to treat disorders of voluntary muscle. Disorders of voluntary muscle include 1) muscular dystrophies (including, for example, Duchenne, Becker, Limb-Girdle, Facioscapulohumeral, limb girdle, Emery-Dreyfus, oculopharyngeal and congenital muscular dystrophies); and 2) myopathies, such as nemaline myopathy, central core disease, congenital myopathies, mitochondrial myopathies, acute myopathy; inflammatory myopathies (such as dermatomyositis/polymyositis and inclusion body myositis), endocrine myopathies (such as those associated with hyper- or hypothyroidism), Cushing’s or Addison’s syndrome or disease and pituitary gland disorders, metabolic myopathies (such as glycogen storage diseases, e.g., McArdle’s disease, Pompe disese, etc), drug-induced myopathy (statins, ant-retroviral drugs, steroid myopathy) restrictive lung disease, sarcoidosis, Schwartz-Jampel Syndrome, focal muscular atrophies, and distal myopathies.

The compounds and compositions described and/or disclosed herein may be used to treat or Amyotrophic Lateral Sclerosis (ALS). ALS is a disease that generally arises later in life (Age 50+) and has a rapid progression from initial limb weakness to paralysis and death. Common life expectancy after diagnosis is 3-5 years. The cause of disease for most ALS patients is unknown (termed the spontaneous form) while a small proportion of patients have an inherited form (familial) of disease. The condition causes progressive death of motor neurons through causes that are not clear. Surviving motor units attempt to compensate for dying ones by innervating more fibers (termed sprouting) but this can only partially correct muscle function, as muscles are subsequently more prone to problems of coordination and fatigue. Eventually, surviving motor neurons die, resulting in complete paralysis of the affected muscle. The disease is commonly fatal 66 WO 2011/133888 PCT/US2011/033614 through the eventual loss of innervation to the diaphragm, resulting in respiratory failure. Current treatment options for ALS are limited.

The compounds and compositions described and/or disclosed herein may be used to treat Spinal Muscular Atrophy (SMA). SMA is a genetic disorder that arises through the mutation of a protein, SMN1, that appears to be required for the survival and health of motor neurons. The disease is most common in children as the majority of patients only survive until 11-12 years of age. There is currently no available treatment for SMA.

The compounds and compositions described and/or disclosed herein may be used to treat myasthenia gravis. Myasthenia gravis is a chronic autoimmune neuromuscular disease wherein the body produces antibodies that block, alter, or destroy proteins involved in signaling at the neuromuscular junction, thus preventing muscle contraction from occurring. These proteins include nicotinic acetylcholine receptor (AChR) or, less frequently, a muscle-specific tyrosine kinase (MuSK) involved in AChR clustering (see, e.g., Drachman, N. Eng. J. of Med., 330:1797-1810, 1994). The disease is characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Although myasthenia gravis may affect any voluntary muscle, certain muscles, such as those that control eye and eyelid movement, facial expression, chewing, talking, and swallowing are often, but not always, involved in the disorder. The muscles that control breathing and neck and limb movements may also be affected. In most cases, the first noticeable symptom is weakness of the eye muscles. In others, difficulty in swallowing and slurred speech may be the first signs. The degree of muscle weakness involved in myasthenia gravis varies greatly among patients, ranging from a localized form, limited to eye muscles (ocular myasthenia), to a severe or generalized form in which many muscles - sometimes including those that control breathing - are affected. Symptoms, which vary in type and severity, may include a drooping of one or both eyelids (ptosis), blurred or double vision (diplopia) due to weakness of the muscles that control eye movements, unstable or waddling gait, weakness in arms, hands, fingers, legs, and neck, a change in facial expression, difficulty in swallowing and shortness of breath, 67 WO 2011/133888 PCT/US2011/033614 and impaired speech (dysarthria). Generalized weakness develops in approximately 85% of patients.

The compounds and compositions described and/or disclosed herein may be used to treat sarcopenia, e.g., sarcopenia associated with aging or disease (e.g. HIV infection). Sarcopenia is characterized by a loss of skeletal muscle mass, quality, and strength. Clinically, a decline in skeletal muscle tissue mass (muscle atrophy) contributes to frailty in older individuals. In human males, muscle mass declines by one-third between the ages of 50 and 80. In older adults, extended hospitalization can result in further disuse atrophy leading to a potential loss of the ability for independent living and to a cascade of physical decline. Moreover, the physical aging process profoundly affects body composition, including significant reductions in lean body mass and increases in central adiposity. The changes in overall adiposity and fat distribution appear to be important factors in many common age-related diseases such as hypertension, glucose intolerance and diabetes, dyslipidemia, and atherosclerotic cardiovascular disease. In addition, it is possible that the age-associated decrement in muscle mass, and subsequently in strength and endurance, may be a critical determinant for functional loss, dependence and disability. Muscle weakness is also a major factor prediposing the elderly to falls and the resulting morbidity and mortality.

The compounds and compositions described and/or disclosed herein may be used to treat cachexia. Cachexia is a state often associated with cancer or other serious diseases or conditions, (e.g, chronic obstructive pulmonary disease, heart failure, chronic kidney disease, kidney dialysis), that is characterized by progressive weight loss, muscle atrophy and fatigue, due to the deletion of adipose tissue and skeletal muscle.

The compounds and compositions described and/or disclosed herein may be used to treat muscular dystrophies. Muscular dystrophy can be characterized by progressive muscle weakness, destruction and regeneration of the muscle fibers, and eventual replacement of the muscle fibers by fibrous and fatty connective tissue.

The compounds and compositions described and/or disclosed herein may be used to treat post-surgical muscle weakness, which is a reduction in the strength of one or more muscles following surgical procedure. Weakness 68 WO 2011/133888 PCT/US2011/033614 may be generalized (i.e. total body weakness) or localized to a specific area, side of the body, limb, or muscle.

The compounds and compositions described and/or disclosed herein may be used to treat post-traumatic muscle weakness, which is a reduction in the strength of one or more muscles following a traumatic episode (e.g. bodily injury). Weakness may be generalized (i.e. total body weakness) or localized to a specific area, side of the body, limb, or muscle.

The compounds and compositions described and/or disclosed herein may be used to treat muscle weakness and fatigue produced by peripheral vascular disease (PVD) or peripheral artery disease (PAD). Peripheral vascular disease is a disease or disorder of the circulatory system outside of the brain and heart. Peripheral artery disease (PAD), also known as peripheral artery occlusive disease (PAOD), is a form of PVD in which there is partial or total blockage of an artery, usually one leading to a leg or arm. PVD and/or PAD can result from, for example, atherosclerosis, inflammatory processes leading to stenosis, embolus/ thrombus formation, or damage to blood vessels due to disease (e.g., diabetes), infection or injury. PVD and/or PAD can cause either acute or chronic ischemia, typically of the legs. The symptoms of PVD and/or PAD include pain, weakness, numbness, or cramping in muscles due to decreased blood flow (claudication), muscle pain, ache, cramp, numbness or fatigue that occurs during exercise and is relieved by a short period of rest (intermittent claudication), pain while resting (rest pain) and biological tissue loss (gangrene). The symptoms of PVD and/or PAD often occur in calf muscles, but symptoms may also be observed in other muscles such as the thigh or hip. Risk factors for PVD and/or PAD include age, obesity, sedentary lifestyle, smoking, diabetes, high blood pressure, and high cholesterol (i.e., high LDL, and/or high triglycerides and/or low HDL). People who have coronary heart disease or a history of heart attack or stroke generally also have an increased frequency of having PVD and/or PAD. Activators of the fast skeletal troponin complex have been shown to reduce muscle fatigue and/or to increase the overall time to fatigue in in vitro and in situ models of vascular insufficiency (see, e.g., Russell et al., “The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force and Reduces Muscle Fatigue in vitro and in situ”, 5th Cachexia Conference, 69 WO 2011/133888 PCT/US2011/033614

Barcelona, Spain, December 2009; Hinken et al., “The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency”, Society for Vascular Medicine’s 2010 Annual Meeting: 21st Annual Scientific Sessions, Cleveland, OH, April 2010).

The compounds and compositions described and/or disclosed herein may be used to treat symptoms of frailty, e.g., frailty associated with aging. Frailty is characterized by one or more of unintentional weight loss, muscle weakness, slow walking speed, exhaustion, and low physical activity.

The compounds and compositions described and/or disclosed herein may be used to treat muscle weakness and/or fatigue due to wasting syndrome, which is a condition characterized by involuntary weight loss associated with chronic fever and diarrhea. In some instances, patients with wasting syndrome lose 10% of baseline body weight within one month.

The compounds and compositions described and/or disclosed herein may be used to treat muscular diseases and conditions caused by structural and/or functional abnormalities of skeletal muscle tissue, including muscular dystrophies, congenital muscular dystrophies, congenital myopathies, distal myopathies, other myopathies (e.g., myofibrillar, inclusion body), myotonic syndromes, ion channel muscle diseases, malignant hyperthermias, metabolic myopathies, congenital myasthenic syndromes, sarcopenia, muscle atrophy and cachexia.

The compounds and compositions described and/or disclosed herein also may be used to treat diseases and conditions caused by muscle dysfunction originating from neuronal dysfunction or transmission, including amyotrophic lateral sclerosis, spinal muscular atrophies, hereditary ataxias, hereditary motor and sensory neuropathies, hereditary paraplegias, stroke, multiple sclerosis, brain injuries with motor deficits, spinal cord injuries, Alzheimer’s disease, Parkinson’s disease with motor deficits, myasthenia gravis and Lambert-Eaton syndrome.

The compounds and compositions described and/or disclosed herein also may be used to treat diseases and conditions caused by CNS, spinal cord or muscle dysfunction originating from endocrine and/or metabolic dysregulation, including claudication secondary to peripheral artery disease, hypothyroidism, hyper- or hypo-parathyroid ism, diabetes, adrenal dysfunction, 70 WO 2011/133888 PCT/US2011/033614 pituitary dysfunction and acid/base imbalances.

The compounds and compositions described and/or disclosed herein may be administered alone or in combination with other therapies and/or therapeutic agents useful in the treatment of the aforementioned disorders.

The compounds and compositions described and/or disclosed herein may be combined with one or more other therapies to treat ALS. Examples of suitable therapies include riluzole, baclofen, diazepam, trihexyphenidyl and amitriptyline. In some embodiments, the compounds and compositions described and/or disclosed herein are combined with riluzole to treat a subject suffering from ALS.

The compounds and compositions described and/or disclosed herein may be combined with one or more other therapies to treat myasthenia gravis. Examples of suitable therapies include administration of anticholinesterase agents (e.g., neostigmine, pyridostigmine), which help improve neuromuscular transmission and increase muscle strength; administration of immunosuppressive drugs (e.g., prednisone, cyclosporine, azathioprine, mycophenolate mofetil) which improve muscle strength by suppressing the production of abnormal antibodies; thymectomy (i.e., the surgical removal of the thymus gland, which often is abnormal in myasthenia gravis patients); plasmapheresis; and intravenous immune globulin.

The compounds and compositions described and/or disclosed herein may be combined with one or more other therapies to treat PVD or PAD (e.g., claudication). Treatment of PVD and PAD is generally directed to increasing arterial blood flow, such as by smoking cessation, controlling blood pressure, controlling diabetes, and exercising. Treatment can also include medication, such as medicines to help improve walking distance (e.g., cilostazol, pentoxifylline), antiplatelet agents (e.g., aspirin, ticlopidine, clopidogrel), anticoagulents (e.g., heparin, low molecular weight heparin, warfarin, enoxaparin) throbmolytics, antihypertensive agents (e.g., diuretics, ACE inhibitors, calcium channel blockers, beta blockers, angiotensin II receptor antagonists), and cholesterol-lowering agents (e.g., statins). In some patients, angioplasty, stenting, or surgery (e.g., bypass surgery or surgery to remove an atherosclerotic plaque) may be necessary.

Suitable therapeutic agents include, for example, anti-obesity agents, 71 WO 2011/133888 PCT/US2011/033614 anti-sarcopenia agents, anti-wasting syndrome agents, anti-frailty agents, anti-cachexia agents, anti-muscle spasm agents, agents against post-surgical and post-traumatic muscle weakness, and anti-neuromuscular disease agents.

Suitable additional therapeutic agents include, for example: orlistat, sibramine, diethylpropion, phentermine, benzaphetamine, phendimetrazine, estrogen, estradiol, levonorgestrel, norethindrone acetate, estradiol valerate, ethinyl estradiol, norgestimate, conjugated estrogens, esterified estrogens, medroxyprogesterone acetate, testosterone, insulin-derived growth factor, human growth hormone, riluzole, cannabidiol, prednisone, albuterol, nonsteroidal anti-inflammatory drugs, and botulinum toxin.

Other suitable therapeutic agents include TRH, diethylstilbesterol, theophylline, enkephalins, E series prostaglandins, compounds disclosed in U.S. Patent No. 3,239,345 (e.g., zeranol), compounds disclosed in U.S.

Patent No. 4,036,979 (e.g., sulbenox), peptides disclosed in U.S. Patent No. 4,411,890, growth hormone secretagogues such as GHRP-6, GHRP-1 (disclosed in U.S. Patent No. 4,411,890 and publications WO 89/07110 and WO 89/07111), GHRP-2 (disclosed in WO 93/04081), NN703 (Novo Nordisk), LY444711 (Lilly), MK-677 (Merck), CP424391 (Pfizer) and B-HT920, growth hormone releasing factor and its analogs, growth hormone and its analogs and somatomedins including IGF-1 and IGF-2, alpha-adrenergic agonists, such as clonidine or serotonin 5-HTD agonists, such as sumatriptan, agents which inhibit somatostatin or its release, such as physostigmine, pyridostigmine, parathyroid hormone, PTH(1-34), and bisphosphonates, such as MK-217 (alendronate).

Still other suitable therapeutic agents include estrogen, testosterone, selective estrogen receptor modulators, such as tamoxifen or raloxifene, other androgen receptor modulators, such as those disclosed in Edwards, J. P. et. al., Bio. Med. Chem. Let., 9, 1003-1008 (1999) and Hamann, L. G. et. al., J. Med. Chem., 42, 210-212 (1999), and progesterone receptor agonists ("PRA"), such as levonorgestrel, medroxyprogesterone acetate (MPA).

Other suitable therapeutic agents include anabolic agents, such as selective androgen receptor modulators (SARMs); antagonists of the activin receptor pathway, such as anti-myostatin antibodies or soluble activin 72 WO 2011/133888 PCT/US2011/033614 receptor decoys, including ACE-031 (Acceleron Pharmaceuticals, a soluble activin receptor type IIB antagonist), MYO-027/PFE-3446879 (Wyeth/Pfizer, an antibody myostatin inhibitor), AMG-745 (Amgen, a peptibody myostatin inhibitor), and an ActRIIB decoy receptor (see Zhou et al., Cell, 142, 531-543, August 20, 2010); and anabolic steroids.

Still other suitable therapeutic agents include aP2 inhibitors, such as those disclosed in U.S. Patent No. 6,548,529, PPAR gamma antagonists, PPAR delta agonists, beta 3 adrenergic agonists, such as AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer), other beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, a lipase inhibitor, such as orlistat or ATL-962 (Alizyme), a serotonin (and dopamine) reuptake inhibitor, such as sibutramine, topiramate (Johnson &amp; Johnson) or axokine (Regeneron), a thyroid receptor beta drug, such as a thyroid receptor ligand as disclosed in WO 97/21993, WO 99/00353, and GB98/284425, and anorectic agents, such as dexamphetamine, phentermine, phenylpropanolamine or mazindol.

Still other suitable therapeutic agents include HIV and AIDS therapies, such as indinavir sulfate, saquinavir, saquinavir mesylate, ritonavir, lamivudine, zidovudine, lamivudine/zidovudine combinations, zalcitabine, didanosine, stavudine, and megestrol acetate.

Still other suitable therapeutic agents include antiresorptive agents, hormone replacement therapies, vitamin D analogues, elemental calcium and calcium supplements, cathepsin K inhibitors, MMP inhibitors, vitronectin receptor antagonists, Src SH.sub.2 antagonists, vacuolar H+-ATPase inhibitors, ipriflavone, fluoride, Tibo lone, pro stanoids, 17-beta hydroxysteroid dehydrogenase inhibitors and Src kinase inhibitors.

The above therapeutic agents, when employed in combination with the compounds and compositions disclosed and/or described herein, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.

The compounds and compositions disclosed and/or described herein are administered at a therapeutically effective dosage, e.g., a dosage sufficient to provide treatment for the disease state. While human dosage 73 WO 2011/133888 PCT/US2011/033614 levels have yet to be optimized for the chemical entities described herein, generally, a daily dose ranges from about 0.05 to 100 mg/kg of body weight; in some embodiments, from about 0.10 to 10.0 mg/kg of body weight, and in some embodiments, from about 0.15 to 1.0 mg/kg of body weight. Thus, for administration to a 70 kg person, in some embodiments, the dosage range would be about from 3.5 to 7000 mg per day; in some embodiments, about from 7.0 to 700.0 mg per day, and in some embodiments, about from 10.0 to 100.0 mg per day. The amount of the chemical entity administered will be dependent, for example, on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. For example, an exemplary dosage range for oral administration is from about 70 mg to about 700 mg per day, and an exemplary intravenous administration dosage is from about 70 mg to about 700 mg per day, each depending upon the compound pharmacokinetics.

Administration of the compounds and compositions disclosed and/or described herein can be via any accepted mode of administration for therapeutic agents including, but not limited to, oral, sublingual, subcutaneous, parenteral, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, or intraocular administration. In some embodiments, the compound or composition is administered orally or intravenously. In some embodiments, the compound or composition disclosed and/or described herein is administered orally.

Pharmaceutically acceptable compositions include solid, semi-solid, liquid and aerosol dosage forms, such as tablet, capsule, powder, liquid, suspension, suppository, and aerosol forms. The compounds disclosed and/or described herein can also be administered in sustained or controlled release dosage forms (e.g., controlled/sustained release pill, depot injection, osmotic pump, or transdermal (including electrotransport) patch forms) for prolonged timed, and/or pulsed administration at a predetermined rate. In some embodiments, the compositions are provided in unit dosage forms suitable for single administration of a precise dose.

The compounds disclosed and/or described herein can be administered either alone or in combination with one or more conventional 74 WO 2011/133888 PCT/US2011/033614 pharmaceutical carriers or excipients (e.g., mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate). If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate). Generally, depending on the intended mode of administration, the pharmaceutical composition will contain about 0.005% to 95%, or about 0.5% to 50%, by weight of a compound disclosed and/or described herein. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.

In some embodiments, the compositions will take the form of a pill or tablet and thus the composition may contain, along with a compounds disclosed and/or described herein, one or more of a diluent (e.g., lactose, sucrose, dicalcium phosphate), a lubricant (e.g., magnesium stearate), and/or a binder (e.g., starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives). Other solid dosage forms include a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils or triglycerides) encapsulated in a gelatin capsule.

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing or suspending etc. a compound disclosed and/or described herein and optional pharmaceutical additives in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution or suspension. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to injection. The percentage of the compound contained in such parenteral compositions depends, for example, on the physical nature of the compound, the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and may be higher if the composition is a solid which will be subsequently diluted to another 75 WO 2011/133888 PCT/US2011/033614 concentration. In some embodiments, the composition will comprise from about 0.2 to 2% of a compound disclosed and/or described herein in solution.

Pharmaceutical compositions of the compounds disclosed and/or described herein may also be administered to the respiratory tract as an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the pharmaceutical composition may have diameters of less than 50 microns, or in some embodiments, less than 10 microns.

In addition, pharmaceutical compositions can include a compound disclosed and/or described herein and one or more additional medicinal agents, pharmaceutical agents, adjuvants, and the like. Suitable medicinal and pharmaceutical agents include those described herein.

The following examples serve to more fully describe the invention described herein. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes.

Bn (S)-4-Benzyl-3-(2-(4-fluorophenyl)acetyl)oxazolidin-2-one. To a cooled (-78 °C) solution of (S)-4-benzyloxazolidin-2-one (10 g, 58 mmol, 1.0 equiv) in 100 mL THF was added dropwise n-BuLi (40 mL, 1.6 M in hexanes, 64 mmol, 1.1 equiv). After stirring for 30 minutes, 4-fluorophenylacetyl chloride (10 g, 58 mmol, 1.0 equiv) was added dropwise. After stirring for an additional 30 minutes, the reaction mixture was allowed to warm to room temperature. The reaction was quenched with saturated aq. NH4CI, extracted with dichloromethane, and washed with brine. The organic layer was then dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel (10-20% EtOAc/hexanes) provided the title compound as a thick oil (14.7 g, 81%). 76 WO 2011/133888 PCT/US2011/033614 10

Bn (S)-4-Benzyl-3-((S)-2-(4-fluorophenyl)propanoyl)oxazolidin-2-one.

To a room-temperature solution of (S)-4-benzyl-3-(2-(4- fluorophenyl)acetyl)oxazolidin-2-one (5.1 g, 16.3 mmol, 1.0 equiv) in dry THF (100 mL) was added iodomethane (1.0 mL, 16.2 mmol, 1.0 equiv) by syringe. The resulting mixture was cooled to -78 °C, and NaHMDS (8.15 mL, 2M in THF, 16.3 mmol, 1.0 equiv) was added dropwise by syringe. After stirring for 15 minutes at -78 °C, the reaction mixture was allowed to warm to room temperature. The reaction was quenched with saturated, aq. NH4CI, and diluted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification by silica gel chromatography (7-20% EtOAc/hexanes) provided the title compound (2.6 g, 49%).

15 20 (S)-2-(4-Fluorophenyl)propan-1-ol. To a room-temperature solution of (S)-4-benzyl-3-((S)-2-(4-fluorophenyl) propanoyl)oxazolidin-2-one (1.8 g, 5.5 mmol, 1.0 equiv) in THF (18 mL) was added a solution of NaBH4 (1.0 g, 26.4 mmol, 4.8 equiv) in water (6.0 mL). The reaction mixture was stirred for 3 h at room temperature and then quenched by the careful addition of aq. 1 M HCI. The reaction mixture was diluted with water and ethyl acetate. The layers were separated and the organic layer was subsequently washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification by silica gel chromatography (10-75% EtOAc/Hexanes) provided the title compound (0.824 g, 97%). 25

(S)-2-(2-(4-Fluorophenyl)propyl)isoindoline-1,3-dione. To a solution 77 WO 2011/133888 PCT/US2011/033614 of (S)-2-(4-fluorophenyl)propan-1-ol (0.82 g, 5.35 mmol, 1.0 equiv), phthalimide (0.82 g, 5.6 mmol, 1.05 equiv), and triphenyl phosphine (2.1 g, 8.03 mmol, 1.5 equiv) in dry THF (18 mL) was added dropwise diethylazodicarboxylate (3.6 mL, 15% in toluene, 8.0 mmol, 1.5 equiv). The 5 reaction mixture was stirred over 72 h and then concentrated in vacuo.

Purification by silica gel chromatography (15 - 25% EtOAc/hexanes) provided the title compound (0.9 g, 59%).

10 (S)-2-(4-Fluorophenyl)propan-1-amine. To a room-temperature solution of (S)-2-(2-(4-fluorophenyl)propyl)isoindoline-1,3-dione (900 mg, 3.2 mmol, 1.0 equiv) in toluene (14 mL) was added hydrazine hydrate (1.4 mL, 45 mmol, 14 equiv) by syringe. The resulting mixture was heated to 80 °C for 30 minutes and then cooled to room temperature. The resulting solution was 15 decanted from the solid in the reaction mixture, and the solid was washed with additional toluene. The combined organic layers were combined and concentrated in vacuo to provide the title compound (491 mg, 99%), which was used without further purification. 20 Example 2: Preparation of 2-(4-Fluorophenyl)-2-methylpropan-1 -amine

To a solution of 4-fluorophenylacetonitrile (50 g, 370 mmol, 1.0 equiv) and iodomethane (70 mL, 1.1 mol, 3 equiv) in THF (370 mL) was added potassium f-butoxide (124 g, 1.1 mol, 3 equiv) as a solid in portions such that 25 the reaction mixture did not exceed 50 °C. The reaction mixture was stirred overnight and then quenched by the addition of brine. The mixture was diluted with EtOAc and washed twice with brine. The organic layer was dried over Na2SO4, filtered, and concentrated in vacuo to provide 2-(4-fluorophenyl)-2-methylpropanenitrile as a yellow oil (57 g, 94%), which was 78 WO 2011/133888 PCT/US2011/033614 used without further purification in the next step. To a solution of the nitrile in dry THF (800 mL) was added a solution of lithium aluminum hydride (210 mL, 2 M in ether, 420 mmol, 1.2 equiv). After the mixture was heated at reflux overnight, the reaction was allowed to cool to room temperature, and a Fieser 5 and Fieser work-up (300 uL water/mmol, 1.0 mL 3N NaOH/mmol, 300 uL water/mmol) was performed. Filtration of the resulting solids provided the title compound as an orange oil (57 g, 92%).

Example 3: Preparation of (1-(4-Fluorophenyl)cyclobutyl)methanamine

A solution of 4-fluorophenylacetonitrile (6.7 g, 75 mmol, 1.5 equiv), 1,3-dibromopropane (10 mL, 50 mmol, 1 equiv), KOH (10.2 g, 150 mmol, 3.0 equiv), and tetrabutylammonium bromide (100 mg) in toluene (135 mL) was heated to 100 °C for 3 hours. The organic layer was separated and 15 concentrated to dryness. Silica gel chromatography using a gradient of 0-30% EtOAc/hexanes resulted in partially purified product which was further purified by Kugelrohr distillation at 200 °C to provide 3.76 g (22 mmol) of the intermediate nitrile product as an oil. The residue was dissolved in dry THF (22 mL) and treated with a solution of lithium aluminum hydride (27 mL, 2 M in 20 ether, 55 mmol, 2.5 equiv). The mixture was stirred at 0 °C for 2 hours followed by a Fieser and Fieser work-up (38 uL water/mmol, 118 uL 3N NaOH/mmol, 38 uL water/mmol). The organic layer was concentrated to dryness to provide the desired product (3.6 g, 40% overall) as a yellow oil. 25 Example 4: Preparation of (1-(6-Methoxypyridin-2-yl)cyclobutyl)methanamine

2-(3-Fluoropyridin-2-yl)acetonitrile. To a 0 °C solution of 2-chloro-3-fluoropyridine (3.0 g, 23 mmol, 1.0 equiv) and acetonitrile (1.3 mL, 25 mmol, 79 WO 2011/133888 PCT/US2011/033614 1.1 equiv) in toluene (50 mL) was added sodium hexamethyldisilazide (NaHMDS) (2.0 M in THF, 13 mL, 25 mmol, 1.1 equiv). The resulting mixture was stirred for 2 hours at 0 °C and then partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc and the combined organic 5 phases were washed with saturated NaCl, dried over Na2SO4 and concentrated in vacuo to provide the crude desired product as an oil which was used without further purification.

Example 5: Preparation of (1-(6-Methoxypyridin-2- 10 yl)cyclobutyl)methanamine

1-(6-Fluoropyridin-2-yl)cyclobutanecarbonitrile. Following the same procedure as above for 2-(3-fluoropyridin-2-yl)acetonitrile with 2,6-difluoropyridine (5.0 g, 43 mmol, 1.0 equiv), cyclobutylcarbonitrile (3.5 g, 43 15 mmol, 1.0 equiv) and NaHMDS (2.0 M in THF, 24 mL, 47 mmol, 1.1 equiv) in toluene (100 mL) gave the desired product (4.9 g, 64%) as a colorless oil following purification over silica gel using 25% EtOAc/hexanes as eluent.

1-(6-Methoxypyridin-2-yl)cyclobutanecarbonitrile. To anhydrous 20 methanol (6.0 mL) at 0 °C under nitrogen was added sodium metal (~1 g) and the mixture stirred for 30 minutes. To the reaction mixture was added 1-(6-fluoropyridin-2-yl)cyclobutanecarbonitrile (1.6 g, 9.1 mmol) followed by heating to 75 °C and stirring for 45 minutes. The solution was cooled to room temperature and partitioned between water and EtOAc. The layers were 25 separated, the aqueous phase was extracted with EtOAc, and the combined organic phases were washed with saturated NaCl, dried over Na2SO4, and concentrated in vacuo to give the desired product (1.7 g, 97%) as a colorless oil. 80 WO 2011/133888 PCT/US2011/033614

(1-(6-Methoxypyridin-2-yl)cyclobutyl)methanamine. To a stirred solution of 1-(6-methoxypyridin-2-yl)cyclobutanecarbonitrile (1.7 g, 8.8 mmol, 1.0 equiv) in THF (20 mL) was added lithium aluminum hydride solution (1.0 5 M in THF, 11 mL, 11 mmol, 1.1 equiv). The mixture was refluxed for 1.5 hours and allowed to cool to room temperature. Water (0.43 mL) was added slowly followed by 0.43 mL of 3 M NaOH and then three additions of 0.43 mL of water (Fieser and Fieser workup). The resulting mixture was filtered through diatomaceous earth and rinsed with THF. The combined organics 10 were dried over Na2SO4 and concentrated to dryness to give the desired product (1.6 g, 97%) as a viscous oil.

Example 6: Preparation of 1-(3-Fluoropyridin-2-yl)cyclobutanamine

15 1-(3-Fluoropyridin-2-yl)cyclobutanecarboxamide. To a 250 mL round bottom flask containing DMSO (60 mL) was added 1-(3-fluoropyridin-2-yl)cyclobutanecarbonitrile (2.96 g, 16.8 mmol, 1.0 equiv) and the mixture was stirred until homogenous. Potassium carbonate (7.0 g, 50.4 mmol, 3.0 equiv) was then added and the reaction mixture was cooled to 0 °C, followed by the 20 addition of 35% hydrogen peroxide (6.5 mL). The reaction was stirred at 0 °C for 30 min and then warmed to room temperature. At this time, the reaction was diluted with water (50 mL) and ethyl acetate (100 mL). After transferring to a separatory funnel and shaking, the organic layer was separated from the aqueous layer and then washed with brine (3 x 50 mL). The organic layer 25 was then dried over Na2SO4, filtered, and concentrated to give a crude solid that was purified by silica gel chromatography (10% EtOAC/hexanes) to afford 1.92 g (59%) of 1-(3-fluoropyridin-2-yl)cyclobutanecarboxamide as a white solid. 81 WO 2011/133888 PCT/US2011/033614 10 10 h2n

Methyl 1-(3-fluoropyridin-2-yl)cyclobutylcarbamate. 1-(3-Fluoropyridin-2-yl)cyclobutanecarboxamide (1.92 g, 9.88 mmol, 1.0 equiv) was dissolved in methanol (20 mL) and potassium hydroxide (1.11 g, 19.8 mmol, 2.0 equiv) was added. The reaction was sonicated until homogeneous, followed by the addition of iodosobenzene diacetate (4.77 g, 14.8 mmol, 1.5 equiv). The reaction was stirred for 20 min and then diluted with water (100 mL) and ethyl acetate (125 mL). After transferring to a separatory funnel and shaking, the organic layer was separated from the aqueous layer, and the aqueous layer was extracted with EtOAc (50 mL). The combined organic layers were then dried over Na2SO4, filtered, and concentrated to give a crude oil that was purified by silica gel chromatography (40% EtOAC/hexanes) to afford 1.47 g (67%) of methyl 1-(3-fluoropyridin-2-yl)cyclobutylcarbamate as a white solid. 15 15 20 20 1-(3-Fluoropyridin-2-yl)cyclobutanamine. To a 20 mL microwave reaction vial was added methyl 1-(3-fluoropyridin-2-yl)cyclobutylcarbamate (1.47 g, 6.56 mmol, 1.0 equiv), ethanol (12 mL) and 3N aqueous sodium hydroxide (7 mL). The reaction mixture was heated in the microwave reactor at 150 °C for 30 min. The ethanol was evaporated under reduced pressure and the mixture was extracted with ethyl acetate (30 mL). The aqueous layer was then extracted with ethyl acetate (2 x 30 mL). The organic layers were combined, dried over Na2SC>4, filtered, and concentrated to give 1-(3-fluoropyridin-2-yl)cyclobutanamine (1.01 g, 93%) as a crude yellow oil that was used in the next reaction step without further purification.

Example 7: 5-(2-(2-(4-Fluorophenyl)-2-methylpropylamino)pyrimidin-5-y 1)-1 H-indazol-3-amine 82 WO 2011/133888 PCT/US2011/033614

5-Bromo-N-(2-(4-fluorophenyl)-2-methylpropyl)pyrimidin-2-amine.

To a 20 dram vial was added 2-chloro-5-bromopyridine (440 mg, 2.3 mmol, 1.1 equiv), 2-(4-fluorophenyl)-2-methylpropan-1-amine (350 mg, 2.1 mmol, 1.0 equiv), DIPEA (1.0 mL, 5.7 mmol, 2.7 equiv), and toluene (5 mL). The vial was heated in an oil bath to 80 °C and stirred for 12 h, concentrated, and purified by silica gel column chromatography (0-30% EtOAc/hexanes) to give 270 mg (40%) of 5-bromo-N-(2-(4-fluorophenyl)-2-methylpropyl)pyrimidin-2-amine as a white solid. 10

15 20 2-Fluoro-5-(2-(2-(4-fluorophenyl)-2-methylpropylamino)pyrimidin-5-yl)benzonitrile. To a 5 mL microwave reaction vessel was added 5-bromo-N-(2-(4-fluorophenyl)-2-methylpropyl)pyrimidin-2-amine (267 mg, 0.8 mmol, 1.0 equiv), 3-cyano-4-fluorophenylboronic acid (203 mg, 1.2 mmol, 1.5 equiv), CI2Pd(dppf) (60 mg, 82 pmol, 0.1 equiv), potassium carbonate (1.2 mL of a 2N aqueous solution, 2.4 mmol, 3.0 equiv), and dioxane (4 mL). The reaction was heated in a microwave reactor at 120 °C for 20 min. The aqueous layer was removed from the reaction, and the organic layer was directly purified by reverse phase column chromatography to give 220 mg (73%) of 2-fluoro-5-(2-(2-(4-fluorophenyl)-2-methylpropylamino)pyrimidin-5-yl)benzonitrile as a white solid.

83 WO 2011/133888 PCT/US2011/033614 5-(2-(2-(4-Fluorophenyl)-2-methylpropylamino)pyrimidin-5-yl)-1H-indazol-3-amine. To a 5 mL microwave reaction vessel was added 2-fluoro-5-(2-(2-(4-fluorophenyl)-2-methylpropylamino)pyrimidin-5-yl)benzonitrile (220 mg, 0.6 mmol), hydrazine (500 pL), and propanol (5 mL). The reaction was 5 heated to 120 °C and stirred for 3 h. The reaction was concentrated and purified by reverse phase column chromatography to give 95 mg (42%) of 5-(2-(2-(4-fluorophenyl)-2-methylpropylamino)pyrimidin-5-yl)-1 H-indazol-3-amine as a white solid (m/z [M+H] = 377.1). 10

Example 8: Preparation of Methyl 2-(2-(4-fluorophenyl)-2-methylpropylamino)pyrimidine-5-carboxylate

15 20

To a 20 dram vial was added methyl 2-chloropyrimidine-5-carboxylate (250 mg, 1.4 mmol, 1.0 equiv), 2-(4-fluorophenyl)-2-methylpropan-1-amine (468 mg, 2.8 mmol, 2.0 equiv), DIPEA (1.0 mL, 5.6 mmol, 4.0 equiv), and toluene (5 mL). The vial was heated in an oil bath to 60 °C and stirred for 20 min, concentrated, and purified by silica gel column chromatography (0-50% EtOAc/hexanes) to give 325 mg (77%) of methyl 2-(2-(4-fluorophenyl)-2-methylpropylamino)pyrimidine-5-carboxylate as a white solid (m/z [M+H] = 304.1).

Example 9: Preparation of 3-(2-(2-(4-Fluorophenyl)-2-methylpropylamino)pyrimidin-5-yl)benzamide.

5-Bromo-N-(2-(4-fluorophenyl)-2-methylpropyl)pyrimidin-2 -amine.

To a solution of 5-bromo-2-fluoropyrimidine (1.0 g, 5.6 mmol, 1.0 equiv) and 2-(4-fluorophenyl)-2-methylpropan-1-amine (1.05 g, 6.3 mmol. 1.1 equiv) in 25 84 WO 2011/133888 PCT/US2011/033614 isopropanol (12 mL) in a microwave vial equipped with a stir bar was added potassium carbonate (3.68 g, 11.2 mmol, 2.0 equiv). The vial was fitted with a microwave vial cap and heated to 120 °C for 45 min. The reaction mixture was filtered to remove the solid potassium carbonate and concentrated in vacuo. After the residue was redissolved in EtOAc and water, the organic layer was washed with brine, dried over sodium sulfate and concentrated in vacuo. Purification by silica gel chromatography (3% - 5% MeOH/DCM) provided the title compound as a yellow solid (1.15 g, 65%), (m/z [M+H] = 324.2). 3-(2-(2-(4-Fluorophenyl)-2-methylpropylamino)pyrimidin-5-yl)benzamide. To a microwave vial equipped with a stirbar was added 5-bromo-N-(2-(4-fluorophenyl)-2-methylpropyl)pyrimidin-2-amine (75 mg, 0.23 mmol, 1.0 equiv), 3-(carboxyamino)phenylboronic acid (25 mg, 0.35 mmol, 1.5 equiv) and (dppf)PdCl2 (18 mg, 0.23 mmol, 1.0 equiv) as solids. The vial was fixed with a rubber septum and purged with a stream of nitrogen for 5 min. Nitrogen-sparged dioxane (1 mL) and aq. 2 N K2CO3 (0.5 mL) were added by syringe, and the rubber septum was quickly replaced with a microwave vial cap. After the reaction was heated in a microwave reactor for 30 min at 125 °C, LCMS analysis indicated consumption of the aryl bromide. The reaction mixture was diluted with EtOAc. The organic layer was washed once with satd. aq. NaHCO3 and once with brine. The combined aqueous layers were washed once with EtOAc, and the combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by silica gel chromatography (3% -10% MeOH/DCM) provided the title compound as a light yellow solid (44 mg, 52%), (m/z [M+H] = 365.3). 85 WO 2011/133888 PCT/US2011/033614

Example 10: Preparation of (1-(3-Fluoropyridin-2-yl)cyclobutyl)methanamine

1-(3-Fluoropyridin-2-yl)cyclobutanecarbonitrile. To a 0 °C solution 5 of 2-chloro-3-fluoropyridine (80.0 g, 611 mmol, 1.0 equiv) and cyclobutane carbonitrile (49.5 g, 611 mmol, 1.0 equiv) in toluene (500 mL) was added sodium hexamethyldisilazide (2.0 M in THF, 306 mL, 612 mmol, 1.0 equiv) in a dropwise manner. The resulting mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction was then quenched 10 with water (500 mL), and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (2x300 mL), and the combined organic phases were washed with saturated brine solution (2x400 mL), dried over Na2SO4, concentrated to give a crude yellow oil, and chromatographed with silica gel (2-10% EtOAc/hex) to give 1-(3-fluoropyridin- 15 2-yl)cyclobutanecarbonitrile (88 g, 83%) as a pale yellow oil.

(1-(3-Fluoropyridin-2-yl)cyclobutyl)methanamine. To a 0 °C solution of 1-(3-fluoropyridin-2-yl)cyclobutanecarbonitrile (88 g, 500 mmol, 1.0 equiv) in THF (400 mL) was added LAH (2M in THF, 575 mL, 1.15 mol) in a 20 dropwise manner over one hour. The reaction was then warmed to room temperature and stirred for 15 min. After the reaction was complete, it was cooled back down to 0 °C and quenched slowly with water (43 mL), 3 N NaOH (43 mL), and water (125 mL). The quenched reaction was stirred for 30 min and then filtered through Celite. The filtrate was concentrated and 25 dried in vacuo to give (1-(3-fluoropyridin-2-yl)cyclobutyl)methanamine (80 g, 88%) as a crude yellow oil that was used without purification. 86 WO 2011/133888 PCT/US2011/033614

Example 11: Preparation of 2-(6-(Difluoromethoxy)pyridin-2-yl)propan- 2-amine

CN

NaHMDS

NC

2-(6-Fluoropyridin-2-yl)-2-methylpropanenitrile. To a 0 °C solution 5 of 2,6-difluoropyridine (69.6 g, 605 mmol, 1.0 equiv) and isobutyronitrile (41.7 g, 610 mmol, 1.0 equiv) in toluene (500 mL) was added sodium hexamethyldisilazide (2.0 M in THF, 302 mL, 605 mmol, 1.0 equiv) in a dropwise manner. The resulting mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction was then quenched with 10 water (500 mL), and the organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (2x300 mL), and the combined organic phases were washed with saturated brine solution (2x400 mL), dried over Na2SO4, concentrated to give a crude yellow oil, and chromatographed with silica gel (2-10% EtOAc/hex) to give 2-(6-fluoropyridin-2-yl)-2- 15 methylpropanenitrile (55.7 g, 56%) as a clear oil.

NC

NaOMe

MeOH

NC N. X).

\ 2-(6-Methoxypyridin-2-yl)-2-methylpropanenitrile. To a solution of 2-(6-fluoropyridin-2-yl)-2-methylpropanenitrile (10 g) in methanol (30 mL) was added sodium methoxide (50 mL of a 30% solution in methanol). The 20 reaction was then refluxed for 1 h, cooled to rt, poured into ethyl acetate (400 mL), and washed with brine (3x200 mL). The organic layer was dried over Na2SO4 and concentrated to give 2-(6-methoxypyridin-2-yl)-2-methylpropanenitrile (9.8 g, 92%) as a pale yellow oil. NC^X>fN<Y'0\ 4N HCI/dioxane^ NC^y’^V'0 25 2-Methyl-2-(6-oxo-1,6-dihydropyridin-2-yl)propanenitrile. To a 20 dram microwave vial was added 2-(6-methoxypyridin-2-yl)-2-methylpropanenitrile (7 g, 40 mmol) and 4N HCI in dioxane (15 mL). The reaction was then sealed and heated in a microwave reactor at 190 °C for 30 min. This reaction was repeated six times using the procedure above. These 87 WO 2011/133888 PCT/US2011/033614 reactions were combined and filtered. The resultant white solid was washed with 20% EtOAc/hexanes and then dried in vacuo to afford 2-methyl-2-(6-oxo-1,6-dihydropyridin-2-yl)propanenitrile (24.7 g, 77%) as a white solid.

5 2-(6-(Difluoromethoxy)pyridin-2-yl)-2-methylpropanenitrile. To a 100 mL round bottom flask was added 2-methyl-2-(6-oxo-1,6-dihydropyridin-2-yl)propanenitrile (8.2 g, 51 mmol, 1.0 equiv), methyl chlorodifluoroacetate (14.9 g, 103 mmol, 2.0 equiv), cesium carbonate (23.3 g, 71 mmol, 1.4 equiv), and DMF (100 mL). The reaction was heated to 95 °C and stirred for 3 hours. 10 The reaction was then quenched with water (100 mL) and diluted with EtOAc (500 mL). The organic layer was separated from the aqueous layer. The aqueous layer was extracted with EtOAc (100 mL), and the combined organic phases were washed with saturated brine solution (3x200 mL), dried over Na2SO4, concentrated, and chromatographed with silica gel (2-5% 15 EtOAc/hex) to give 2-(6-(difluoromethoxy)pyridin-2-yl)-2-methylpropanenitrile (6.2 g, 57%) as a clear oil.

2-(6-(Difluoromethoxy)pyridin-2-yl)-2-methylpropanamide. To a 1 L round bottom flask was added 2-(6-(difluoromethoxy)pyridin-2-yl)-2- 20 methylpropanenitrile (19.2 g, 91 mmol, 1 equiv), potassium carbonate (37.0 g, 270 mmol, 3 equiv), and DMSO (150 mL). The reaction was cooled to 0 °C and 30% hydrogen peroxide (25 mL) was added slowly in 2 mL portions over ten minutes. The reaction was then warmed to room temperature and stirred for 1 h. After consumption of starting material, the reaction was poured into 25 ethyl acetate (600 mL), washed with brine (3x300 mL), dried over Na2SO4, and concentrated to give 2-(6-(difluoromethoxy)pyridin-2-yl)-2-methylpropanamide (20 g, 97%) as a clear oil.

Methyl 2-(6-(difluoromethoxy)pyridin-2-yl)propan-2-ylcarbamate. 88 WO 2011/133888 PCT/US2011/033614

To a 500 mL round bottom flask was added 2-(6-(difluoromethoxy)pyridin-2-yl)-2-methylpropanamide (20.0 g, 91 mmol, 1 equiv) and methanol (150 mL). The mixture was cooled to 0 °C and sodium hydroxide solution (7.3 g dissolved in 150 mL of methanol, 182 mmol, 2.0 equiv) was added. The 5 reaction was stirred for 2 minutes, and iodosobenzenediacetate (40.8 g, 127 mmol, 1.4 equiv) was added. The reaction was stirred for 2 hours while warming slowly to rt. The reaction was then poured into ethyl acetate (700 mL), washed with saturated brine solution (2x400 mL), dried over Na2SO4, concentrated, and chromatographed with silica gel (10-20% EtOAc/hex) to 10 afford methyl 2-(6-(difluoromethoxy)pyridin-2-yl)propan-2-ylcarbamate (12.4 g, 55%) as a white solid.

2-(6-(Difluoromethoxy)pyridin-2-yl)propan-2-amine. To a solution of 2-(6-(difluoromethoxy)pyridin-2-yl)propan-2-ylcarbamate (12.4 g, 48 mmol) in 15 acetonitrile (50 mL) was added TMSI (10 mL). The reaction was stirred 30 min and then poured into methanol (100 mL) and water (5 mL). The mixture was concentrated, dissolved in ethyl acetate (200 mL), and then washed with 1N NaOH (2x30 mL). The organic layer was separated, dried over Na2SO4, concentrated, and chromatographed with silica gel (50% EtOAc/hex, then 5- 20 20 % MeOH/CH2CI2) to afford 2-(6-(difluoromethoxy)pyridin-2-yl)propan-2- amine (8.8 g, 92%) as a yellow oil.

Example 12: Preparation of frans-3-Fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methanamine

1 -(3-Fluoropyridin-2-yl)-3-methylenecyclobutanecarbonitrile. To a solution of 3-methylenecyclobutanecarbonitrile (150 g, 1.61 mol, 1 equiv) and 2-chloro-3-fluoropyridine (212 g, 1.61 mmol, 1 equiv) in toluene (1 L) was added NaHMDS (2 M in THF, 885 mL, 1.1 equiv) dropwise at 0-10 °C. Upon 89 WO 2011/133888 PCT/US2011/033614 completion of addition, the reaction mixture was warmed to rt, stirred overnight, and quenched with NH4CI(Sat) solution. The organic layer was washed with water (2x500 mL) and brine (500 mL), dried over Na2SO4, filtered, and concentrated to give the crude title compound (272 g, 90%) which 5 was used in next step without further purification. LRMS (M+lT) m/z 189.1.

1-(3-Fluoropyridin-2-yl)-3-oxocyclobutanecarbonitrile. To a mixture of 1-(3-fluoropyridin-2-yl)-3-methylenecyclobutanecarbonitrile (272 g, 1.45 mol) and RuCI3.H2O (9.0 g, 0.044 mol) in DCM (1 L), acetonitrile (1 L), and 10 water (1.5 L) mixture was added solid NalO4 (1235 g, 5.8 mol) portionwise at 10-30 °C. Upon the completion of addition, the reaction was stirred 1 h at 15 °C and overnight at rt. The solid precipitate was filtered off and washed with DCM (2x1000 mL). The organic layer was washed with water (2x500 mL) and brine (500 mL), dried over Na2SO4, and concentrated to provide a crude title 15 compound as a dark solid (238 g, 86.3%). LRMS (M+lT) m/z 191.1.

1-(3-Fluoropyridin-2-yl)-3-hydroxycyclobutanecarbonitrile. To a solution of 1-(3-fluoropyridin-2-yl)-3-oxocyclobutanecarbonitrile (231 g, 1.22 mol) in a mixture of DCM (2 L) and MeOH (200 mL) was added NaBH4 20 portionwise at -78 °C. The reaction mixture was stirred at -78 °C for 1 h and quenched with a mixture of methanol and water (1/1). The organic layer was washed with water (500 mL x 3), dried over Na2SO4, and concentrated. The residue was purified on silica gel (50% EtOAc/hexanes) to provide the title compound as an amber oil (185.8 g, 77.5%). LRMS (M+lT) m/z 193.2. 90 WO 2011/133888 PCT/US2011/033614

frans-3-Fluoro-1-(3-fluoropyridin-2-yl)cyclobutanecarbonitrile To a solution of 1-(3-fluoropyridin-2-yl)-3-hydroxycyclobutanecarbonitrile (185 g, 0.96 mol) in DCM (1 L) was added DAST portionwise at 0-10 °C. Upon the 5 completion of addition, the reaction was refluxed for 6 h. The reaction was cooled to rt and poured onto sat. NaHCO3 solution. The mixture was separated and the organic layer was washed with water, dried over Na2SO4, and concentrated. The residue was purified on silica gel (100% DCM) to provide the title compound as a brown oil (116 g, 62%) in a 8:1 trans:cis 10 mixture. The above brown oil (107 g) was dissolved in toluene (110 mL) and hexanes (330 mL) at 70 °C. The solution was cooled to 0 °C and stirred at 0 °C overnight. The precipitate was filtered and washed with hexanes to provide the trans isomer as a white solid (87.3 g, 81.6%). LRMS (M+H+) m/z 195.1.

frans-3-Fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methanamine. A mixture of frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutanecarbonitrile (71 g, 0.37 mol) and Raney nickel (~7 g) in 7N ammonia in methanol (700 mL) was charged with hydrogen (60 psi) for 2 days. The reaction was filtered through a 20 celite pad and washed with methanol. The filtrate was concentrated under high vacuum to provide the title compound as a light green oil (70 g, 97.6%). LRMS (M+H+) m/z 199.2.

Example 13: Preparation of f-Butyl 5-bromopyrimidin-2-yl((irans-3- 25 fluoro-1 -(3-fluoropyridin-2-yl)cyclobutyl)methyl)carbamate 91 WO 2011/133888 PCT/US2011/033614

A mixture of frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methanamine (37.6 g, 190 mmol), 5-bromo-2-fluoropyrimidine 5 (32.0 g, 181 mmol), DIPEA (71 mL, 407 mmol), and NMP (200 mL) was stirred at rt overnight. The reaction mixture was then diluted with EtOAc (1500 mL) and washed with saturated sodium bicarbonate (500 mL). The organic layer was separated, dried over Na2SO4, and concentrated. The resultant solid was dissolved in THF (600 mL), followed by the slow addition 10 of DMAP (14 g, 90 mmol) and Boc2O (117.3 g, 542 mmol). The reaction was heated to 60 °C and stirred for 3 h. The reaction mixture was then concentrated and purified by silica gel chromatography (EtOAc/hex) to give 59.7 g of f-butyl 5-bromopyrimidin-2-yl((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)carbamate as a white solid. 15

Example 14: Preparation of 1-(2-(((trans)-3-fluoro-1 -(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-1 H-pyrrole-3-carboxamide

f-Butyl 5-(3-cyano-1 H-pyrrol-1 -yl)pyrimidin-2-yl(((frans)-3-fluoro-1 - 20 (3-fluoropyridin-2-yl)cyclobutyl)methyl)carbamate. To a solution of f-butyl 5-bromopyrimidin-2-yl((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl) carbamate (1.0 g, 2.8 mmol) in 15 mL of toluene (degassed with nitrogen) was added copper iodide (100 mg, 0.6 mmol), potassium phosphate (1.31 g, 6.2 mmol), trans-N,N'-dimethylcyclohexane-1,2-diamine (320 mg, 2.2 mmol), 25 and 3-cyanopyrrole (310 mg, 3.6 mmol). The reaction was heated to 100 °C and stirred for 2 h. The reaction was then concentrated and purified by silica gel chromatography (EtOAc/hexanes) to afford 1.1 g of f-butyl 5-(3-cyano-1 H-pyrrol-1-yl)pyrimidin-2-yl(((frans)-3-fluoro-1-(3-fluoropyridin-2- 92 WO 2011/133888 PCT/US2011/033614 10 10 15 15 20 20 yl)cyclobutyl)methyl)carbamate as a clear oil.

NC

H,N

O 1 -(2-((( frans)-3-fluoro-1 -(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide. To a solution off-butyl 5-(3-cyano-1 H-pyrrol-1 -yl)pyrimidin-2-yl(((frans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)carbamate (1.1 g, 3.1 mmol) in DMSO (10 mL) was added potassium carbonate (1.3 g, 9.3 mmol). The mixture was cooled to 0 °C and hydrogen peroxide (3 mL) was slowly added. The reaction was warmed to rt and stirred for 90 min. The reaction was diluted with EtOAc (75 mL) and washed three times with brine (50 mL). The organic layer was then dried over Na2SO4, filtered, and concentrated to give a crude solid that was purified by silica gel chromatography (10% MeOH/CH2CI2) to afford 1.07 g of 1-(2-(((frans)-3-fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methylamino)pyrimidin-5-yl)-1 H-pyrrole-3-carboxamide as a white solid. This compound was dissolved in 25% TFA/CH2CI2 and stirred for 1 h. The reaction was then concentrated, dissolved in ethyl acetate (75 mL), and washed three times with potassium carbonate. The organic layer was then dried over Na2SO4, filtered, and concentrated to give a crude solid that was triturated with 75% ethyl acetate/hexanes. The resultant slurry was sonicated and filtered to give 500 mg of 1-(2-(((frans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-1 H-pyrrole-3-carboxamide as a white solid (M+H=385).

Example 15: Preparation of 2-(2-((frans-3-Fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)thiazole-5-carboxamide

Br-

F

O

JohnPhos

2. NH4OH 3. TFA, CH2CI2

F 93 WO 2011/133888 PCT/US2011/033614

To a 20 mL microwave vial was added ί-butyl 5-bromopyrimidin-2-yl((frans-3-fluoro-1 -(3-fluoropyridin-2-yl)cyclobutyl)methyl)carbamate (850 mg, 1.95 mmol), ethyl thiazole-5-carboxylate (459 mg, 2.92 mmol), Cl2Pd(PPh3)2 (205 mg, 0.29 mmol), Johnphos (213 mg, 0.58 mmol), Cs2CC>3 (1.9 g, 5.85 mmol) and toluene (8 mL). The reaction was stirred and heated at 140 °C for 30 min in a microwave reactor. The reaction mixture was then was poured into ethyl acetate (100 mL), washed with NaHCO3 (50 mL), washed with brine (50 mL), and then dried over Na2SC>4, filtered, concentrated, and purified by silica gel chromatography (EtOAC/hexanes) to afford 191 mg of methyl 2-(2-(f-butoxycarbonyl((frans-3-fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)thiazole-5-carboxylate. This compound was subsequently dissolved in ethanol (4 mL), and ammonium hydroxide (2 mL) was added. The reaction was heated to 60 °C and stirred for 30 min. The reaction was then concentrated, dissolved in CH2CI2 (30 mL), washed with NaHCO3 (10 mL), washed with brine (10 mL), and then dried over MgSCU, filtered, and concentrated. The crude solid was redissolved in CH2CI2 (5 mL) and TFA (2 mL) was added. The reaction was stirred at rt for 30 min, concentrated, and then purified by reverse phase chromatography to yield 51 mg of 2-(2-((frans-3-fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methylamino)pyrimidin-5-yl)thiazole-5-carboxamide as white solid (M+H=385.1).

Example 16: Preparation of 4-Fluoro-3-(2-((frans-3-fluoro-1-(3 fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2- hydroxybenzamide

4-Fluoro-3-(2-((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2-methoxybenzonitrile. To a 250 mL round bottom flask was added f-butyl 5-bromopyrimidin-2-yl((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)carbamate (5.0 g, 11.0 mmol), 94 WO 2011/133888 PCT/US2011/033614 3-bromo-6-fluoro-2-methoxyphenylboronic acid (2.7 g, 11.0 mmol), (dppf)PdCI2 (0.80 g, 1.1 mmol), dioxane (25 mL degassed for 10 min with nitrogen), K2CO3 (3.0 g, 22 mmol), and water (4 mL). The mixture was heated to 95 °C and stirred overnight. The reaction mixture was then was poured into ethyl acetate (200 mL), washed sequentially with NaHCO3 (50 mL) and brine (50 mL), and then dried over Na2SO4, filtered, concentrated, and purified by silica gel chromatography to afford 2.4 g (4.1 mmol) of 5-(3-bromo-6-fluoro-2-methoxyphenyl)-N-((frans-3-fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methyl)pyrimidin-2-amine as a pale yellow solid. To this solid was added zinc cyanide (0.76 g, 6.5 mmol), Pd(PPh3)4 (2.9 g, 2.5 mmol), and DMF (25 mL). The mixture was heated to 100 °C for 2 h and then diluted with EtOAc and washed with satd. aq. NaHCO3 and brine. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified using reverse phase chromatography to afford 1.1 grams of4-fluoro-3-(2-((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2- methoxybenzonitrile.

4-Fluoro-3-(2-((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2-hydroxybenzamide. To a mixture of 4-fluoro-3-(2-((frans-3-fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2-methoxybenzonitrile (1.0 g, 1.9 mmol), K2CO3 (0.8 g, 5.7 mmol), and DMSO (5 mL) were combined in a round bottom flask and cooled to 0 °C. H2O2 (8.0 mL of 35% solution) was added dropwise. The reaction was warmed to rt and stirred for 1 h. The reaction mixture was diluted with EtOAc and washed with satd. aq. NaHCO3 and brine (three times). The organic layer was dried over sodium sulfate, filtered, and concentrated, and purified by reverse phase chromatography to provide 0.55 g (1 mmol) of 4-fluoro-3-(2-((frans-3-fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2-methoxybenzamide a white solid. This compound was mixed with pyridine (6 mL) and Lil (1.22 g, 9 mmol) and 95 WO 2011/133888 PCT/US2011/033614 heated in a microwave reactor at 125 °C for 15 min. The reaction mixture was diluted with EtOAc and washed with satd. aq. NaHCO3 and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated, and purified by reverse phase chromatography to afford 163 mg of4-fluoro-3-(2-((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-2-hydroxybenzamide as a white solid (M+H+430.1).

Example 17: Preparation of 2-(2-(2-((1-(3-Chloropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)thiazol-5-yl)acetamide

To a 50 mL round bottom flask was added ί-butyl 5-bromopyrimidin-2-yl((1-(3-chloropyridin-2-yl)cyclobutyl)methyl)carbamate (1.0g, 2.2 mmol), Pd(PPh3)4 (0.25 g, 0.22 mmol), hexamethylditin (0.92 mL, 2.2 mmol), LiCI (0.25 g, 5.9 mmol), and dioxane (10 mL). The mixture was heated to 90 °C for 1 h. To the resultant dark brown solution was added 2-(2-bromothiazol-5-yl)acetonitrile (0.89 g, 4.4 mmol), Pd(PPh3)4 (0.076 g, 0.066 mmol), and Cul (4.2 g, 22.2 mmol). The reaction mixture was stirred at 90 °C for 1 h. The reaction was then cooled to rt, diluted with ethyl acetate (50 mL), and filtered through Celite. The filtrate was washed with water (30 mL) and brine (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated, and purified by silica gel chromatography (EtOAc/hex) to afford 222 mg of t-butyl (1-(3-chloropyridin-2-yl)cyclobutyl)methyl(5-(5-(cyanomethyl)thiazol-2-yl)pyrimidin-2-yl)carbamate as a viscous brown oil. To this compound was added potassium carbonate (185 mg, 1.3 mmol) and DMSO (3 mL). The mixture was cooled to 0 °C and hydrogen peroxide (0.5 mL) was slowly added. The reaction was warmed to rt and stirred for 1 h. The reaction was diluted with EtOAc (75 mL) and washed three times with brine (50 mL). The organic layer was then dried over Na2SO4, filtered, and concentrated to give a crude solid that was purified by reverse phase chromatography to afford 48 96 WO 2011/133888 PCT/US2011/033614 mg of ί-butyl 5-(5-(2-amino-2-oxoethyl)thiazol-2-yl)pyrimidin-2-yl((1-(3-chloropyridin-2-yl)cyclobutyl)methyl)carbamate as a white solid. This compound was dissolved in 25% TFA/CH2CI2 and stirred for 10 min. The reaction was then concentrated, dissolved in ethyl acetate (75 mL), and washed three times with saturated sodium bicarbonate solution. The organic layer was dried over Na2SO4, filtered, and concentrated to give 39 mg of 2-(2-(2-((1-(3-chloropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)thiazol-5-yl)acetamide as a white solid (M+H=415.1).

Example 18: Preparation of 3-(2-((frans-3-Fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxy-N- methylbenzamide

3-(2-((( frans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxybenzoic acid. To a 20 mL microwave tube was added 5-bromo-N-(((frans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)pyrimidin-2-amine (1.2 g, 3.8 mmol), methyl 4-hydroxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.1 g, 4.0 mmol), (dppf)PdCI2 (0.25 g, 0.38 mmol), dioxane (15 mL), K2CO3 (1.4 g, 10.1 mmol), and water (3 mL). The mixture was heated to 135 °C and stirred for 15 min. The reaction mixture was then was poured into ethyl acetate (200 mL), washed with brine (50 mL), and dried over Na2SO4, filtered, concentrated, and purified by silica gel chromatography (EtOAc/hex) to afford 0.65 g of methyl 3-(2-(((frans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxybenzoate as a tan solid. This compound was dissolved in methanol (7 mL) and KOH (2 mL of a 3N aqueous solution) was added. The reaction was stirred at 80 °C for 1 h and then was concentrated. The crude residue was purified by reverse phase chromatography to afford 0.24 g of 3-(2-(((frans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxybenzoic acid as a white 97 WO 2011/133888 PCT/US2011/033614

3-(2-((irans-3-Fluoro-1-(3-fluoropyridin-2- 5 yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxy-N- methylbenzamide. To a 50 mL round bottom flask was added 3-(2-(((frans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxybenzoic acid (147 mg, 0.36 mmol), HATU (204 mg, 0.54 mmol), HOBT (72 mg, 0.54 mmol), methylamine hydrochloride (239 mg, 3.6 mmol), 10 DIPEA (187 pL, 1.1 mmol), and DMF (1.5 mL). The reaction mixture was stirred at rt overnight. The reaction mixture was concentrated and purified by reverse phase chromatography to afford 93 mg of 3-(2-((frans-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)-4-hydroxy-N-methylbenzamide as a white solid (M+H=412.1). 15

Example 19: Preparation of 6-(2-(2-(3-Chloropyridin-2-yl)propan-2-ylamino)pyrimidin-5-yl)imidazo[2,1-b]thiazole-3-carboxamide

20 2-Bromo-1-(2-(2-(3-chloropyridin-2-yl)propan-2-ylamino)pyrimidin 5-yl)ethanone. To a stirring solution of dioxane (50 mL, degassed) was added 5-bromo-N-(2-(3-chloropyridin-2-yl)propan-2-yl)pyrimidin-2-amine (3.0 g, 12 mmol), Cl2Pd(PPh3)2 (0.65 g, 1.2 mmol), and tributyl(1ethoxyvinyl)tin (2.66 mL, 13.8 mmol). The reaction was heated to 90 °C and stirred for 2 h. 25 The reaction was then concentrated, followed by the addition of EtOAc (100 mL) and potassium fluoride (50 mL of a saturated aqueous solution). The mixture was stirred for 10 min and then filtered through a pad of ceiite. The filtrate was concentrated and then dissolved in THF (20 mL) and water (20 mL). NBS (4.9 g, 27.6 mmol) was then added, and the reaction was stirred 98 WO 2011/133888 PCT/US2011/033614 for 20 min at rt. The reaction mixture was poured into ethyl acetate (200 mL), washed with saturated aqueous sodium bicarbonate (50 mL), dried over Na2SO4, filtered, concentrated, and purified by silica gel chromatography to afford 1.5 g of 2-bromo-1-(2-(2-(3-chloropyridin-2-yl)propan-2- 5 ylamino)pyrimidin-5-yl)ethanone as a white powder.

6-(2-(2-(3-Chloropyridin-2 -yl)propan-2 -ylamino)pyrimidin-5-yl)imidazo[2,1-b]thiazole-3-carboxamide. To a 20 dram vial was added 2-bromo-1-(2-(2-(3-chloropyridin-2-yl)propan-2-ylamino)pyrimidin-5-yl)ethanone 10 (103 mg, 0.28 mmol), ethyl-2-aminothiazole-4-carboxylate (48 mg, 0.28 mmol), and methylethylketone (2 mL). The mixture was heated to 90 °C in a sealed tube and stirred overnight. The reaction was then concentrated and purified by silica gel chromatography (EtOAc/hex) to afford 33 mg of ethyl 6-(2-(2-(3-chloropyridin-2-yl)propan-2-ylamino)pyrimidin-5-yl)imidazo[2,1- 15 b]thiazole-3-carboxylate as a tan solid. This compound was dissolved in methanol (1 mL) and ammonium hydroxide (3 mL) was added. The resulting mixture was heated in a microwave reactor to 135 °C and stirred for 15 min. The reaction was concentrated, followed by the addition of HBTU (68 mg, 179 pmol), HOBt (24 mg, 179 pmol), NH4CI (48 mg, 1.1 mmol), DIPEA (78 pL, 441 20 pmol), and NMP (2 mL). The reaction was stirred for 2 h and then purified directly by reverse phase chromatography to afford 18 mg of 6-(2-(2-(3-chloropyridin-2-yl)propan-2-ylamino)pyrimidin-5-yl)imidazo[2,1-b]thiazole-3-carboxamide as an off-white solid (M+H=414.1). 25 Example 20: Preparation of 4-(2-(((c/s)-3-fluoro-1-(3-fluoropyrid in-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)picolinamide

NC

NCx /=N )=\ /=N

NQ^Br + ' VjrVN^CI 4-(2-chloropyrimidin-5-yl)picolinonitrile. 4-bromoopicolinonitrile (11.8 g, 74.5 mmol), 2-chloropyrimidin-5-ylboronic acid (15.0 g, 82.0 mmol), 99 WO 2011/133888 PCT/US2011/033614 (dppf)PdCI2 ( 5.5 g, 7.45 mmol), dioxane (150 mL, degassed with nitrogen), and aq. 2 N K2CO3 (33 mL) were combined and heated in a round bottom flask at 100 °C overnight. The hot mixture was filtered through a pad of Celite, diluted with EtOAc, washed with water, concentrated, and purified using silica gel chromatography to afford 4-(2-chloropyrimidin-5-yl)picolinonitrile as a tan solid (2.1 g, 13%).

4-(2-(((c/s)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)picolinamide. 4-(2-chloropyrimidin-5-yl)picolinonitrile (0.9 g, 4.2 mmol), (3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methanamine (1.0 g, 5.0 mmol), DIPEA (1 mL), and ACN (20 mL) were mixed and heated at 90 °C for 4 h. The reaction mixture was concentrated, diluted with EtOAc, and washed with sat. aq. NaHCO3 and brine. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified using reverse phase chromatography to afford 4-(2-(((c/s)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methylamino)pyrimidin-5-yl)picolinonitrile as a clear oil (the cis isomer elutes first). This compound was then treated with DMSO (3 mL), K2CO3 (200 mg), and H2O2 (2 mL). The reaction mixture was stirred for 4 h and then diluted with EtOAc and washed with brine. The organic layer was dried over sodium sulfate, filtered, concentrated, and purified using reverse phase chromatography to afford 93 mg of 4-(2-(((c/s)-3-fluoro-1-(3-fluoropyridin-2- yl)cyclobutyl)methylamino)pyrimidin-5-yl)picolinamide as an off white solid (m/z [M+H] = 397.2).

Example 21: Preparation and assay of fast skeletal myofibrils

Preparation of fast skeletal myofibrils. Rabbit skeletal myofibrils were prepared based upon the method of Herrmann et al. (Biochem. 32(28):7255-7263(1993). Myofibrils were prepared from rabbit psoas muscle purchased from Pel-Freez Biologicals (Arkansas) within 2 days of ordering, 100 WO 2011/133888 PCT/US2011/033614 stored on ice. Minced muscle was homogenized in 10 volumes of ice-cold “standard” buffer (50mM Tris, pH 7.4, 0.1 M potassium acetate, 5 mM KCl, 2 mM DTT, 0.2 mM PMSF, 10 μΜ leupeptin, 5 μΜ pepstatin, and 0.5 mM sodium azide) containing 5 mM EDTA and 0.5% Triton X-100 using an Omni-Macro homogenizer. Myofibrils were recovered by low speed centrifugation (3000 rpm for 10 minutes) and washed 2 times in the Triton X-100 containing buffer to ensure removal of cellular membrane. Following the Triton washes, myofibrils were washed 3 times in “standard” buffer containing 2 mM magnesium acetate. A final wash in assay buffer (12 mM PIPES, pH 6.8, 60 mM KCl, 1 mM DTT) was performed and brought to 10% sucrose for flash freezing in liquid nitrogen and storage at -80°C.

Activation of Fast Skeletal Myofibrils. Fast fiber activators were identified by measuring the enzymatic activity of muscle myofibril preparations

TM using the proprietary PUMA (see, e.g., U.S. Patent Nos. 6,410,254, 6,743,599, 7,202,051, and 7,378,254) assay system. Myofibril preparations consisted of rabbit skeletal muscle (approximately 90% fast fibers) that had been mechanically homogenized and washed with a detergent (triton X-100) to remove cellular membranes. This preparation retained all of the sarcomeric components in a native conformation and the enzymatic activity was still regulated by calcium. Compounds were tested using a myofibril suspension and a level of calcium sufficient to increase enzymatic activity of the myofibrils to 25% of their maximal rate (termed pCa25). Enzymatic activity was tracked via a pyruvate kinase and lactate dehydrogenase-coupled enzyme system. This assay regenerates myosin-produced ADP into ATP by oxidizing NADH, producing an absorbance change at 340 nm. The buffering system was 12 mM Pipes, 2 mM MgCl2, 1 mM DTT at pH 6.8 (PM12 buffer). Data was reported as AC1.4, which is the concentration at which the compound increased the enzymatic activity by 40%. The results are summarized in Table 2 below. 101 WO 2011/133888 PCT/US2011/033614

Example 22: Preparation and Assay of Sarcomeric Proteins from Skeletal Muscle

Powder Preparation 1. Volumes are given per about 1000 g of the minced muscle. 2. Pre-cut and boil cheesecloth for 10 min in water. Drain and dry. 3. Mince chicken breast in a prechilled meat grinder. 4. Extract with stirring in 2 L of 0.1 M KCI, 0.15 M K-phosphate, pH 6.5 for 10 min at 4 °C. Spin 5000 rpm, 10 min, 4 °C in JLA. Collect the pellet. 5. Extract pellets with stirring with 2 L of 0.05 M NaHCO3 for 5 min. Spin 5000 rpm, 10min, 4 °C in JLA. Collect the pellet. Repeat the extraction once more. 6. Extract the filtered residue with 2 L of 1 mM EDTA, pH 7.0 for 10 min with stirring. 7. Extract with 2 L of H2O for 5 min with stirring. Spin 10000 rpm, 15min, 4 °C in JLA. Carefully collect the pellet, part of which will be loose and gelatinous. 8. Extract 5 times with acetone (2 L of acetone for 10 min each with stirring). Squeeze through cheesecloth gently. All acetone extractions are performed at room temperature. Acetone should be prechilled to 4 °C. 9. Drying: Place the filtered residue spread on a cheesecloth in a large glass tray and leave in a hood overnight. When the residue is dry, put in a wide mouth plastic bottle and store at 20 °C.

Alternate Powder Preparation (See Zot &amp; Potter (1981) Prep. Biochem. 11 (4) pp. 381 -395) 1. Dissect left ventricles of the cardiac muscle. Remove as much of the pericardial tissue and fat as possible. Grind in a prechilled meat grinder. Weigh. 2. Prepare 5 volumes of Extract buffer (see below). Homogenize the meat in a blender, 4 times 15 sec on blend with 15 secs in between. Do this with 1 volume (weight/volume) of buffer taken from the 5 volumes already prepared. Add the homogenate back to the extract buffer and stir until well mixed (5 minutes). 3. Filter through one layer of cheesecloth in large polypropylene strainer. Resuspend back into 5 volumes of extract buffer as above. 102 WO 2011/133888 PCT/US2011/033614 4. Repeat Step 3 four more times. At the end, do not resuspend in extraction buffer but proceed to Step 5. The pellets should be yellow white. 5. Resuspend in 3 volumes (according to original weight) of 95% cold ethanol. Stir for 5 min and squeeze through cheesecloth as above, repeat two more times. 6. Weigh squeezed residue and then resuspend in 3 volumes (new weight/volume) of cold diethyl ether. 7. Repeat Step 6 a total of three times. 8. Leave overnight in a single layer on a cheesecloth in a glass tray. 9. When dry, collect the powder, weigh and store in a wide-mouth jar at 4 °C. EXTRACT BUFFER: 50 mM KCI, 5 mM Tris pH 8.0 Prepare as 50 times concentrate. For 2L: 250 mM Tris pH 8.0. Tris Base (121.14 g/mol, 60.6 g), pH to 8.0 with cone. HCI, then add 2.5 M KCI (74.55 g/mol, 372 g).

Actin Preparation 1. Extract powder (as described above) with 20 ml buffer A (see below, add BME and ATP just prior to use in each of the following steps) per gram of powder (200 ml per 10 g). Use a large 4 L beaker for 150 g of powder. Mix vigorously to dissolve powder. Stir at 4 °C. for 30 min. 2. Separate extract from the hydrated powder by squeezing through several layers of cheesecloth. Cheesecloth should be pre-sterilized by microwaving damp for 1-2 min. 3. Re-extract the residue with the same volume of buffer A and combine extracts. 4. Spin in JLA10 rotor(s) for 1 hr at 10K rpm (4 °C.). Collect supernatant through 2 layers of cheesecloth. 5. Add ATP to 0.2 mM and MgCI2 to 50 mM. Stir on stir plate at 4 °C for 60 minutes to allow actin to polymerize/form para-crystals. 6. Slowly add solid KCI to 0.6 M (45 g/l). Stir at 4 °C for 30 min. 7. Spin in JLA10 rotor(s) at 10K rpm for 1 hr. 8. Depolymerization: Quickly rinse surface of pellets with buffer A and dispose of wash. Soften the pellets by pre-incubation on ice with small amount of buffer A in each tube (use less than half of final resuspension volume total in all tubes). Resuspend by hand first with cell scraper and 103 WO 2011/133888 PCT/US2011/033614 combine pellets. Wash tubes with extra buffer using a 25 ml pipette and motorized pipettor, aggressively removing actin from sides of tubes. Homogenize in large dounce in cold buffer A on ice. Use 3 ml per gram of powder originally extracted. 9. Dialyze against buffer A with 4 changes over 48 hour period. 10. Collect dialyzed actin and spin in the 45Ti rotor at 40K rpm for 1.5 hr (4 °C). 11. Collect supernatant (G-Actin). Save a sample for gel analysis and determination of protein concentration. 12. To polymerize G-actin for storage, add KCI to 50 mM (from 3 M stock), MgCI2 to 1 mM, and NaN3 to 0.02% (from 10% stock). Store at 4 °C. Do not freeze.

Buffer A: 2 mM tris/HCI, 0.2 mM CaCI2, 0.5 mM (36 μΙ/L) 2-mercaptoethanol, 0.2 mM Na2 ATP (added fresh), and 0.005% Na-azide; pH 8.0.

Purification of Skeletal Muscle Myosin (See Margossian, S.S. and Lowey, S. (1982) Methods Enzymol. 85, 55-123; and Goldmann, W.H. and Geeves, M.A. (1991) Anal. Biochem. 192, 55-58) Solution A: 0.3 M KCI, 0.15 M potassium phosphate, 0.02 M EDTA, 0.005 M MgCI2, 0.001 M ATP, pH 6.5.

Solution B: 1 M KCI, 0.025 M EDTA, 0.06 M potassium phosphate, pH 6.5. Solution C: 0.6 M KCI, 0.025 M potassium phosphate, pH 6.5.

Solution D: 0.6 M KCI, 0.05 M potassium phosphate, pH 6.5.

Solution E: 0.15 M potassium phosphate, 0.01 M EDTA, pH 7.5.

Solution F: 0.04 M KCI, 0.01 M potassium phosphate, 0.001 M DTT, pH 6.5. Solution G: 3 M KCI, 0.01 M potassium phosphate, pH 6.5.

All procedures are carried out at 4 °C. 1. Obtain approx. 1000 g skeletal muscle, such as rabbit skeletal muscle. 2. Grind twice; extract with 2 L solution A for 15 min while stirring; add 4 L cold H2O, filter through gauze; dilute with cold H2O to ionic strength of 0.04, (about 10-fold); let settle for 3 h; collect precipitate at 7,000 rpm in GSA rotor for 15 min. 3. Disperse pellet in 220 ml solution B; dialyze overnight against 6 L solution C; slowly add -400 ml equal volume cold distilled H2O; stir for 30 min; centrifuge at 10,000 rpm for 10 min in GSA rotor. 104 WO 2011/133888 PCT/US2011/033614 4. Centrifuge supernatant at 19,000 rpm for 1 h. 5. Dilute supernatant to ionic strength of 0.04 (~8-fold); let myosin settle overnight; collect about 5-6 L fluffy myosin precipitate by centrifuging at 10,000 rpm for 10 min in GSA rotor. 6. Resuspend pellet in minimal volume of solution G; dialyze overnight against 2 L solution D; centrifuge at 19,000 rpm for 2 h, in cellulose nitrate tubes; puncture tubes and separate myosin from fat and insoluble pellet. 7. Dilute supernatant to 5-10 mg/ml and dialyze against solution E extensively, load onto DEAE-sephadex column. 8. Pre-equilibrate with solution E; apply 500-600 g myosin at 30 ml/h; wash with 350 ml solution E; elute with linear gradient of 0-0.5 M KCl in solution E (2 x 1 liter); collect 10 ml fractions; pool myosin fractions (>0.1 M KCl); concentrate by overnight dialysis against solution F; centrifuge at 25,000 rpm for 30 min; store as above. 9. The myosin is then cut with chymotrypsin or papain in the presence of EDTA to generate the S1 fragment which is soluble at the low salt conditions optimal for ATPase activity (Margossian, supra).

Preparation and Assay

Myosin is prepared by precipitation from salt extracts of rabbit psoas muscle, and a soluble S1 fraction is prepared by digestion with chymotrypsin (Margossian and Lowey, 1982).

Actin is purified by first preparing an ether powder of cardiac muscle (Zot HG and Potter J D. (1981) Preparative Biochemistry 11:381-395) as described above. Subsequently, actin is cycled between the filamentous and soluble state through rounds of centrifugation and dialysis (Spudich J A and Watts. (1971) J. Biol. Chem. 246:4866-4871).

Tropomyosin is extracted from the ether powder and separated from the other proteins based on pH dependent precipitations followed by successive ammonium sulfate cuts at 53% and 65% (Smillie LB. (1981) Methods Enzymol 85 Pt B:234-41). The troponins are isolated as an intact complex of TnC, TnT, and Tnl. Ether powder is extracted in a high salt buffer. Successive ammonium sulfate cuts of 30% and 45% are done; the precipitate is solubilized by dialysis into a low salt buffer and then further purified on a DEAE Toyopearl column with a 25-350 mM KCl gradient. There is no 105 WO 2011/133888 PCT/US2011/033614 measurable ATPase in any of the components except for myosin which naturally had a very low basal ATPase in the absence of actin.

Prior to screening, the actin, tropomyosin, and troponin complex are mixed together in the desired ratio (e.g., 7:1:1) to achieve maximal calcium 5 regulation of the actin filament. The screen is conducted at a concentration that gives 25% activation. This calcium concentration is in the physiological range during muscle contraction.

To measure the generation of ADP during the reaction, a pyruvate kinase/lactate dehydrogenase/NADH coupled enzyme system (PK/LDH) is 10 added to the actin. The myosin is kept separately, and added to the regulated thin filaments to initiate the reaction. Oxidation of NADH is monitored in real time, so that kinetic curves are obtained. Compounds are dissolved in DMSO and spotted onto the bottoms of 384 well plates at 10 to 40 pg/ml final concentration. 15 Using procedures similar to those described herein, utilizing reagents and intermediates commercially available (e.g., Sigma-Aldrich,) or readily synthesized by one of skill in the art, the compounds in Table 2 were synthesized, characterized and tested. AC1.4 values were determined according to the procedure described in Example 21, and the reported median 20 AC1.4 values are as follows: A = < 1 uM; B = 1 -10 uM; C = 10-20 uM; D = >20 uM. 106 WO 2011/133888 PCT/US2011/033614

Table 2

Compound 4- (2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyrimidin-5-yl)benzamide 3-(2-{[2-(4-fluorophenyl)-2- methylpropyl]amino}pyrimidin-5- yl)benzamide 5- (2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyrimidin-5-yl )pyrid ine-3-carbon itri le 5-(2-{[2-(4-fluorophenyl)-2- methylpropyl]amino}pyrimidin-5- yl)pyridine-3-carboxamide 3-(2-aminopyrimidin-5- yl)benzamide [2-(4-fluorophenyl)-2- methylpropyl]-5,6,7,8- tetrahydropyridino[4,3-d]pyrimidin- 2-ylamine

Structure n—N. x rO <

m/z (M+H) 365.3 365.3 348.3 366.3 215.3 301.0

Mean AC1.4

B 107 WO 2011/133888 PCT/US2011/033614 methyl 2-{[2-(4-fluorophenyl)-2- methylpropyl]amino}pyrimidine-5- carboxylate N-[2-(4-fluorophenyl)-2- methylpropyl](2-{[2-(4- fluorophenyl)-2- methylpropyl]amino}pyrimidin-5- yl)carboxamide ethyl 1-[(2-{[2-(4-fluorophenyl)-2- methylpropyl]amino}pyrimidin-5- yl)carbonylamino]cyclopropanecar boxylate 2-{[2-(4-fluorophenyl)-2- methylpropyl]amino}pyrimidine-5- carboxylic acid

F 304.1 439.1 401.1 289.0 (5-bromopyrimidin-2-yl)[2-(4- fluorophenyl)-2- methylpropyl]amine 1 -[(2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyrimidin-5-yl)carbonylamino]cyclopropanecar boxylic acid 1 -[(2-{[2-(4-fluorophenyl)-2- methylpropyl]amino}pyrimidin-5- yl)carbonylamino]cyclopropanecar boxamide

F

324.0 373.1 373.1 108 WO 2011/133888 PCT/US2011/033614 5- (2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}pyrimidin-5-yl)-3-hydrobenzimidazol-2-one 6- acetyl-2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-5,6,7,8-tetrahydropyridino[4,3-d]pyrimidine 2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-6-(methylsulfonyl)-5,6,7,8- tetrahydropyridino[4,3-d]pyrimidine [2-(4-fluorophenyl)-2-methylpropyl](6-methyl(5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-2-yl))amine 2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-5,6,7,8-tetrahyd ropyrid i no[4,3-d]pyrimidine-6-carboxamide 2-(2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}(5,6,7,8-tetrahydropyridino[4,3-d]pyrimidin-6-yl))-2-oxoacetamide 2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-5,6,7,8-tetrahyd ropyrid i no[3,4-d]pyrimidine-7-carboxamide

378.1 343.0 379.0 315.0 301.0

372.0 344.0 109 WO 2011/133888 PCT/US2011/033614 2-(2-{[2-(4-fluorophenyl)-2- methylpropyl]amino}(5,6,7,8- tetrahydropyridino[3,4-d]pyrimidin- 7-yl))-2-oxoacetamide 2-{[2-(4-fluorophenyl)-2-methylpropyl]amino}-7-(methylsulfonyl)-5,6,7,8-tetrahydropyridino[3,4-d]pyrimidine [5-(3-amino(1 H-indazol-5- yl))pyrimidin-2-yl][2-(4- fluorophenyl)-2- methylpropyl]aimine 4-fluoro-3-(2-{[(3-fluoro(2- pyridyl))cyclobutyl]amino}pyrimidin -5-yl)benzamide 4-(2-{[(4- fluorophenyl)cyclobutyl]amino}pyri midin-5-yl)pyridine-2-carbonitrile 4-fluoro-3-(2-{[(4- fluorophenyl)cyclobutyl]amino}pyri midin-5-yl)benzamide 4- (2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}pyrimidin- 5- yl)pyndine-2-carbonitrile

372.0 379.0 377.1 382.1 346.1 381.1 347.1 110 WO 2011/133888 PCT/US2011/033614 4- (2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}pyrimidin- 5- yl)pyndine-2-carboxamide 4- (2-{[(4- fluorophenyl)cyclobutyl]amino}pyri midin-5-yl)pyridine-2-carboxamide (5-( 1 H-indazol-5-yl)pyrim idin-2- yl)[(3-fluoro(2- pyridyl))cyclobutyl]amine 5- (2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}pyrimidin- 5-yl)-1H-indazole-3-carbonitrile 365.1 364.1 361.1 386.1 5-(2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}pyrimidin- 5- yl)-1H-indazole-3-carboxamide [5-(6-fluoro(1 H-indazol-5- yl))pyrimidin-2-yl][(3-fluoro(2- pyridyl))cyclobutyl]amine 6- fluoro-5-(2-{[(3-fluoro(2-pyridyl))cyclobutyl]amino}pyrimidin -5-yl)-1H-indazole-3-carbonitrile

404.1 379.1 404.1 111 WO 2011/133888 PCT/US2011/033614 6-fluoro-5-(2-{[(3-fluoro(2- pyridyl))cyclobutyl]amino}pyrimidin -5-yl)-1H-indazole-3-carboxamide (5-bromopyrimidin-2-yl)[(4- fluorophenyl)cyclobutyl]amine (5-bromopyrimidin-2-yl)[(3-fluoro(2- pyridyl))cyclobutyl]amine (6-bromoquinazolin-2-yl)[(3- fluoro(2-pyridyl))cyclobutyl]amine 2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}quinazolin e-6-carbonitrile [(3-fluoro(2- pyridyl))cyclobutyl]quinazolin-2- ylamine 2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}quinazolin e-6-carboxamide 2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}pyrimidine -5-carbonitrile 2-{[(4- fluorophenyl)cyclobutyl]amino}pyri midine-5-carbonitrile

422.1 322.0 323.0 373.0 320.1 295.1 338.1 270.1 269.1 112 WO 2011/133888 PCT/US2011/033614 (5-bromopyrimidin-2-yl)[1-(4- fluorophenyl)-isopropyl]amine 2-{[(4- fluorophenyl)cyclobutyl]amino}pyri midine-4-carboxamide 2-{[(4- fluorophenyl)cyclobutyl]amino}pyri midine-4-carbonitrile [(4- fluorophenyl)cyclobutyl]pyrazolo[5, 4-d]pyrimidin-6-ylamine 2-{[(4- fluorophenyl)cyclobutyl]amino}pyri midine-5-carboxamide 2-{[(3-fluoro-2- pyridyl)cyclobutyl]amino}pyrimidine -5-carboxamide 2-{[(4- fluorophenyl)cyclobutyl]amino}-4- (trifluoromethyl)pyrimidine-5- carboxamide 2-{[(4- fluorophenyl)cyclobutyl]amino}-4-(trifluoromethyl)pyrimidine-5-carboxylic acid

310.0 C

287.1 C

269.1 D

284.1 D

287.1 D

288.1 D

355.1 B

356.1 D

[(4-fluorophenyl)cyclobutyl][4- (trifluoromethyl)pyrimidin-2- yl]amine

312.1 C 113 WO 2011/133888 PCT/US2011/033614 N-[(4-fluorophenyl)cyclobutyl](2- {[(4- fluorophenyl)cyclobutyl]amino}-4- (trifluoromethyl)pyrimidin-5- yl)carboxamide 2-{[(3-fluoro(2- pyridyl))cyclobutyl]amino}-4- (trifluoromethyl)pyrimidine-5- carboxamide 2-{[(3-fluoro(2- pyridyl))cyclobutyl]amino}-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(3-fluoro(2-pyridyl))cyclobutyl][4- (trifluoromethyl)pyrimidin-2- yl]amine

ethyl 1-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5-yl]pyrazole-4-carboxylate

1-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5-yl]pyrazole-4- carboxamide 1-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5-yl]pyrazole-4-carboxylic acid

114 WO 2011/133888 PCT/US2011/033614 2-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazole-4- carboxamide 2-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazole-5- carboxamide ethyl 2-[2-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazole-4-carboxylate

2-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazole-4- carboxylic acid

386.2 C 2-[2-({1-[6-(difluoromethoxy)(2- pyridyl)]-isopropyl}amino)pyrimidin- 5-y I]-1,3-th iazole-5-ca rboxa m id e 2-(2-{[(2- pyridylcyclobutyl)methyl]amino}pyri midin-5-yl)-1,3-thiazole-5- carboxamide

115 WO 2011/133888 PCT/US2011/033614 2-(2-{[(2- pyridylcyclobutyl)methyl]amino}pyri m idin-5-yl)-1,3-thiazole-5- carbonitrile 2-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazole-5- carbonitrile

2-(2-{[ 1 -(4-m ethoxy py ri m id i n-2-y I )-isopropyl]amino}pyrimidin-5-yl)- 1,3-thiazole-5-carboxamide {4-[6-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yridazin-3-yl]pyrimidin-2-yl}(methylsulfonyl)amine ethyl 2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)thi opheno[2,3-d]pyrimidine-6- carboxylate 2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)thi opheno[2,3-d]pyrimidine-6- carboxamide 2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)thi opheno[2,3-d]pyrimidine-6-carboxylic acid

358.1 358.1 116 WO 2011/133888 PCT/US2011/033614 4-fluoro-3-(2-{[2-(3-fluoro(2- pyridyl ))-2- methylpropyl]amino}pyrimidin-5- yl)benzamide 4-fluoro-3-[2-({[(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl] benzamide 3-(2-{[2-(3-fluoro(2-pyridyl))-2- methylpropyl]amino}pyrimidin-5- yl)benzamide 3-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5-yl]benzamide 3-[2-({1-[6-(difluoromethoxy)(2- pyridyl)]-isopropyl}amino)pyrimidin- 5-yl]-4-fluorobenzamide 3-[2-({1-[6-(difluoromethoxy)(2- pyridyl)]-isopropyl}amino)pyrimidin-5-yl] benzamide 3-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)benzamide

384.1 396.1 366.1 378.2 418.2 400.3 352.3 117 WO 2011/133888 PCT/US2011/033614 5-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)- 1,3-thiazolo[5,4-d]pyrimidine-2- carboxamide

5-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)· 1,3-thiazolo[5,4-d]pyrimidine-2- carboxylic acid

4- fluoro-3-(2-{[1 -(3-fluoro(2-pyridyl))-isopropyl]amino}pyrimidin- 5- yl)benzamide

F N-{[4-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)phenyl]methyl}acetamide [5-(2-aminopyrimidin-5-y I )py ri m id i n-2-y I] [ 1 -(3-f I uoro(2- pyridyl))-isopropyl]amine 2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1,3-thiazole-5-carboxamide 2-(2-{[2-(3-fluoro(2-pyridyl))-2- methylpropyl]amino}pyrimidin-5- yl)pyrimidine-4-carboxamide

118 WO 2011/133888 PCT/US2011/033614 methyl 2-[4-fluoro-3-(2-{[1-(3- fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)phenyl]acetate N-{[3-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)phenyl]methyl}acetamide 3-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)benzamide 3-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-4- fluorobenzamide 1 -(2-{[ 1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5- yl)pyrazole-4-carbonitrile 1 -(2-{[ 1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)pyrazole-4-carboxamide 2-[4-fluoro-3-(2-{[1-(3-fluoro(2- pyridyl))-isopropyl]amino}pyrimidin- 5-yl)phenyl]acetamide 2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-y I )py ri m id i n e-4-ca rboxa m id e

399.1 380.1 368.1 386.1 340.1 358.1 384.1 354.1 119 WO 2011/133888 PCT/US2011/033614 {5-[5-(aminomethyl)(1,3-thiazol-2- yl)]pyrimidin-2-yl}[1-(3-fluoro(2- pyridyl))-isopropyl]amine N-{[2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1,3-thiazol-5-yl]methyl}acetamide 2-amino-N-{[2-(2-{[1-(3-fluoro(2- pyridyl))-isopropyl]amino}pyrimidin- 5-yl)(1,3-thiazol-5- yl)]methyl}acetamide N-{[2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)(1,3-thiazol-5- yl)]methyl}imidazol-5- ylcarboxamide N-{[2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)(1,3-thiazol-5-yl)]methyl}(2- hydroxyimidazol-5-yl)carboxamide (aminocyclopropyl)-N-{[2-(2-{[1-(3- fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)(1,3-thiazol-5-yl)]methyl}carboxamide ((2R)pyrrolidin-2-yl)-N-{[2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)(1,3-thiazol-5- yl)]methyl}carboxamide

345.2 387.1 402.2 439.1 455.1 428.1 442.2 120 WO 2011/133888 PCT/US2011/033614 ((2S)pyrrolid in-2-yl)-N-{[2-(2-{[1 -(3- fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)(1,3-thiazol-5- yl)]methyl}carboxamide N-{[2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- thiazol-4-yl]methyl}acetamide 2-[2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- thiazol-4-yl]acetamide 1 -(2-{[ 1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5- yl)pyrrole-3-carboxamide 1 -(2-{[ 1 -(3-fluoro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)pyrazole-4-carboxamide {5-[4-(aminomethyl)(1,3-thiazol-2- yl)]pyrimidin-2-yl}[1-(3-fluoro(2- pyridyl))-isopropyl]amine

387.3 373.3 357.1 342.2 345.3 2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- thiazole-4-carbonitrile 2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- thiazole-4-carboxamide

121 WO 2011/133888 PCT/US2011/033614 2-amino-N-{[2-(2-{[1-(3-fluoro(2- pyridyl))-isopropyl]amino}pyrimidin- 5-yl)(1,3-thiazol-4- yl)]methyl}acetamide ((2S)pyrrolid i n-2-y l)-N-{[2-(2-{[1 -(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)(1,3-thiazol-4- yl)]methyl}carboxamide ((2R)pyrrolidin-2-yl)-N-{[2-(2-{[1-(3- fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)(1,3-thiazol-4- yl)]methyl}carboxamide 2-(2-{[1-(3-fluoro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- thiazole-5-carbonitrile 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- thiazole-5-carboxamide 1 -(2-{[ 1 -(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrazole-4-carboxylic acid N-(2-carbamoylethyl)[1 -(2-{[ 1 -(3- chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrazol-4-yl]carboxamide

402.2 442.3 442.3 341.2 375.2 359.1 429.1 122 WO 2011/133888 PCT/US2011/033614 [1 -(2-{[1 -(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrazol-4-yl]-N-(2- hyd roxyet hy I )ca rboxa m id e 2-[ 1 -(2-{[1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)pyrazol-4-yl]propan-2-ol 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)isoxazole-3-carboxamide [1-(3-chloro(2-pyridyl))- isopropyl](5-pyrazol-4-ylpyrimidin- 2-yl)amine 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyridine-3-carboxamide 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)thiophene-2-carboxylic acid 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)thiophene-2-carboxamide (5-bromopyrimidin-2-yl)[1-(3- fluoro(2-pyridyl))-isopropyl]amine 2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidine-5- carbonitrile

315.1 369.1 375.0 374.1 311.0 274.1 123 WO 2011/133888 PCT/US2011/033614 (5-bromopyrimidin-2-yl)[1-(3- chloro(2-pyridyl))-isopropyl]amine 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- oxazole-4-carboxamide 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- oxazole-4-carboxylic acid 4-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridine-2- carboxamide 4-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridine-2- carboxamide 4-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5-yl]pyridine-2- carboxamide [1-(3-chloro(2-pyridyl))- isopropyl](5-pyrrolo[3,2-b]pyridin-6- ylpyrimidin-2-yl)amine 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- oxazole-5-carboxamide

328.1 359.2 360.2

397.3

397.3

379.3 365.2 359.2 124 WO 2011/133888 PCT/US2011/033614 4-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyridine-2-carboxamide 4-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)· 1,3-thiazole-2-carboxamide 2-{[1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidine-5- carboxamide [5-(3-amino(1 H-indazol-5- yl))pyrimidin-2-yl][1-(3-chloro(2· pyridyl))-isopropyl]amine

369.3 375.2 292.1 380.1 3-(2-{[1-methyl-1-(4- methylthiophenyl)ethyl]amino}pyri midin-5-yl)benzenecarbonitrile 3-(2-{[1-methyl-1-(2- methylthiophenyl)ethyl]amino}pyri midin-5-yl)benzenecarbonitrile 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrazole-3-carboxamide 3-(2-(2-(4- (methylsulfinyl)phenyl)propan-2-ylamino)pyrimidin-5-yl)benzamide 3-[2-({1-methyl-1-[4-(methylsulfonyl)phenyl]ethyl}amino )pyrimidin-5-yl] benzamide

361.2 361.2 358.1 395.2 411.2 125 WO 2011/133888 PCT/US2011/033614 3-[2-({1 -methyl-1 -[2- (methylsulfonyl)phenyl]ethyl}amino )pyrimidin-5-yl] benzamide 3-[2-({ 1-methyl-1-[3- (methylsulfonyl)(2- pyridyl)]ethyl}amino)pyrimidin-5- yl] benzamide 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1,3-thiazole-4-carboxamide

411.2 412.2 375.2 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.3- thiazole-4-carboxylic acid 2- (2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)- 1.3- oxazole-5-carboxylic acid 3- (2-{[ 1 -methyl-1 -(3-methylthio(2-pyridyl))ethyl]amino}pyrimidin-5-yl)benzenecarbonitrile 3-(2-{[1-methyl-1-(2- methylthiophenyl)ethyl]amino}pyri midin-5-yl)benzamide 3-(2-(2-(2- (methylsulfinyl)phenyl)propan-2- ylamino)pyrimidin-5-yl)benzamide

376.2 360.2 362.2 379.3 395.2 126 WO 2011/133888 PCT/US2011/033614 [1-(3-chloro(2-pyridyl))- isopropyl]pyrimidin-2-ylamine 3-(2-{[ 1 -methyl-1 -(3-methylthio(2- pyridyl))ethyl]amino}pyrimidin-5- yl)benzamide 3-(2-(2-(3-(methylsulfinyl)pyridin-2- yl)propan-2-ylamino)pyrimidin-5- yl)benzamide 3-[2-({ 1-methyl-1-[3- (methylsulfonyl)(2- pyridyl)]ethyl}(hydroxyamino))pyri midin-5-yl] benzamide 3-[2-({1-[3-(difluoromethyl)(2- pyridyl)]-isopropyl}amino)pyrimidin- 5-yl]-4-fluorobenzenecarbonitrile 3-[2-({1-[3-(difluoromethyl)(2- pyridyl)]-isopropyl}amino)pyrimidin- 5-yl]-4-fluorobenzamide (5-(51-1-1,2,3,4-tetraazol-5- yl)pyrimidin-2-yl)[1-(3-chloro(2- pyridyl))-isopropyl]amine ethyl 5-(2-{[1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)- 1,3,4-oxadiazole-2-carboxylate

249.2 380.2 396.2 428.2 384.1 402.1 317.1 389.1 127 WO 2011/133888 PCT/US2011/033614 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1,3,4-oxadiazole-2-carboxamide methyl 4-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin- 5-yl)thiophene-2-carboxylate 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1,3-thiazole-2-carboxamide

5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1,3,4-thiadiazole-2-carboxamide

methyl 4-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-y I)-1 -methylim idazole-2- carboxylate

6-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyridine-2-carboxamide

3-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1.2.4- oxadiazole-5-carboxamide ethyl 5-(2-{[1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)- 1.2.4- oxadiazole-3-carboxylate

128 WO 2011/133888 PCT/US2011/033614 [5-(3-amino(1 H-indazol-5- yl))pyrimidin-2-yl][1-(3-fluoro(2- pyridyl))-isopropyl]amine 4-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)thiophene-2-carboxamide [1-(3-chloro(2-pyridyl))-isopropyl](5-( 1,2,4-oxad iazol-5-yl)pyrimidin-2-yl)amine 4- fluoro-3-(2-{[1-(3-methoxy(2-pyridyl))-isopropyl]amino}pyrimidin· 5- yl)benzenecarbonitrile 4-fluoro-3-(2-{[1 -methyl-1 -(3-methyl(2- pyridyl))ethyl]amino}pyrimidin-5- yl)benzamide 4- fluoro-3-(2-{[1-(3-methoxy(2-pyridyl))-isopropyl]amino}pyrimidin· 5- yl)benzamide {5-[5-(aminomethyl)(1,3-thiazol-2- yl)]pyrimidin-2-yl}[1-(3-chloro(2- pyridyl))-isopropyl]amine N-{[2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)- 1,3-thiazol-5-yl]methyl}acetamide

364.2 374.1 317.1 364.1 366.1 382.1 361.0 403.1 129 WO 2011/133888 PCT/US2011/033614 N-{[2-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)( 1,3-thiazol-5-yl)]methyl}-2- hydroxy-2-methylpropanamide N-{[2-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)(1,3-thiazol-5-yl)]methyl}(2-hydroxyim idazol-4-yl)carboxam ide 3-(2-{[1-(3-chloro-6-hydroxy(2- pyridyl))-isopropyl]amino}pyrimidin· 5-yl)benzamide 3-(2-{[1 -(3-chloro-6-methoxy(2- pyridyl))-isopropyl]amino}pyrimidin· 5-yl)benzamide [1-(3-chloro(2-pyridyl))-isopropyl](5-(1,3-thiazol-2-yl)pyrimidin-2-yl)amine 2-[4-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)pyrazolyl]ethan-1 -ol 2-[4-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)pyrazolyl]acetic acid 2-[4-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrazolyl]acetamide

447.1 471.1 384.1 398.1 332.1 359.1 373.1 372.1 130 WO 2011/133888 PCT/US2011/033614 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyridine-4-carbonitrile 2- (2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5- yl)pyridine-4-carboxamide N-{[ 1 -(2-{[1 -(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrazol-4-yl]methyl}acetamide 4-fluoro-3-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl] benzamide 3- [2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl] benzamide 6-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-2- pyrrolino[3,2-b]pyridin-2-one 6-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl )im idazo[2,1 -b] 1,3-th iazoli ne-2- carboxamide [5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)(1H- indazol-3-yl)](methylsulfonyl)amine

351.1 369.1 386.1 414.3 396.3 381.1 414.1 458.1 131 WO 2011/133888 PCT/US2011/033614 [1-(3-chloro(2-pyridyl))-isopropyl](4-(1,3-thiazol-2-yl)pyrimidin-2-yl)amine {1-[6-(difluoromethoxy)(2-pyridyl)]-isopropyl}(4-(1,3-thiazol-2-yl)pyrimidin-2-yl)amine 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-1- methylpyrazole-3-carboxamide

332.2 364.2 372.2 3-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-1- methylpyrazole-5-carboxamide

6-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)imidazo[2,1-b]1,3-thiazoline-3- carboxamide 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-2- methoxypyridine-3-carbonitrile 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-2- methoxypyridine-3-carboxamide 5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-2- oxohydropyridine-3-carboxamide

414.1 381.1 399.1 385.1 132 WO 2011/133888 PCT/US2011/033614 2-[(tert-butoxy)carbonylamino]-N-{[1 -(2-{[1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5- yl)pyrazol-4-yl]methyl}acetamide 2- am ino-N-{[1 -(2-{[1 -(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)pyrazol-4-yl]methyl}acetamide 3- [(tert-butoxy)carbonylamino]-N-{[T(2-{[1 -(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrazol-4- yl]methyl}propanamide 3-am ino-N-{[1 -(2-{[1 -(3-chloro(2- pyridyl))-isopropyl]amino}pyrimidin- 5-yl)pyrazol-4- yl]methyl}propanamide

1 -[2-({[3-f luoro-1 -(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrim id in-5-yl] pyrazole-4-carbon itri le

368.2 {[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}pyrimidin -2-ylamine 1 -[2-({[3-fluoro-1 -(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrazole-4- carboxamide

277.2 382.3 133 WO 2011/133888 PCT/US2011/033614 3-(2-{[2-(3-chloro(2-pyridyl))-2- methylpropyl]amino}pyrimidin-5- yl)benzamide 3-(2-{[2-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyrimidin-5-y I )-4-f I uoro be nza m id e 2-(2-{[(1R)-1-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyrimidin-5-yl)-1,3-thiazole-5-carbonitrile 2-(2-{[( 1 S)-1 -(3-ch loro(2-py ridy I ))-2-methylpropyl]amino}pyriimidin-5-yl)-1,3-thiazole-5-carbonitrile 2-(2-{[(1R)-1-(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyrimidin-5-yl)-1,3-thiazole-5-carboxamide

382.3 400.2 371.2 371.2 389.2 2-(2-{[( 1 S)-1 -(3-chloro(2-pyridyl))-2-methylpropyl]amino}pyrimidin-5-yl)-1,3-thiazole-5-carboxamide ethyl 3-(2-{[ 1 -(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)isoxazole-5-carboxylate

134 WO 2011/133888 PCT/US2011/033614 3-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)isoxazole-5-carboxamide (5-( 1 H-indazol-5-yl)pyrim idin-2- yl)[1-(3-chloro(2-pyridyl))- isopropyl]amine N-[5-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-1H- indazol-3-yl]acetamide

359.2 3-[2-({[1-(3-chloro(2-pyridyl))-3- fluorocyclobutyl]methyl}amino)pyri midin-5-yl]-4-fluorobenzamide 3-[2-({[1-(3-chloro(2-pyridyl))-3- fluorocyclobutyl]methyl}amino)pyri midin-5-yl]-4-fluorobenzamide 4-fluoro-3-(2-{[(3-fluoro-1-(2- pyridyl)cyclobutyl)methyl]amino}py rimidin-5-yl)benzamide 4-fluoro-3-(2-{[(3-fluoro-1-(2- pyridyl)cyclobutyl)methyl]amino}py rimidin-5-yl)benzamide

365.1 422.1 430.2 430.2 396.2 396.2 135 WO 2011/133888 PCT/US2011/033614 6-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5- yl)pyrimidine-4-carboxamide methyl 6-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin· 5-yl)pyrimidine-4-carboxylate 3-{2-[(tert-butyl)amino]pyrimidin-5- yljbenzamide [5-(3-amino(1 H-indazol-5-yl))pyrimidin-2-yl](tert-butyl)amine

370.2 385.2 271.3 283.3 3-(2-{[1-(3-chloro(2-pyridyl))-3- fluorocyclobutyl]amino}pyrimidin-5- y I )-4-f I uoro be nza m id e 3-[2-({[(3-chloro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4-fluorobenzamide 3-[2-({[(3-chloro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5-yl]benzamide 3-(2-{[(2- pyridylcyclobutyl)methyl]amino}pyri midin-5-yl)benzamide

416.2 412.2 394.3 360.3 136 WO 2011/133888 PCT/US2011/033614 4-fluoro-3-(2-{[(2- pyridylcyclobutyl)methyl]amino}pyri midin-5-yl)benzamide 3-[2-({[(3-chloro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4- fluorobenzenecarbonitrile 3-[2-({[(3-chloro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5-yl]benzenecarbonitrile {[(3-chloro(2- pyridyl))cyclobutyl]methyl}pyrimidin -2-ylamine 3-(2-{[1-(2-chloro(3-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-4- fluorobenzamide 6-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)imidazo[2,1-b]1,3-thiazoline-3-carboxylic acid 2-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)-4-hydroimidazo[1,2-a]pyridine-6-carboxylic acid

378.3 394.2 376.2 275.2 386.2 415.0 409.1 137 WO 2011/133888 PCT/US2011/033614 2-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)-4-hydroimidazo[1,2-a]pyridine-6- carboxamide

methyl 1-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrrole-3-carboxylate 1 -[2-({[3-f luoro-1 -(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrrole-3-carboxylic acid

1 -[2-({[3-fluoro-1 -(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrrole-3- carboxamide

Ν' [' V-NH nh2

385.3 2-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)-4-hydroimidazo[1,2-a]pyridine-8- carboxamide 2-(2-{[1-(3-chloro(2-pyridyl))- isopropyl]amino}pyrimidin-5-yl)-4- hydroimidazo[1,2-a]pyridine-7- carboxamide 5-(2-{[1-(3-chloro(2-pyridyl))-isopropyl]amino}pyrimidin-5-yl)pyridazine-3-carboxam ide

408.1 408.1 370.2 138 WO 2011/133888 PCT/US2011/033614 N-(tert-butyl)[5-(2-{[1-(3-chloro(2- pyridyl))-isopropyl]amino}pyrimidin- 5-yl)pyridazin-3-yl]carboxamide {3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N- (methylsulfonyl)carboxamide 2-{2-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rim id in-5-yl]-1,3-thiazol-5- yl}ethanenitrile 2-{2-[2-({[(3-chloro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazol-5- yljacetamide

426.2 474.1 381.2 415.1 3-[2-({[1-(3-chloro(2-pyridyl))-3,3- difluorocyclobutyl]methyl}amino)py rimidin-5-yl]-4-fluorobenzamide

448.2 3- [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)- 4- methylpyrimidin-5-yl] benzamide 2-{2-[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazol-5-yl}acetamide

139 WO 2011/133888 PCT/US2011/033614 2-{2-[2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrim id in-5-yl]-1,3-thiazol-5- yljacetamide (tert-butoxy)-N-({2-[2-({[(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]( 1,3-thiazol-5-yl)}methyl)carboxamide {5-[5-(aminomethyl)(1,3-thiazol-2- yl)]pyrimidin-2-yl}{[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine N-({2-[2-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazol-5- yl}methyl)acetamide (tert-butoxy )-N-({2-[2-({[(3-chloro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]( 1,3-thiazol-5- yl)}methyl)carboxamide {5-[5-(aminomethyl)(1,3-thiazol-2- yl)]pyrimidin-2-yl}{[(3-chloro(2- pyridyl))cyclobutyl]methyl}amine N-({2-[2-({[(3-chloro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]-1,3-thiazol-5-yl}methyl)acetamide

417.1

471.2 371.1

387.1 429.1 140 WO 2011/133888 PCT/US2011/033614 ({2-[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]( 1,3-thiazol-5- yl)}methyl)(methylsulfonyl)amine 2-{2-[2-({[1-(3-chloro(2-pyridyl))-3-fluorocyclobutyl]methyl}amino)pyri midin-5-yl]-1,3-thiazol-5-yljacetamide (tert-butoxy)-N-{[2-(2-{[(2-pyridylcyclobutyl)methyl]amino}pyri midin-5-yl)(1,3-thiazol-5-yl)]methyl}carboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-isoxazol-3- ylcarboxamide

449.1

433.2 369.2 [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(1,3-thiazol-2- yl)carboxamide 2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rimidine-5-carboxamide

HN '-N

385.2 302.2 ru

141 WO 2011/133888 PCT/US2011/033614 [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N- methylcarboxamide N-ethyl[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]carboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(2- hydroxyethyl)carboxamide N-{2-[(tert- butoxy)carbonylamino]ethyl}[2- ({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]carboxamide N-(2-{[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rimidin-5- yl]carbonylamino}ethyl)acetamide methyl 2-{[2-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]carbonylam inojacetate

316.2 D

330.2 D

346.2 D

445.2 D

387.2 D

374.2 D 142 WO 2011/133888 PCT/US2011/033614 {3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N- methylcarboxamide {4-fluoro-3-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N- methylcarboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-pyrazol-5- ylcarboxamide 5-aminopyrazolyl 2-({[(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl ketone [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(3-methylpyrazol- 5-yl)carboxamide N-(2-aminoethyl)[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]carboxamide

410.3 428.3 368.2 368.2 382.2 346.2 143 WO 2011/133888 PCT/US2011/033614 [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-{2- [(methylsulfonyl)amino]ethyl}carbo xamide

2-{[2-({[(3-fluoro-2- pyridyl)cyclobutyl]methyl}amino)py rim idin-5-yl]carbonylam ino}acetic acid {3-[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N- methylcarboxamide {4-fluoro-3-[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N- methylcarboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-benzamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(3- pyridyl)carboxamide

360.2 392.3 410.3 378.2 379.2 144 WO 2011/133888 PCT/US2011/033614 {3-[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4-hydroxyphenyl}-N- methylcarboxamide 3-[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4-hydroxybenzamide {3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4-hydroxyphenyl}-N- methylcarboxamide 3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4-hydroxybenzamide

408.1 394.2 426.1 412.1 {1-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrrol-3-yl}-N- methylcarboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(1-methylpyrazol- 5-yl)carboxamide

145 WO 2011/133888 PCT/US2011/033614 [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(4- pyridyl)carboxamide 2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl pyrazolyl ketone [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(1,3,4-thiadiazol-2- yl)carboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(2- fluorophenyl)carboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(3- fluorophenyl)carboxamide

379.2 B

353.2 C

386.2 B

396.2 D

396.2 D 146 WO 2011/133888 PCT/US2011/033614 [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(4- fluorophenyl)carboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-(6-methoxy(3- pyridyl))carboxamide {2-[2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrim idin-5-yl](4-pyridyl)}-N- methylcarboxamide

396.2 409.2 411.3 {[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]amino}-N-(1,3-thiazol- 2-yl)carboxamide

400.2 B

[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-N-methyl-N-(1,3-thiazol-2-yl)carboxamide

147 WO 2011/133888 PCT/US2011/033614 {[(3-fluoro(2- pyridyl))cyclobutyl]methyl}(5- imidazol-2-ylpyrimidin-2-yl)amine N-[2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrim id in-5-yl]-1,3-thiazol-2-ylcarboxamide

325.3

385.2 7-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]indolin-2-one 3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4-hydroxybenzoic acid methyl 3-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4-hydroxybenzoate 1 -[2-({[3-f luoro-1 -(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-6-oxohydropyridine- 3-carboxylic acid

408.3 413.1 427.1 414.1 148 WO 2011/133888 PCT/US2011/033614 1 -[2-({[3-f luoro-1 -(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-6-oxohydropyridine- 3-ca rboxa m ide 2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrimidine-4- carbonitrile {2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrimidin-4-yl}-N- methylcarboxamide 2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrimidine-4- carboxamide 7-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]isoindolin-1-one {[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}[5-(2- fluorophenyl)pyrimidin-2-yl]amine

F 149 WO 2011/133888 PCT/US2011/033614 2-[2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl] benzamide 2-{2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}acetamide N-{2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}acetamide 2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl] benzene-1,4- dicarboxamide 4-fluoro-2-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl] benzamide 2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridine-4-carbonitrile 2-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridine-4- carboxamide

396.3 410.3 410.3 439.3 414.3 379.2 397.3 150 WO 2011/133888 PCT/US2011/033614 2-{3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)- 4-methylpyrimidin-5- yl]phenyl}acetamide 4-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)- 4-methylpyrimidin-5- yl]benzenecarbonitrile

4-[2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)-4-methylpyrimidin-5-yl] benzamide

410.3 6-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridin-3-ol

[5-(5-aminopyrazin-2-yl)pyrimidin- 2-yl]{[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine

5-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-2-hydroxybenzamide

412.1 2-{4-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)- 4-methylpyrimidin-5- yl]phenyl}acetamide

151 WO 2011/133888 PCT/US2011/033614 2- {4-[2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)-4-methylpyrimidin-5-yl]phenyl}acetic acid [5-(2-amino-5-methylpyrimidin-4- yl)pyrimidin-2-yl]{[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amine [5-(2-amino-4-methylpyrimidin-5- yl)pyrimidin-2-yl]{[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amine 3- [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridin-2-ol

384.3 384.3 370.2 425.3 [5-(6-aminopyridazin-3- yl)pyrimidin-2-yl]{[3-fluoro-1 -(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine [5-(2-aminopyrimidin-5-yl)pyrimidin-2-yl]{[3-fluoro-1 -(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine 5-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridin-2-ol

370.1 370.2 152 WO 2011/133888 PCT/US2011/033614 {[3-fluoro-1 -(3-fluoro(2-pyridyl))cyclobutyl]methyl}[5-(6-methoxy(3-pyridyl))pyrimidin-2-yl]amine [5-(6-aminopyrazin-2-yl)pyrimidin 2-yl]{[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine [5-(2-aminopyrimidin-4- yl)pyrimidin-2-yl]{[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amine [5-(2-amino-5-fluoropyrimidin-4-yl)pyrimidin-2-yl]{[3-fluoro-1 -(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine 5-{2-[4-(3-fluoro-2-pyridyl)-2- azabicyclo[2.1.1]hex-2- y I] py ri m id i n-5-y I} pyr i m id i n-2-ol (5-bromo-4-methoxypyrimidin-2- yl){[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine

(5-bromo-4-methoxypyrimidin-2-yl ){[3-f I uoro-1 -(3-f I uoro(2-pyridyl))cyclobutyl]methyl}amine

370.1 370.1 388.1 351.2 387.1 387.1 153 WO 2011/133888 PCT/US2011/033614 3- [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)- 4- m ethoxypyrim id i n-5- yl] benzamide 3- [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)- 4- hydroxypyrimidin-5-yl] benzoic acid 3- [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)- 4- hydroxypyrimidin-5-yl] benzamide 5- [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyrimidin-2-ol

426.3 413.2 412.2

371.3 {[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}[5-(2- methoxypyrimidin-5-yl)pyrimidin-2- yl]amine

6-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridazin-3-ol

371.2 {[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}[5-(6- methoxypyridazin-3-yl)pyrimidin-2- yl]amine

154 WO 2011/133888 PCT/US2011/033614 1 -[2-({[3-fluoro-1 -(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-4- hydroxyhydropyridin-2-one

F

5-fluoro-6-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]pyridin-3-ol {3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N-(1-methylazetidin-3-yl)ca rboxa m id e {4-fluoro-3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N-(1- methylazetidin-3-yl)ca rboxa m id e N-(1-acetylazetidin-3-yl){3-[2-({[3- fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}carboxamide N-( 1 -acetylazetidin-3-yl){4-fluoro-3· [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}carboxamide

511.3 155 WO 2011/133888 PCT/US2011/033614 {4-fluoro-3-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N-[1- (methylsulfonyl)azetidin-3- yl] carboxamide {3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N-[1 - (methylsulfonyl)azetidin-3- yl] carboxamide

{[3-f luoro-1 -(3-f I uoro(2-pyridyl))cyclobutyl]methyl}(4-methoxy-5-phenylpyrimidin-2 yl)amine {[3-f luoro-1 -(3-f I uoro(2-pyridyl))cyclobutyl]methyl}(4-methoxy-5-phenylpyrimidin-2· yl)amine {[3-f luoro-1 -(3-f I uoro(2-pyridyl))cyclobutyl]methyl}(4-methoxy-5-phenylpyrimidin-2· yl)methylamine {[3-f luoro-1 -(3-f I uoro(2- pyridyl))cyclobutyl]methyl}(4- methoxypyrimidin-2-yl)aimine

383.2 383.3 397.2 307.1 156 WO 2011/133888 PCT/US2011/033614 (4-amino-5-phenylpyrimidin-2- yl){[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amine

{[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}[4- (methylamino)-5-phenylpyrimidin- 2-yl]amine [2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)- 5-phenylpyrimidin-4- yl]dimethylamine [2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)- 5-phenylpyrimidin-4-yl](2- methoxyethyl)amine {3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N-(3- hyd roxycyclobu ty I )ca rboxa m id e {4-fluoro-3-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]phenyl}-N-(3- hyd roxycyclobu ty I )ca rboxa m id e F’

-NH

466.3

484.3 382.1 396.1 426.1 157 WO 2011/133888 PCT/US2011/033614 4- fluoro-3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-2-hydroxybenzamide 3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-2-hydroxybenzamide [5-(2,6-dimethoxypyrimidin-4- yl)pyrimidin-2-yl]{[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amine [5-(2,4-dimethoxypyrimidin-5- yl)pyrimidin-2-yl]{[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amine 6-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-1,3-dihydropyrimidine-2,4-dione 5- [2-({[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-1,3- dihydropyrimidine-2,4-dione 3-amino-6-[2-({[3-fluoro-1-(3- fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]hydropyrazin-2-one

430.1 412.1

415.2 415.2

,λγγν/·

-NH \^=N 387.2

387.2 386.2 158 WO 2011/133888 PCT/US2011/033614 {3-[2-({[3-fluoro-1-(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl]-2-hydroxyphenyl}-N- methylcarboxamide [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-4-yl]-N-benzamide

378.3 [2-({[(3-fluoro(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-4-yl]-N-methyl-N- benzamide {[3-fluoro-1-(3-fluoro(2-pyridyl))cyclobutyl]methyl}[5-(3-m ethoxy-6-m et hy I (2-pyridyl))pyrimidin-2-yl]amine ((1R)-1-phenylethyl)[4- (cyclohexylamino)-6- methylpyrimidin-2-yl]amine

392.3 398.2 311.3 3-[2-({[3-fluoro-1-(3-fluoro-6- methyl(2- pyridyl))cyclobutyl]methyl}amino)p yrimidin-5-yl] benzamide

159 WO 2011/133888 PCT/US2011/033614

While the present invention has been described with reference to the specific embodiments described herein, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In 5 addition, modifications may be made to adapt a particular situation, material, composition of matter and/or process to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. 160

Contents44

163 members in 34 offices

This recordMember, by publication datePriority claim24 more offices are in the list below

Priority claims12

Priority claims
Document	Office	Kind	Date
32759710	United States of America	P	2010-04-23
32759710	United States of America	P	2010-04-23
41229910	United States of America	P	2010-11-10
41229910	United States of America	P	2010-11-10
2011033614	United States of America	W	2011-04-22
2011033614	United States of America	W	2011-04-22
61327597	–	–	–
61412299	–	–	–
PCTUS2011033614	–	–	–
US20100327597P	–	–	–
US20100412299P	–	–	–
WO2011US33614	–	–	–

Members163

Family members, oldest first
Document	Office	Kind
CA2796390A1	Canada	A1	2011-10-27
CA2796637A1	Canada	A1	2011-10-27
WO2011133882A1	World Intellectual Property Organization (WIPO)	A1	2011-10-27
WO2011133888A1	World Intellectual Property Organization (WIPO)	A1	2011-10-27
WO2011133920A1	World Intellectual Property Organization (WIPO)	A1	2011-10-27
TW201204363A	Taiwan Province of China	A	2012-02-01
TW201204712A	Taiwan Province of China	A	2012-02-01
AR081331A1	Argentina	A1	2012-08-08
AR081626A1	Argentina	A1	2012-10-10
MX2012012259A	Mexico	A	2012-11-23
SG184954A1	Singapore	A1	2012-11-29
SG184959A1	Singapore	A1	2012-11-29
MX2012012189A	Mexico	A	2012-11-30
AU2011242569A1	Australia	A1	2012-12-06
AU2011242575A1	Australia	A1	2012-12-06
ECSP12012293A	Ecuador	A	2012-12-28
IL222465A0	Israel	A0	2012-12-31
IL222465D0	Israel	D0	2012-12-31
IL222467A0	Israel	A0	2012-12-31
IL222467D0	Israel	D0	2012-12-31
CL2012002944A1	Chile	A1	2013-01-25
CL2012002945A1	Chile	A1	2013-01-25
PH12012502096A1	Philippines	A1	2013-02-11
CO6620055A2	Colombia	A2	2013-02-15
EP2560488A1	European Patent Office (EPO)	A1	2013-02-27
EP2560653A1	European Patent Office (EPO)	A1	2013-02-27
CO6630154A2	Colombia	A2	2013-03-01
EP2563365A1	European Patent Office (EPO)	A1	2013-03-06
CN103002897A	China	A	2013-03-27
ECSP12012292A	Ecuador	A	2013-03-28
CN103025331A	China	A	2013-04-03
EA201201377A1	Eurasian Patent Organization (EAPO)	A1	2013-04-30
EA201201378A1	Eurasian Patent Organization (EAPO)	A1	2013-04-30
EP2560653A4	European Patent Office (EPO)	A4	2013-05-15
US2013123289A1	United States of America	A1	2013-05-16
US2013143862A1	United States of America	A1	2013-06-06
US2013150368A1	United States of America	A1	2013-06-13
JP2013525376A	Japan	A	2013-06-20
JP2013525377A	Japan	A	2013-06-20
KR20130092402A	Republic of Korea	A	2013-08-20
KR20130092403A	Republic of Korea	A	2013-08-20
HK1180604A	Hong Kong, China	A	2013-10-25
HK1180604A1	Hong Kong, China	A1	2013-10-25
EP2560488A4	European Patent Office (EPO)	A4	2013-11-13
HK1181662A	Hong Kong, China	A	2013-11-15
HK1181662A1	Hong Kong, China	A1	2013-11-15
EP2563365A4	European Patent Office (EPO)	A4	2014-01-15
NZ603594A	New Zealand	A	2014-01-31
US2014206709A1	United States of America	A1	2014-07-24
NZ603593A	New Zealand	A	2014-10-31
US8962632B2	United States of America	B2	2015-02-24
US8969346B2	United States of America	B2	2015-03-03
US9018223B2	United States of America	B2	2015-04-28
US9133123B2	United States of America	B2	2015-09-15
TWI501963B	Taiwan Province of China	B	2015-10-01
EP2560488B1	European Patent Office (EPO)	B1	2015-10-28
AU2011242575B2	Australia	B2	2015-10-29
US2015315181A1	United States of America	A1	2015-11-05
US2015322018A1	United States of America	A1	2015-11-12
JP5852099B2	Japan	B2	2016-02-03
AU2011242569B2	Australia	B2	2016-02-04
TWI520737B	Taiwan Province of China	B	2016-02-11
NZ627973A	New Zealand	A	2016-02-26
CN103025331B	China	B	2016-03-02
EP2560653B1	European Patent Office (EPO)	B1	2016-04-13
EP2563365B1	European Patent Office (EPO)	B1	2016-04-20
JP5918217B2	Japan	B2	2016-05-18
AU2016202617A1	Australia	A1	2016-05-19
CN105712974A	China	A	2016-06-29
BR112012026950A2	Brazil	A2	2016-07-12
US2016200717A1	United States of America	A1	2016-07-14
PT2560653T	Portugal	T	2016-07-19
DK2560653T3	Denmark	T3	2016-07-25
SI2560653T1	Slovenia	T1	2016-08-31
SMT201600226B	San Marino	B	2016-08-31
JP2016166217A	Japan	A	2016-09-15
ME02439B	Montenegro	B	2016-09-20
HRP20160827T1	Croatia	T1	2016-09-23
LT2560653T	Lithuania	T	2016-10-10
ES2586302T3	Spain	T3	2016-10-13
MX343264B	Mexico	B	2016-10-28
EA024881B1	Eurasian Patent Organization (EAPO)	B1	2016-10-31
PL2560653T3	Poland	T3	2016-10-31
RS54948B1	Serbia	B1	2016-11-30
HUE028953T2	Hungary	T2	2017-01-30
EP3127540A1	European Patent Office (EPO)	A1	2017-02-08
EP3127541A1	European Patent Office (EPO)	A1	2017-02-08
SG10201700219XA	Singapore	A	2017-02-27
US9604965B2	United States of America	B2	2017-03-28
IL222465A	Israel	A	2017-03-30
IL250824A0	Israel	A0	2017-04-30
IL250824D0	Israel	D0	2017-04-30
CY1117809T1	Cyprus	T1	2017-05-17
CN103002897B	China	B	2017-06-09
US9730886B2	United States of America	B2	2017-08-15
IL222467AThis record	Israel	A	2017-08-31
MY163498A	Malaysia	A	2017-09-15
HK1226068A	Hong Kong, China	A	2017-09-22
HK1226068A1	Hong Kong, China	A1	2017-09-22
KR101781484B1	Republic of Korea	B1	2017-09-25

Showing 100 of 163

3 legal events, as the office reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code
2021-04-29	Patent renewedKB	KB
2018-02-28	Patent renewedKB	KB
2017-12-31	Patent grantedGrantedFF	FF